id	sid	tid	token	lemma	pos
njb-29	1	1	nepal	nepal	ADJ
njb-29	1	2	journal	journal	NOUN
njb-29	1	3	of	of	ADP
njb-29	1	4	biotechnology	biotechnology	NOUN
njb-29	1	5	.	.	PUNCT
njb-29	2	1	d	d	X
njb-29	2	2	e	e	PROPN
njb-29	2	3	c	c	PROPN
njb-29	2	4	.	.	PUNCT
njb-29	3	1	2	2	NUM
njb-29	3	2	0	0	NUM
njb-29	3	3	1	1	NUM
njb-29	3	4	6	6	NUM
njb-29	3	5	vol	vol	NOUN
njb-29	3	6	.	.	PROPN
njb-29	4	1	4	4	NUM
njb-29	4	2	,	,	PUNCT
njb-29	4	3	no	no	NOUN
njb-29	4	4	.	.	NOUN
njb-29	4	5	1	1	NUM
njb-29	4	6	:	:	SYM
njb-29	4	7	1	1	NUM
njb-29	4	8	-	-	SYM
njb-29	4	9	13	13	NUM
njb-29	4	10	issn	issn	PROPN
njb-29	4	11	2091	2091	NUM
njb-29	4	12	-	-	SYM
njb-29	4	13	1130(print)/issn	1130(print)/issn	NUM
njb-29	4	14	2467	2467	NUM
njb-29	4	15	-	-	SYM
njb-29	4	16	9319	9319	NUM
njb-29	4	17	(	(	PUNCT
njb-29	4	18	online	online	ADJ
njb-29	4	19	)	)	PUNCT
njb-29	4	20	original	original	ADJ
njb-29	4	21	research	research	NOUN
njb-29	4	22	article	article	NOUN
njb-29	4	23	©	©	PROPN
njb-29	4	24	njb	njb	PROPN
njb-29	4	25	,	,	PUNCT
njb-29	4	26	biotechnology	biotechnology	NOUN
njb-29	4	27	society	society	NOUN
njb-29	4	28	of	of	ADP
njb-29	4	29	nepal	nepal	ADJ
njb-29	4	30	1	1	NUM
njb-29	5	1	nepjol.info/index.php/njb	nepjol.info/index.php/njb	NOUN
njb-29	5	2	assessing	assess	VERB
njb-29	5	3	the	the	DET
njb-29	5	4	role	role	NOUN
njb-29	5	5	of	of	ADP
njb-29	5	6	potential	potential	ADJ
njb-29	5	7	biomarkers	biomarker	NOUN
njb-29	5	8	in	in	ADP
njb-29	5	9	antimony	antimony	NOUN
njb-29	5	10	susceptible	susceptible	ADJ
njb-29	5	11	and	and	CCONJ
njb-29	5	12	resistant	resistant	ADJ
njb-29	5	13	clinical	clinical	ADJ
njb-29	5	14	isolates	isolate	NOUN
njb-29	5	15	of	of	ADP
njb-29	5	16	l.	l.	PROPN
njb-29	5	17	donovani	donovani	PROPN
njb-29	5	18	from	from	ADP
njb-29	5	19	india	india	PROPN
njb-29	5	20	mahendra	mahendra	PROPN
njb-29	5	21	maharjan1,2	maharjan1,2	PROPN
njb-29	5	22	*	*	PROPN
njb-29	5	23	,	,	PUNCT
njb-29	5	24	swati	swati	PROPN
njb-29	5	25	mandal1	mandal1	PROPN
njb-29	5	26	,	,	PUNCT
njb-29	5	27	rentala	rentala	PROPN
njb-29	5	28	madhubala1	madhubala1	PROPN
njb-29	6	1	1school	1school	NUM
njb-29	6	2	of	of	ADP
njb-29	6	3	life	life	NOUN
njb-29	6	4	sciences	sciences	PROPN
njb-29	6	5	,	,	PUNCT
njb-29	6	6	jawaharlal	jawaharlal	PROPN
njb-29	6	7	nehru	nehru	PROPN
njb-29	6	8	university	university	PROPN
njb-29	6	9	,	,	PUNCT
njb-29	6	10	new	new	PROPN
njb-29	6	11	delhi	delhi	PROPN
njb-29	6	12	,	,	PUNCT
njb-29	6	13	110067	110067	NUM
njb-29	6	14	,	,	PUNCT
njb-29	6	15	india	india	PROPN
njb-29	6	16	.	.	PUNCT
njb-29	7	1	2	2	NUM
njb-29	7	2	central	central	PROPN
njb-29	7	3	department	department	PROPN
njb-29	7	4	of	of	ADP
njb-29	7	5	zoology	zoology	PROPN
njb-29	7	6	,	,	PUNCT
njb-29	7	7	tribhuvan	tribhuvan	PROPN
njb-29	7	8	university	university	PROPN
njb-29	7	9	,	,	PUNCT
njb-29	7	10	kathmandu	kathmandu	PROPN
njb-29	7	11	,	,	PUNCT
njb-29	7	12	nepal	nepal	ADJ
njb-29	7	13	.	.	PUNCT
njb-29	8	1	abstract	abstract	ADJ
njb-29	8	2	failure	failure	NOUN
njb-29	8	3	of	of	ADP
njb-29	8	4	antimonial	antimonial	ADJ
njb-29	8	5	drugs	drug	NOUN
njb-29	8	6	,	,	PUNCT
njb-29	8	7	the	the	DET
njb-29	8	8	mainstay	mainstay	NOUN
njb-29	8	9	therapy	therapy	NOUN
njb-29	8	10	for	for	ADP
njb-29	8	11	leishmaniasis	leishmaniasis	NOUN
njb-29	8	12	has	have	AUX
njb-29	8	13	become	become	VERB
njb-29	8	14	an	an	DET
njb-29	8	15	escalating	escalate	VERB
njb-29	8	16	problem	problem	NOUN
njb-29	8	17	in	in	ADP
njb-29	8	18	the	the	DET
njb-29	8	19	treatment	treatment	NOUN
njb-29	8	20	of	of	ADP
njb-29	8	21	indian	indian	ADJ
njb-29	8	22	leishmaniasis	leishmaniasis	NOUN
njb-29	8	23	.	.	PUNCT
njb-29	9	1	using	use	VERB
njb-29	9	2	14	14	NUM
njb-29	9	3	clinical	clinical	ADJ
njb-29	9	4	isolates	isolate	NOUN
njb-29	9	5	from	from	ADP
njb-29	9	6	both	both	DET
njb-29	9	7	visceral	visceral	NOUN
njb-29	9	8	(	(	PUNCT
njb-29	9	9	vl	vl	NOUN
njb-29	9	10	)	)	PUNCT
njb-29	9	11	and	and	CCONJ
njb-29	9	12	post	post	ADJ
njb-29	9	13	-	-	ADJ
njb-29	9	14	kala	kala	ADJ
njb-29	9	15	-	-	PUNCT
njb-29	9	16	azar	azar	PROPN
njb-29	9	17	dermal	dermal	NOUN
njb-29	9	18	leismaniasis	leismaniasis	NOUN
njb-29	9	19	(	(	PUNCT
njb-29	9	20	pkdl	pkdl	NOUN
njb-29	9	21	)	)	PUNCT
njb-29	9	22	patients	patient	NOUN
njb-29	9	23	,	,	PUNCT
njb-29	9	24	we	we	PRON
njb-29	9	25	have	have	AUX
njb-29	9	26	examined	examine	VERB
njb-29	9	27	the	the	DET
njb-29	9	28	role	role	NOUN
njb-29	9	29	of	of	ADP
njb-29	9	30	atp	atp	NOUN
njb-29	9	31	-	-	PUNCT
njb-29	9	32	binding	bind	VERB
njb-29	9	33	cassette	cassette	NOUN
njb-29	9	34	transporter	transporter	NOUN
njb-29	9	35	(	(	PUNCT
njb-29	9	36	abc	abc	PROPN
njb-29	9	37	transporter	transporter	PROPN
njb-29	9	38	)	)	PUNCT
njb-29	9	39	gene	gene	NOUN
njb-29	9	40	,	,	PUNCT
njb-29	9	41	multidrug	multidrug	VERB
njb-29	9	42	resistant	resistant	ADJ
njb-29	9	43	protein	protein	NOUN
njb-29	9	44	a	a	DET
njb-29	9	45	(	(	PUNCT
njb-29	9	46	mrpa	mrpa	PROPN
njb-29	9	47	)	)	PUNCT
njb-29	9	48	and	and	CCONJ
njb-29	9	49	two	two	NUM
njb-29	9	50	building	building	NOUN
njb-29	9	51	blocks	block	NOUN
njb-29	9	52	of	of	ADP
njb-29	9	53	the	the	DET
njb-29	9	54	major	major	ADJ
njb-29	9	55	thiol	thiol	PROPN
njb-29	9	56	,	,	PUNCT
njb-29	9	57	trypanothione	trypanothione	PROPN
njb-29	9	58	namely	namely	ADV
njb-29	9	59	,	,	PUNCT
njb-29	9	60	ornithine	ornithine	ADJ
njb-29	9	61	decarboxylase	decarboxylase	NOUN
njb-29	9	62	gene	gene	NOUN
njb-29	9	63	(	(	PUNCT
njb-29	9	64	odc	odc	PROPN
njb-29	9	65	)	)	PUNCT
njb-29	9	66	(	(	PUNCT
njb-29	9	67	a	a	DET
njb-29	9	68	rate	rate	NOUN
njb-29	9	69	limiting	limit	VERB
njb-29	9	70	enzyme	enzyme	NOUN
njb-29	9	71	in	in	ADP
njb-29	9	72	the	the	DET
njb-29	9	73	polyamine	polyamine	NOUN
njb-29	9	74	biosynthesis	biosynthesis	NOUN
njb-29	9	75	)	)	PUNCT
njb-29	9	76	and	and	CCONJ
njb-29	9	77	γ	γ	PROPN
njb-29	9	78	glutamylcysteine	glutamylcysteine	PROPN
njb-29	9	79	synthetase	synthetase	PROPN
njb-29	9	80	(	(	PUNCT
njb-29	9	81	γ	γ	PROPN
njb-29	9	82	-	-	PROPN
njb-29	9	83	gcs	gcs	PROPN
njb-29	9	84	)	)	PUNCT
njb-29	9	85	(	(	PUNCT
njb-29	9	86	a	a	DET
njb-29	9	87	rate	rate	NOUN
njb-29	9	88	limiting	limit	VERB
njb-29	9	89	enzyme	enzyme	NOUN
njb-29	9	90	in	in	ADP
njb-29	9	91	glutathione	glutathione	NOUN
njb-29	9	92	biosynthesis	biosynthesis	NOUN
njb-29	9	93	)	)	PUNCT
njb-29	9	94	in	in	ADP
njb-29	9	95	antimony	antimony	ADJ
njb-29	9	96	resistance	resistance	NOUN
njb-29	9	97	.	.	PUNCT
njb-29	10	1	amplification	amplification	NOUN
njb-29	10	2	of	of	ADP
njb-29	10	3	these	these	DET
njb-29	10	4	three	three	NUM
njb-29	10	5	genes	gene	NOUN
njb-29	10	6	was	be	AUX
njb-29	10	7	observed	observe	VERB
njb-29	10	8	in	in	ADP
njb-29	10	9	some	some	PRON
njb-29	10	10	but	but	CCONJ
njb-29	10	11	not	not	PART
njb-29	10	12	all	all	DET
njb-29	10	13	clinical	clinical	ADJ
njb-29	10	14	isolates	isolate	NOUN
njb-29	10	15	.	.	PUNCT
njb-29	11	1	increased	increase	VERB
njb-29	11	2	expression	expression	NOUN
njb-29	11	3	of	of	ADP
njb-29	11	4	the	the	DET
njb-29	11	5	three	three	NUM
njb-29	11	6	rnas	rna	NOUN
njb-29	11	7	as	as	SCONJ
njb-29	11	8	determined	determine	VERB
njb-29	11	9	by	by	ADP
njb-29	11	10	real	real	ADJ
njb-29	11	11	-	-	PUNCT
njb-29	11	12	time	time	NOUN
njb-29	11	13	pcr	pcr	NOUN
njb-29	11	14	was	be	AUX
njb-29	11	15	observed	observe	VERB
njb-29	11	16	in	in	ADP
njb-29	11	17	all	all	DET
njb-29	11	18	sag	sag	ADJ
njb-29	11	19	-	-	PUNCT
njb-29	11	20	r	r	NOUN
njb-29	11	21	clinical	clinical	ADJ
njb-29	11	22	isolates	isolate	NOUN
njb-29	11	23	.	.	PUNCT
njb-29	12	1	significant	significant	ADJ
njb-29	12	2	increase	increase	NOUN
njb-29	12	3	in	in	ADP
njb-29	12	4	cysteine	cysteine	NOUN
njb-29	12	5	and	and	CCONJ
njb-29	12	6	glutathione	glutathione	NOUN
njb-29	12	7	levels	level	NOUN
njb-29	12	8	was	be	AUX
njb-29	12	9	observed	observe	VERB
njb-29	12	10	in	in	ADP
njb-29	12	11	the	the	DET
njb-29	12	12	resistant	resistant	ADJ
njb-29	12	13	isolates	isolate	NOUN
njb-29	12	14	.	.	PUNCT
njb-29	13	1	our	our	PRON
njb-29	13	2	studies	study	NOUN
njb-29	13	3	report	report	VERB
njb-29	13	4	the	the	DET
njb-29	13	5	underlying	underlie	VERB
njb-29	13	6	mechanism	mechanism	NOUN
njb-29	13	7	of	of	ADP
njb-29	13	8	antimony	antimony	ADJ
njb-29	13	9	resistance	resistance	NOUN
njb-29	13	10	in	in	ADP
njb-29	13	11	the	the	DET
njb-29	13	12	clinical	clinical	ADJ
njb-29	13	13	isolates	isolate	NOUN
njb-29	13	14	.	.	PUNCT
njb-29	14	1	key	key	ADJ
njb-29	14	2	words	word	NOUN
njb-29	14	3	:	:	PUNCT
njb-29	14	4	abc	abc	PROPN
njb-29	14	5	transporter	transporter	PROPN
njb-29	14	6	,	,	PUNCT
njb-29	14	7	ornithine	ornithine	ADJ
njb-29	14	8	decarboxylase	decarboxylase	NOUN
njb-29	14	9	,	,	PUNCT
njb-29	14	10	γglutamylcysteine	γglutamylcysteine	PROPN
njb-29	14	11	synthetase	synthetase	PROPN
njb-29	14	12	,	,	PUNCT
njb-29	14	13	antimony	antimony	ADJ
njb-29	14	14	resistance	resistance	NOUN
njb-29	14	15	.	.	PUNCT
njb-29	15	1	*	*	PUNCT
njb-29	15	2	corresponding	correspond	VERB
njb-29	15	3	author	author	NOUN
njb-29	15	4	email	email	NOUN
njb-29	15	5	:	:	PUNCT
njb-29	16	1	maharjan.m@gmail.com	maharjan.m@gmail.com	PROPN
njb-29	16	2	introduction	introduction	VERB
njb-29	16	3	the	the	DET
njb-29	16	4	protozoan	protozoan	NOUN
njb-29	16	5	parasite	parasite	NOUN
njb-29	16	6	leishmania	leishmania	PROPN
njb-29	16	7	is	be	AUX
njb-29	16	8	the	the	DET
njb-29	16	9	causative	causative	ADJ
njb-29	16	10	agent	agent	NOUN
njb-29	16	11	of	of	ADP
njb-29	16	12	kala	kala	PROPN
njb-29	16	13	-	-	PUNCT
njb-29	16	14	azar	azar	PROPN
njb-29	16	15	and	and	CCONJ
njb-29	16	16	is	be	AUX
njb-29	16	17	responsible	responsible	ADJ
njb-29	16	18	for	for	ADP
njb-29	16	19	a	a	DET
njb-29	16	20	variety	variety	NOUN
njb-29	16	21	of	of	ADP
njb-29	16	22	clinical	clinical	ADJ
njb-29	16	23	manifestations	manifestation	NOUN
njb-29	16	24	.	.	PUNCT
njb-29	17	1	it	it	PRON
njb-29	17	2	causes	cause	VERB
njb-29	17	3	a	a	DET
njb-29	17	4	wide	wide	ADJ
njb-29	17	5	spectrum	spectrum	NOUN
njb-29	17	6	of	of	ADP
njb-29	17	7	diseases	disease	NOUN
njb-29	17	8	ranging	range	VERB
njb-29	17	9	from	from	ADP
njb-29	17	10	the	the	DET
njb-29	17	11	simple	simple	ADJ
njb-29	17	12	self	self	NOUN
njb-29	17	13	healing	heal	VERB
njb-29	17	14	cutaneous	cutaneous	ADJ
njb-29	17	15	form	form	NOUN
njb-29	17	16	to	to	ADP
njb-29	17	17	the	the	DET
njb-29	17	18	debilitating	debilitating	ADJ
njb-29	17	19	visceral	visceral	NOUN
njb-29	17	20	form	form	NOUN
njb-29	17	21	.	.	PUNCT
njb-29	18	1	visceral	visceral	NOUN
njb-29	18	2	leishmaniasis	leishmaniasis	NOUN
njb-29	18	3	(	(	PUNCT
njb-29	18	4	vl	vl	PROPN
njb-29	18	5	)	)	PUNCT
njb-29	18	6	is	be	AUX
njb-29	18	7	caused	cause	VERB
njb-29	18	8	by	by	ADP
njb-29	18	9	l.	l.	PROPN
njb-29	18	10	donovani	donovani	PROPN
njb-29	18	11	in	in	ADP
njb-29	18	12	the	the	DET
njb-29	18	13	indian	indian	ADJ
njb-29	18	14	subcontinent	subcontinent	PROPN
njb-29	18	15	.	.	PUNCT
njb-29	19	1	pentavalent	pentavalent	NOUN
njb-29	19	2	antimonials	antimonial	NOUN
njb-29	19	3	(	(	PUNCT
njb-29	19	4	sbv	sbv	PROPN
njb-29	19	5	)	)	PUNCT
njb-29	19	6	are	be	AUX
njb-29	19	7	the	the	DET
njb-29	19	8	first	first	ADJ
njb-29	19	9	line	line	NOUN
njb-29	19	10	of	of	ADP
njb-29	19	11	drug	drug	NOUN
njb-29	19	12	used	use	VERB
njb-29	19	13	in	in	ADP
njb-29	19	14	the	the	DET
njb-29	19	15	treatment	treatment	NOUN
njb-29	19	16	against	against	ADP
njb-29	19	17	all	all	DET
njb-29	19	18	forms	form	NOUN
njb-29	19	19	of	of	ADP
njb-29	19	20	leishmanial	leishmanial	ADJ
njb-29	19	21	infections	infection	NOUN
njb-29	20	1	[	[	X
njb-29	20	2	1,2	1,2	NUM
njb-29	20	3	]	]	PUNCT
njb-29	20	4	.	.	PUNCT
njb-29	21	1	resistance	resistance	NOUN
njb-29	21	2	to	to	ADP
njb-29	21	3	this	this	DET
njb-29	21	4	drug	drug	NOUN
njb-29	21	5	is	be	AUX
njb-29	21	6	becoming	become	VERB
njb-29	21	7	a	a	DET
njb-29	21	8	major	major	ADJ
njb-29	21	9	barrier	barrier	NOUN
njb-29	21	10	in	in	ADP
njb-29	21	11	the	the	DET
njb-29	21	12	treatment	treatment	NOUN
njb-29	21	13	of	of	ADP
njb-29	21	14	vl	vl	PROPN
njb-29	21	15	in	in	ADP
njb-29	21	16	many	many	ADJ
njb-29	21	17	endemic	endemic	ADJ
njb-29	21	18	regions	region	NOUN
njb-29	21	19	particularly	particularly	ADV
njb-29	21	20	in	in	ADP
njb-29	21	21	india	india	PROPN
njb-29	22	1	[	[	PUNCT
njb-29	22	2	3	3	NUM
njb-29	22	3	]	]	X
njb-29	22	4	.	.	PUNCT
njb-29	23	1	kala	kala	PROPN
njb-29	23	2	-	-	PUNCT
njb-29	23	3	azar	azar	PROPN
njb-29	23	4	transmission	transmission	NOUN
njb-29	23	5	in	in	ADP
njb-29	23	6	india	india	PROPN
njb-29	23	7	is	be	AUX
njb-29	23	8	thought	think	VERB
njb-29	23	9	to	to	PART
njb-29	23	10	be	be	AUX
njb-29	23	11	anthroponotic	anthroponotic	ADJ
njb-29	23	12	and	and	CCONJ
njb-29	23	13	postkala	postkala	PROPN
njb-29	23	14	-	-	PUNCT
njb-29	23	15	azar	azar	NOUN
njb-29	23	16	dermal	dermal	NOUN
njb-29	23	17	leismaniasis	leismaniasis	NOUN
njb-29	23	18	(	(	PUNCT
njb-29	23	19	pkdl	pkdl	NOUN
njb-29	23	20	)	)	PUNCT
njb-29	23	21	patients	patient	NOUN
njb-29	23	22	are	be	AUX
njb-29	23	23	considered	consider	VERB
njb-29	23	24	to	to	PART
njb-29	23	25	serve	serve	VERB
njb-29	23	26	as	as	ADP
njb-29	23	27	a	a	DET
njb-29	23	28	source	source	NOUN
njb-29	23	29	for	for	ADP
njb-29	23	30	new	new	ADJ
njb-29	23	31	outbreaks	outbreak	NOUN
njb-29	23	32	[	[	PUNCT
njb-29	23	33	4	4	NUM
njb-29	23	34	]	]	PUNCT
njb-29	23	35	.	.	PUNCT
njb-29	24	1	the	the	DET
njb-29	24	2	post	post	ADJ
njb-29	24	3	-	-	ADJ
njb-29	24	4	kala	kala	ADJ
njb-29	24	5	-	-	PUNCT
njb-29	24	6	azar	azar	PROPN
njb-29	24	7	dermal	dermal	NOUN
njb-29	24	8	leismaniasis	leismaniasis	NOUN
njb-29	24	9	(	(	PUNCT
njb-29	24	10	pkdl	pkdl	PROPN
njb-29	24	11	)	)	PUNCT
njb-29	24	12	is	be	AUX
njb-29	24	13	a	a	DET
njb-29	24	14	sequel	sequel	NOUN
njb-29	24	15	to	to	ADP
njb-29	24	16	vl	vl	PROPN
njb-29	24	17	in	in	ADP
njb-29	24	18	india	india	PROPN
njb-29	24	19	and	and	CCONJ
njb-29	24	20	sudan	sudan	PROPN
njb-29	24	21	;	;	PUNCT
njb-29	24	22	the	the	DET
njb-29	24	23	disease	disease	NOUN
njb-29	24	24	develops	develop	VERB
njb-29	24	25	months	month	NOUN
njb-29	24	26	to	to	ADP
njb-29	24	27	years	year	NOUN
njb-29	24	28	after	after	ADP
njb-29	24	29	the	the	DET
njb-29	24	30	patient	patient	NOUN
njb-29	24	31	’s	’s	PART
njb-29	24	32	recovery	recovery	NOUN
njb-29	24	33	from	from	ADP
njb-29	24	34	vl	vl	PROPN
njb-29	25	1	[	[	PUNCT
njb-29	25	2	5	5	NUM
njb-29	25	3	]	]	PUNCT
njb-29	25	4	.	.	PUNCT
njb-29	26	1	the	the	DET
njb-29	26	2	mechanism	mechanism	NOUN
njb-29	26	3	of	of	ADP
njb-29	26	4	action	action	NOUN
njb-29	26	5	of	of	ADP
njb-29	26	6	sodium	sodium	NOUN
njb-29	26	7	antimony	antimony	NOUN
njb-29	26	8	gluconate	gluconate	NOUN
njb-29	26	9	(	(	PUNCT
njb-29	26	10	sag	sag	PROPN
njb-29	26	11	)	)	PUNCT
njb-29	26	12	remained	remain	VERB
njb-29	26	13	an	an	DET
njb-29	26	14	enigma	enigma	NOUN
njb-29	26	15	for	for	ADP
njb-29	26	16	more	more	ADJ
njb-29	26	17	than	than	ADP
njb-29	26	18	60	60	NUM
njb-29	26	19	years	year	NOUN
njb-29	26	20	of	of	ADP
njb-29	26	21	its	its	PRON
njb-29	26	22	effective	effective	ADJ
njb-29	26	23	use	use	NOUN
njb-29	26	24	against	against	ADP
njb-29	26	25	all	all	DET
njb-29	26	26	forms	form	NOUN
njb-29	26	27	of	of	ADP
njb-29	26	28	leishmaniasis	leishmaniasis	NOUN
njb-29	26	29	.	.	PUNCT
njb-29	27	1	it	it	PRON
njb-29	27	2	is	be	AUX
njb-29	27	3	generally	generally	ADV
njb-29	27	4	agreed	agree	VERB
njb-29	27	5	that	that	SCONJ
njb-29	27	6	pentavalent	pentavalent	NOUN
njb-29	27	7	form	form	NOUN
njb-29	27	8	(	(	PUNCT
njb-29	27	9	sbv	sbv	PROPN
njb-29	27	10	)	)	PUNCT
njb-29	27	11	is	be	AUX
njb-29	27	12	reduced	reduce	VERB
njb-29	27	13	to	to	ADP
njb-29	27	14	a	a	DET
njb-29	27	15	more	more	ADV
njb-29	27	16	toxic	toxic	ADJ
njb-29	27	17	trivalent	trivalent	ADJ
njb-29	27	18	form	form	NOUN
njb-29	27	19	(	(	PUNCT
njb-29	27	20	sbiii	sbiii	NOUN
njb-29	27	21	)	)	PUNCT
njb-29	27	22	which	which	PRON
njb-29	27	23	constitutes	constitute	VERB
njb-29	27	24	the	the	DET
njb-29	27	25	active	active	ADJ
njb-29	27	26	form	form	NOUN
njb-29	27	27	of	of	ADP
njb-29	27	28	the	the	DET
njb-29	27	29	drug	drug	NOUN
njb-29	27	30	against	against	ADP
njb-29	27	31	the	the	DET
njb-29	27	32	parasite	parasite	NOUN
njb-29	27	33	[	[	PUNCT
njb-29	27	34	6	6	NUM
njb-29	27	35	]	]	X
njb-29	27	36	.	.	PUNCT
njb-29	28	1	molecules	molecule	NOUN
njb-29	28	2	possibly	possibly	ADV
njb-29	28	3	implicated	implicate	VERB
njb-29	28	4	in	in	ADP
njb-29	28	5	reduction	reduction	NOUN
njb-29	28	6	of	of	ADP
njb-29	28	7	sbv	sbv	NOUN
njb-29	28	8	to	to	ADP
njb-29	28	9	sbiii	sbiii	PROPN
njb-29	28	10	include	include	VERB
njb-29	28	11	host	host	NOUN
njb-29	28	12	and	and	CCONJ
njb-29	28	13	parasite	parasite	NOUN
njb-29	28	14	thiols	thiol	NOUN
njb-29	28	15	and	and	CCONJ
njb-29	28	16	two	two	NUM
njb-29	28	17	newly	newly	ADV
njb-29	28	18	discovered	discover	VERB
njb-29	28	19	parasite	parasite	NOUN
njb-29	28	20	enzymes	enzyme	NOUN
njb-29	28	21	thioldependent	thioldependent	PROPN
njb-29	28	22	reductase	reductase	NOUN
njb-29	28	23	(	(	PUNCT
njb-29	28	24	tdr1	tdr1	PROPN
njb-29	28	25	)	)	PUNCT
njb-29	28	26	and	and	CCONJ
njb-29	28	27	arsenate	arsenate	ADJ
njb-29	28	28	reductase	reductase	NOUN
njb-29	28	29	(	(	PUNCT
njb-29	28	30	acr2	acr2	PROPN
njb-29	28	31	)	)	PUNCT
njb-29	29	1	[	[	PUNCT
njb-29	29	2	7	7	NUM
njb-29	29	3	-	-	SYM
njb-29	29	4	9	9	NUM
njb-29	29	5	]	]	PUNCT
njb-29	29	6	.	.	PUNCT
njb-29	30	1	a	a	DET
njb-29	30	2	loss	loss	NOUN
njb-29	30	3	of	of	ADP
njb-29	30	4	drug	drug	NOUN
njb-29	30	5	activation	activation	NOUN
njb-29	30	6	is	be	AUX
njb-29	30	7	reported	report	VERB
njb-29	30	8	to	to	PART
njb-29	30	9	lead	lead	VERB
njb-29	30	10	to	to	ADP
njb-29	30	11	resistance	resistance	NOUN
njb-29	30	12	[	[	PUNCT
njb-29	30	13	10	10	NUM
njb-29	30	14	]	]	PUNCT
njb-29	30	15	.	.	PUNCT
njb-29	31	1	the	the	DET
njb-29	31	2	route	route	NOUN
njb-29	31	3	of	of	ADP
njb-29	31	4	entry	entry	NOUN
njb-29	31	5	of	of	ADP
njb-29	31	6	sbv	sbv	NOUN
njb-29	31	7	into	into	ADP
njb-29	31	8	leishmania	leishmania	PROPN
njb-29	31	9	cells	cell	NOUN
njb-29	31	10	is	be	AUX
njb-29	31	11	still	still	ADV
njb-29	31	12	unknown	unknown	ADJ
njb-29	31	13	but	but	CCONJ
njb-29	31	14	sbiii	sbiii	NOUN
njb-29	31	15	has	have	AUX
njb-29	31	16	been	be	AUX
njb-29	31	17	reported	report	VERB
njb-29	31	18	to	to	PART
njb-29	31	19	be	be	AUX
njb-29	31	20	transported	transport	VERB
njb-29	31	21	in	in	ADP
njb-29	31	22	leishmania	leishmania	PROPN
njb-29	31	23	through	through	ADP
njb-29	31	24	aquaglyceroporin	aquaglyceroporin	PROPN
njb-29	31	25	(	(	PUNCT
njb-29	31	26	aqp1	aqp1	PROPN
njb-29	31	27	)	)	PUNCT
njb-29	32	1	[	[	PUNCT
njb-29	32	2	11,12	11,12	NUM
njb-29	32	3	]	]	PUNCT
njb-29	32	4	.	.	PUNCT
njb-29	33	1	recent	recent	ADJ
njb-29	33	2	evidence	evidence	NOUN
njb-29	33	3	has	have	AUX
njb-29	33	4	suggested	suggest	VERB
njb-29	33	5	that	that	SCONJ
njb-29	33	6	part	part	NOUN
njb-29	33	7	of	of	ADP
njb-29	33	8	the	the	DET
njb-29	33	9	mode	mode	NOUN
njb-29	33	10	of	of	ADP
njb-29	33	11	nepal	nepal	ADJ
njb-29	33	12	journal	journal	NOUN
njb-29	33	13	of	of	ADP
njb-29	33	14	biotechnology	biotechnology	NOUN
njb-29	33	15	.	.	PUNCT
njb-29	34	1	d	d	X
njb-29	34	2	e	e	PROPN
njb-29	34	3	c	c	PROPN
njb-29	34	4	.	.	PUNCT
njb-29	35	1	2	2	NUM
njb-29	35	2	0	0	NUM
njb-29	35	3	1	1	NUM
njb-29	35	4	6	6	NUM
njb-29	35	5	vol	vol	NOUN
njb-29	35	6	.	.	PROPN
njb-29	36	1	4	4	NUM
njb-29	36	2	,	,	PUNCT
njb-29	36	3	no	no	NOUN
njb-29	36	4	.	.	NOUN
njb-29	36	5	1	1	NUM
njb-29	36	6	:	:	SYM
njb-29	36	7	1	1	NUM
njb-29	36	8	-	-	SYM
njb-29	36	9	13	13	NUM
njb-29	36	10	maharjan	maharjan	NOUN
njb-29	36	11	et	et	NOUN
njb-29	36	12	al	al	PROPN
njb-29	36	13	.	.	PUNCT
njb-29	37	1	©	©	PROPN
njb-29	37	2	njb	njb	PROPN
njb-29	37	3	,	,	PUNCT
njb-29	37	4	biotechnology	biotechnology	NOUN
njb-29	37	5	society	society	NOUN
njb-29	37	6	of	of	ADP
njb-29	37	7	nepal	nepal	ADJ
njb-29	37	8	2	2	NUM
njb-29	37	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	37	10	action	action	NOUN
njb-29	37	11	of	of	ADP
njb-29	37	12	sbv	sbv	NOUN
njb-29	37	13	could	could	AUX
njb-29	37	14	be	be	AUX
njb-29	37	15	in	in	ADP
njb-29	37	16	depleting	deplete	VERB
njb-29	37	17	the	the	DET
njb-29	37	18	cells	cell	NOUN
njb-29	37	19	of	of	ADP
njb-29	37	20	its	its	PRON
njb-29	37	21	reduced	reduce	VERB
njb-29	37	22	thiols	thiols	ADJ
njb-29	37	23	[	[	X
njb-29	37	24	13	13	NUM
njb-29	37	25	]	]	PUNCT
njb-29	37	26	.	.	PUNCT
njb-29	38	1	trypanothione	trypanothione	PROPN
njb-29	38	2	(	(	PUNCT
njb-29	38	3	tsh	tsh	PROPN
njb-29	38	4	)	)	PUNCT
njb-29	38	5	,	,	PUNCT
njb-29	38	6	a	a	DET
njb-29	38	7	major	major	ADJ
njb-29	38	8	reduced	reduced	ADJ
njb-29	38	9	thiol	thiol	PROPN
njb-29	38	10	of	of	ADP
njb-29	38	11	leishmania	leishmania	PROPN
njb-29	38	12	is	be	AUX
njb-29	38	13	a	a	DET
njb-29	38	14	n1	n1	PROPN
njb-29	38	15	,	,	PUNCT
njb-29	38	16	n8	n8	ADJ
njb-29	38	17	bisglutathione	bisglutathione	NOUN
njb-29	38	18	spermidine	spermidine	NOUN
njb-29	38	19	conjugate	conjugate	NOUN
njb-29	38	20	.	.	PUNCT
njb-29	39	1	it	it	PRON
njb-29	39	2	is	be	AUX
njb-29	39	3	thought	think	VERB
njb-29	39	4	to	to	PART
njb-29	39	5	bind	bind	VERB
njb-29	39	6	to	to	ADP
njb-29	39	7	the	the	DET
njb-29	39	8	active	active	ADJ
njb-29	39	9	reduced	reduce	VERB
njb-29	39	10	form	form	NOUN
njb-29	39	11	of	of	ADP
njb-29	39	12	the	the	DET
njb-29	39	13	metal	metal	NOUN
njb-29	39	14	.	.	PUNCT
njb-29	40	1	these	these	DET
njb-29	40	2	metal	metal	NOUN
njb-29	40	3	-	-	PUNCT
njb-29	40	4	trypanothione	trypanothione	NOUN
njb-29	40	5	conjugates	conjugate	NOUN
njb-29	40	6	are	be	AUX
njb-29	40	7	either	either	CCONJ
njb-29	40	8	sequestered	sequester	VERB
njb-29	40	9	into	into	ADP
njb-29	40	10	an	an	DET
njb-29	40	11	intracellular	intracellular	ADJ
njb-29	40	12	organelle	organelle	NOUN
njb-29	40	13	by	by	ADP
njb-29	40	14	the	the	DET
njb-29	40	15	abc	abc	PROPN
njb-29	40	16	transporter	transporter	PROPN
njb-29	40	17	mrpa	mrpa	PROPN
njb-29	40	18	or	or	CCONJ
njb-29	40	19	extruded	extrude	VERB
njb-29	40	20	outside	outside	ADP
njb-29	40	21	the	the	DET
njb-29	40	22	cell	cell	NOUN
njb-29	40	23	by	by	ADP
njb-29	40	24	an	an	DET
njb-29	40	25	efflux	efflux	NOUN
njb-29	40	26	pump	pump	NOUN
njb-29	40	27	[	[	PUNCT
njb-29	40	28	13	13	NUM
njb-29	40	29	-	-	SYM
njb-29	40	30	16	16	NUM
njb-29	40	31	]	]	PUNCT
njb-29	40	32	.	.	PUNCT
njb-29	41	1	a	a	DET
njb-29	41	2	number	number	NOUN
njb-29	41	3	of	of	ADP
njb-29	41	4	candidate	candidate	NOUN
njb-29	41	5	genes	gene	NOUN
njb-29	41	6	associated	associate	VERB
njb-29	41	7	with	with	ADP
njb-29	41	8	increased	increase	VERB
njb-29	41	9	thiol	thiol	ADJ
njb-29	41	10	concentration	concentration	NOUN
njb-29	41	11	have	have	AUX
njb-29	41	12	been	be	AUX
njb-29	41	13	described	describe	VERB
njb-29	41	14	in	in	ADP
njb-29	41	15	leishmania	leishmania	PROPN
njb-29	41	16	laboratory	laboratory	PROPN
njb-29	41	17	mutants	mutant	NOUN
njb-29	41	18	.	.	PUNCT
njb-29	42	1	resistance	resistance	NOUN
njb-29	42	2	was	be	AUX
njb-29	42	3	induced	induce	VERB
njb-29	42	4	in	in	ADP
njb-29	42	5	these	these	DET
njb-29	42	6	mutants	mutant	NOUN
njb-29	42	7	in	in	ADP
njb-29	42	8	vitro	vitro	X
njb-29	42	9	in	in	ADP
njb-29	42	10	the	the	DET
njb-29	42	11	presence	presence	NOUN
njb-29	42	12	of	of	ADP
njb-29	42	13	antimony	antimony	NOUN
njb-29	42	14	related	relate	VERB
njb-29	42	15	metals	metal	NOUN
njb-29	42	16	such	such	ADJ
njb-29	42	17	as	as	ADP
njb-29	42	18	arsenic	arsenic	ADJ
njb-29	42	19	or	or	CCONJ
njb-29	42	20	antimony	antimony	NOUN
njb-29	42	21	[	[	PUNCT
njb-29	42	22	2,17,18	2,17,18	NUM
njb-29	42	23	]	]	PUNCT
njb-29	42	24	.	.	PUNCT
njb-29	43	1	however	however	ADV
njb-29	43	2	,	,	PUNCT
njb-29	43	3	till	till	SCONJ
njb-29	43	4	date	date	NOUN
njb-29	43	5	it	it	PRON
njb-29	43	6	remains	remain	VERB
njb-29	43	7	unclear	unclear	ADJ
njb-29	43	8	as	as	ADP
njb-29	43	9	to	to	ADP
njb-29	43	10	whether	whether	SCONJ
njb-29	43	11	similar	similar	ADJ
njb-29	43	12	mechanisms	mechanism	NOUN
njb-29	43	13	can	can	AUX
njb-29	43	14	be	be	AUX
njb-29	43	15	extrapolated	extrapolate	VERB
njb-29	43	16	to	to	ADP
njb-29	43	17	clinical	clinical	ADJ
njb-29	43	18	isolates	isolate	NOUN
njb-29	43	19	from	from	ADP
njb-29	43	20	geographical	geographical	ADJ
njb-29	43	21	zones	zone	NOUN
njb-29	43	22	with	with	ADP
njb-29	43	23	a	a	DET
njb-29	43	24	high	high	ADJ
njb-29	43	25	incidence	incidence	NOUN
njb-29	43	26	of	of	ADP
njb-29	43	27	primary	primary	ADJ
njb-29	43	28	antimony	antimony	NOUN
njb-29	43	29	resistance	resistance	NOUN
njb-29	43	30	.	.	PUNCT
njb-29	44	1	to	to	PART
njb-29	44	2	address	address	VERB
njb-29	44	3	this	this	DET
njb-29	44	4	question	question	NOUN
njb-29	44	5	,	,	PUNCT
njb-29	44	6	we	we	PRON
njb-29	44	7	have	have	AUX
njb-29	44	8	characterized	characterize	VERB
njb-29	44	9	both	both	CCONJ
njb-29	44	10	the	the	DET
njb-29	44	11	vl	vl	NOUN
njb-29	44	12	and	and	CCONJ
njb-29	44	13	the	the	DET
njb-29	44	14	pkdl	pkdl	NOUN
njb-29	44	15	isolates	isolate	VERB
njb-29	44	16	from	from	ADP
njb-29	44	17	india	india	PROPN
njb-29	44	18	and	and	CCONJ
njb-29	44	19	report	report	VERB
njb-29	44	20	that	that	SCONJ
njb-29	44	21	diverse	diverse	ADJ
njb-29	44	22	mechanisms	mechanism	NOUN
njb-29	44	23	of	of	ADP
njb-29	44	24	resistance	resistance	NOUN
njb-29	44	25	are	be	AUX
njb-29	44	26	operative	operative	ADJ
njb-29	44	27	in	in	ADP
njb-29	44	28	these	these	DET
njb-29	44	29	isolates	isolate	NOUN
njb-29	44	30	.	.	PUNCT
njb-29	45	1	this	this	DET
njb-29	45	2	work	work	NOUN
njb-29	45	3	aims	aim	VERB
njb-29	45	4	at	at	ADP
njb-29	45	5	characterizing	characterize	VERB
njb-29	45	6	possible	possible	ADJ
njb-29	45	7	biomarkers	biomarker	NOUN
njb-29	45	8	for	for	ADP
njb-29	45	9	monitoring	monitor	VERB
njb-29	45	10	antimonial	antimonial	ADJ
njb-29	45	11	resistant	resistant	ADJ
njb-29	45	12	visceral	visceral	NOUN
njb-29	45	13	leishmaniasis	leishmaniasis	NOUN
njb-29	45	14	and	and	CCONJ
njb-29	45	15	post	post	ADJ
njb-29	45	16	-	-	ADJ
njb-29	45	17	kala	kala	ADJ
njb-29	45	18	-	-	PUNCT
njb-29	45	19	azar	azar	PROPN
njb-29	45	20	dermal	dermal	ADJ
njb-29	45	21	leismaniasis	leismaniasis	NOUN
njb-29	45	22	in	in	ADP
njb-29	45	23	the	the	DET
njb-29	45	24	field	field	NOUN
njb-29	45	25	isolates	isolate	NOUN
njb-29	45	26	.	.	PUNCT
njb-29	46	1	in	in	ADP
njb-29	46	2	the	the	DET
njb-29	46	3	present	present	ADJ
njb-29	46	4	study	study	NOUN
njb-29	46	5	,	,	PUNCT
njb-29	46	6	we	we	PRON
njb-29	46	7	report	report	VERB
njb-29	46	8	the	the	DET
njb-29	46	9	role	role	NOUN
njb-29	46	10	of	of	ADP
njb-29	46	11	thiols	thiols	NOUN
njb-29	46	12	and	and	CCONJ
njb-29	46	13	also	also	ADV
njb-29	46	14	assessed	assess	VERB
njb-29	46	15	the	the	DET
njb-29	46	16	role	role	NOUN
njb-29	46	17	of	of	ADP
njb-29	46	18	abc	abc	PROPN
njb-29	46	19	transporter	transporter	PROPN
njb-29	46	20	(	(	PUNCT
njb-29	46	21	mrpa	mrpa	PROPN
njb-29	46	22	)	)	PUNCT
njb-29	46	23	,	,	PUNCT
njb-29	46	24	ornithine	ornithine	PROPN
njb-29	46	25	decarboxylase	decarboxylase	NOUN
njb-29	46	26	(	(	PUNCT
njb-29	46	27	odc	odc	PROPN
njb-29	46	28	)	)	PUNCT
njb-29	46	29	and	and	CCONJ
njb-29	46	30	γglutamylcysteine	γglutamylcysteine	PROPN
njb-29	46	31	synthetase	synthetase	PROPN
njb-29	46	32	(	(	PUNCT
njb-29	46	33	γ	γ	PROPN
njb-29	46	34	-	-	PROPN
njb-29	46	35	gcs	gcs	PROPN
njb-29	46	36	)	)	PUNCT
njb-29	46	37	genes	gene	NOUN
njb-29	46	38	as	as	ADP
njb-29	46	39	potential	potential	ADJ
njb-29	46	40	biomarkers	biomarker	NOUN
njb-29	46	41	for	for	ADP
njb-29	46	42	monitoring	monitor	VERB
njb-29	46	43	antimonial	antimonial	ADJ
njb-29	46	44	resistance	resistance	NOUN
njb-29	46	45	in	in	ADP
njb-29	46	46	indian	indian	ADJ
njb-29	46	47	leishmaniasis	leishmaniasis	NOUN
njb-29	46	48	.	.	PUNCT
njb-29	47	1	materials	material	NOUN
njb-29	47	2	and	and	CCONJ
njb-29	47	3	methods	method	NOUN
njb-29	47	4	parasite	parasite	NOUN
njb-29	47	5	and	and	CCONJ
njb-29	47	6	culture	culture	NOUN
njb-29	47	7	conditions	condition	NOUN
njb-29	47	8	promastigotes	promastigote	NOUN
njb-29	47	9	of	of	ADP
njb-29	47	10	leishmania	leishmania	PROPN
njb-29	47	11	donovani	donovani	PROPN
njb-29	47	12	clones	clone	NOUN
njb-29	47	13	,	,	PUNCT
njb-29	47	14	ag83	ag83	PROPN
njb-29	47	15	(	(	PUNCT
njb-29	47	16	mhom	mhom	PROPN
njb-29	47	17	/	/	SYM
njb-29	47	18	in/80	in/80	PROPN
njb-29	47	19	/	/	SYM
njb-29	47	20	ag83	ag83	PROPN
njb-29	47	21	)	)	PUNCT
njb-29	47	22	,	,	PUNCT
njb-29	47	23	2001	2001	NUM
njb-29	47	24	,	,	PUNCT
njb-29	47	25	mc4	mc4	PROPN
njb-29	47	26	,	,	PUNCT
njb-29	47	27	mc7	mc7	PROPN
njb-29	47	28	,	,	PUNCT
njb-29	47	29	mc8	mc8	PROPN
njb-29	47	30	and	and	CCONJ
njb-29	47	31	mc9	mc9	PROPN
njb-29	47	32	were	be	AUX
njb-29	47	33	isolated	isolate	VERB
njb-29	47	34	from	from	ADP
njb-29	47	35	patients	patient	NOUN
njb-29	47	36	with	with	ADP
njb-29	47	37	vl	vl	NOUN
njb-29	47	38	and	and	CCONJ
njb-29	47	39	strains	strain	NOUN
njb-29	47	40	,	,	PUNCT
njb-29	47	41	rk1	rk1	PROPN
njb-29	47	42	,	,	PUNCT
njb-29	47	43	ms2	ms2	PROPN
njb-29	47	44	,	,	PUNCT
njb-29	47	45	nr3a	nr3a	PROPN
njb-29	47	46	,	,	PUNCT
njb-29	47	47	rmp8	rmp8	PROPN
njb-29	47	48	(	(	PUNCT
njb-29	47	49	hm	hm	INTJ
njb-29	47	50	/	/	SYM
njb-29	47	51	in	in	ADP
njb-29	47	52	/	/	SYM
njb-29	47	53	rmp-8	rmp-8	NOUN
njb-29	47	54	)	)	PUNCT
njb-29	47	55	,	,	PUNCT
njb-29	47	56	rmp-19	rmp-19	PROPN
njb-29	47	57	(	(	PUNCT
njb-29	47	58	hm	hm	INTJ
njb-29	47	59	/	/	SYM
njb-29	47	60	in	in	ADP
njb-29	47	61	/	/	SYM
njb-29	47	62	rmp-19	rmp-19	PROPN
njb-29	47	63	)	)	PUNCT
njb-29	47	64	,	,	PUNCT
njb-29	47	65	rmp142	rmp142	PROPN
njb-29	47	66	(	(	PUNCT
njb-29	47	67	hm	hm	INTJ
njb-29	47	68	/	/	SYM
njb-29	47	69	in	in	ADP
njb-29	47	70	/	/	SYM
njb-29	47	71	rmp-142	rmp-142	NOUN
njb-29	47	72	)	)	PUNCT
njb-29	47	73	,	,	PUNCT
njb-29	47	74	rmp155	rmp155	PROPN
njb-29	47	75	(	(	PUNCT
njb-29	47	76	hm	hm	INTJ
njb-29	47	77	/	/	SYM
njb-29	47	78	in	in	ADP
njb-29	47	79	/	/	SYM
njb-29	47	80	rmp-155	rmp-155	NUM
njb-29	47	81	)	)	PUNCT
njb-29	47	82	and	and	CCONJ
njb-29	47	83	rmp240	rmp240	NOUN
njb-29	47	84	(	(	PUNCT
njb-29	47	85	hm	hm	INTJ
njb-29	47	86	/	/	SYM
njb-29	47	87	in	in	ADP
njb-29	47	88	/	/	SYM
njb-29	47	89	rmp-240	rmp-240	NOUN
njb-29	47	90	)	)	PUNCT
njb-29	47	91	used	use	VERB
njb-29	47	92	in	in	ADP
njb-29	47	93	the	the	DET
njb-29	47	94	present	present	ADJ
njb-29	47	95	study	study	NOUN
njb-29	47	96	were	be	AUX
njb-29	47	97	isolated	isolate	VERB
njb-29	47	98	from	from	ADP
njb-29	47	99	patients	patient	NOUN
njb-29	47	100	with	with	ADP
njb-29	47	101	pkdl	pkdl	PROPN
njb-29	47	102	[	[	PUNCT
njb-29	47	103	19	19	NUM
njb-29	47	104	]	]	PUNCT
njb-29	47	105	.	.	PUNCT
njb-29	48	1	clinical	clinical	ADJ
njb-29	48	2	isolates	isolate	NOUN
njb-29	48	3	obtained	obtain	VERB
njb-29	48	4	from	from	ADP
njb-29	48	5	vl	vl	PROPN
njb-29	48	6	and	and	CCONJ
njb-29	48	7	pkdl	pkdl	PROPN
njb-29	48	8	patients	patient	NOUN
njb-29	48	9	who	who	PRON
njb-29	48	10	responded	respond	VERB
njb-29	48	11	to	to	ADP
njb-29	48	12	sag	sag	ADJ
njb-29	48	13	chemotherapy	chemotherapy	NOUN
njb-29	48	14	were	be	AUX
njb-29	48	15	designated	designate	VERB
njb-29	48	16	as	as	ADP
njb-29	48	17	sag	sag	PROPN
njb-29	48	18	-	-	PUNCT
njb-29	48	19	s	s	NOUN
njb-29	48	20	(	(	PUNCT
njb-29	48	21	sag	sag	ADJ
njb-29	48	22	-	-	PUNCT
njb-29	48	23	sensitive	sensitive	ADJ
njb-29	48	24	)	)	PUNCT
njb-29	48	25	whereas	whereas	SCONJ
njb-29	48	26	isolates	isolate	VERB
njb-29	48	27	from	from	ADP
njb-29	48	28	vl	vl	PROPN
njb-29	48	29	and	and	CCONJ
njb-29	48	30	pkdl	pkdl	PROPN
njb-29	48	31	patients	patient	NOUN
njb-29	48	32	who	who	PRON
njb-29	48	33	did	do	AUX
njb-29	48	34	not	not	PART
njb-29	48	35	respond	respond	VERB
njb-29	48	36	to	to	ADP
njb-29	48	37	sag	sag	PROPN
njb-29	48	38	were	be	AUX
njb-29	48	39	designated	designate	VERB
njb-29	48	40	as	as	ADP
njb-29	48	41	sag	sag	ADJ
njb-29	48	42	-	-	PUNCT
njb-29	48	43	r	r	NOUN
njb-29	48	44	(	(	PUNCT
njb-29	48	45	sag	sag	ADJ
njb-29	48	46	-	-	PUNCT
njb-29	48	47	resistant	resistant	ADJ
njb-29	48	48	)	)	PUNCT
njb-29	48	49	.	.	PUNCT
njb-29	49	1	sag	sag	ADJ
njb-29	49	2	-	-	PUNCT
njb-29	49	3	sensitive	sensitive	ADJ
njb-29	49	4	strains	strain	NOUN
njb-29	49	5	,	,	PUNCT
njb-29	49	6	ag83	ag83	PROPN
njb-29	49	7	-	-	PUNCT
njb-29	49	8	s	s	PROPN
njb-29	49	9	,	,	PUNCT
njb-29	49	10	2001	2001	NUM
njb-29	49	11	-	-	PUNCT
njb-29	49	12	s	s	PROPN
njb-29	49	13	,	,	PUNCT
njb-29	49	14	mc7	mc7	PROPN
njb-29	49	15	-	-	PUNCT
njb-29	49	16	s	s	PROPN
njb-29	49	17	,	,	PUNCT
njb-29	49	18	rk1	rk1	PROPN
njb-29	49	19	-	-	PUNCT
njb-29	49	20	s	s	PROPN
njb-29	49	21	,	,	PUNCT
njb-29	49	22	ms2	ms2	PROPN
njb-29	49	23	-	-	PUNCT
njb-29	49	24	s	s	PROPN
njb-29	49	25	and	and	CCONJ
njb-29	49	26	the	the	DET
njb-29	49	27	nine	nine	NUM
njb-29	49	28	sag	sag	ADJ
njb-29	49	29	-	-	PUNCT
njb-29	49	30	r	r	NOUN
njb-29	49	31	isolates	isolate	NOUN
njb-29	49	32	,	,	PUNCT
njb-29	49	33	mc4	mc4	PROPN
njb-29	49	34	-	-	PUNCT
njb-29	49	35	r	r	NOUN
njb-29	50	1	mc8	mc8	PROPN
njb-29	50	2	-	-	PUNCT
njb-29	50	3	r	r	PROPN
njb-29	50	4	,	,	PUNCT
njb-29	50	5	mc9	mc9	PROPN
njb-29	50	6	-	-	PUNCT
njb-29	50	7	r	r	PROPN
njb-29	50	8	,	,	PUNCT
njb-29	50	9	nr3a	nr3a	ADV
njb-29	50	10	-	-	PUNCT
njb-29	50	11	r	r	ADJ
njb-29	50	12	,	,	PUNCT
njb-29	50	13	rmp8	rmp8	PROPN
njb-29	50	14	-	-	PUNCT
njb-29	50	15	r	r	PROPN
njb-29	50	16	,	,	PUNCT
njb-29	50	17	rmp19	rmp19	NOUN
njb-29	50	18	-	-	PUNCT
njb-29	50	19	r	r	NOUN
njb-29	50	20	,	,	PUNCT
njb-29	50	21	rmp142	rmp142	PROPN
njb-29	50	22	-	-	PUNCT
njb-29	50	23	r	r	PROPN
njb-29	50	24	,	,	PUNCT
njb-29	50	25	rmp155	rmp155	PROPN
njb-29	50	26	-	-	PUNCT
njb-29	50	27	r	r	PROPN
njb-29	50	28	and	and	CCONJ
njb-29	50	29	rmp240	rmp240	PROPN
njb-29	50	30	-	-	PUNCT
njb-29	50	31	r	r	NOUN
njb-29	50	32	have	have	AUX
njb-29	50	33	been	be	AUX
njb-29	50	34	characterized	characterize	VERB
njb-29	50	35	earlier	early	ADV
njb-29	50	36	[	[	ADP
njb-29	50	37	20	20	NUM
njb-29	50	38	]	]	PUNCT
njb-29	50	39	.	.	PUNCT
njb-29	51	1	clinical	clinical	ADJ
njb-29	51	2	history	history	NOUN
njb-29	51	3	of	of	ADP
njb-29	51	4	the	the	DET
njb-29	51	5	patient	patient	NOUN
njb-29	51	6	infected	infect	VERB
njb-29	51	7	with	with	ADP
njb-29	51	8	the	the	DET
njb-29	51	9	strain	strain	NOUN
njb-29	51	10	rk1	rk1	PROPN
njb-29	51	11	-	-	PUNCT
njb-29	51	12	s	s	PROPN
njb-29	51	13	showed	show	VERB
njb-29	51	14	that	that	SCONJ
njb-29	51	15	the	the	DET
njb-29	51	16	interval	interval	NOUN
njb-29	51	17	between	between	ADP
njb-29	51	18	the	the	DET
njb-29	51	19	cure	cure	NOUN
njb-29	51	20	of	of	ADP
njb-29	51	21	vl	vl	NOUN
njb-29	51	22	and	and	CCONJ
njb-29	51	23	the	the	DET
njb-29	51	24	onset	onset	NOUN
njb-29	51	25	of	of	ADP
njb-29	51	26	pkdl	pkdl	PROPN
njb-29	51	27	was	be	AUX
njb-29	51	28	2.5	2.5	NUM
njb-29	51	29	years	year	NOUN
njb-29	51	30	where	where	SCONJ
njb-29	51	31	as	as	SCONJ
njb-29	51	32	in	in	ADP
njb-29	51	33	the	the	DET
njb-29	51	34	case	case	NOUN
njb-29	51	35	of	of	ADP
njb-29	51	36	pkdl	pkdl	PROPN
njb-29	51	37	patients	patient	NOUN
njb-29	51	38	infected	infect	VERB
njb-29	51	39	with	with	ADP
njb-29	51	40	the	the	DET
njb-29	51	41	strains	strain	NOUN
njb-29	51	42	,	,	PUNCT
njb-29	51	43	ms2s	ms2s	PROPN
njb-29	51	44	and	and	CCONJ
njb-29	51	45	nr3a	nr3a	ADV
njb-29	51	46	-	-	PUNCT
njb-29	51	47	r	r	NOUN
njb-29	51	48	,	,	PUNCT
njb-29	51	49	the	the	DET
njb-29	51	50	interval	interval	NOUN
njb-29	51	51	between	between	ADP
njb-29	51	52	the	the	DET
njb-29	51	53	cure	cure	NOUN
njb-29	51	54	of	of	ADP
njb-29	51	55	vl	vl	NOUN
njb-29	51	56	and	and	CCONJ
njb-29	51	57	the	the	DET
njb-29	51	58	onset	onset	NOUN
njb-29	51	59	of	of	ADP
njb-29	51	60	pkdl	pkdl	PROPN
njb-29	51	61	was	be	AUX
njb-29	51	62	7	7	NUM
njb-29	51	63	and	and	CCONJ
njb-29	51	64	11	11	NUM
njb-29	51	65	years	year	NOUN
njb-29	51	66	respectively	respectively	ADV
njb-29	51	67	.	.	PUNCT
njb-29	52	1	the	the	DET
njb-29	52	2	interval	interval	NOUN
njb-29	52	3	between	between	ADP
njb-29	52	4	the	the	DET
njb-29	52	5	cure	cure	NOUN
njb-29	52	6	of	of	ADP
njb-29	52	7	vl	vl	NOUN
njb-29	52	8	and	and	CCONJ
njb-29	52	9	the	the	DET
njb-29	52	10	onset	onset	NOUN
njb-29	52	11	of	of	ADP
njb-29	52	12	pkdl	pkdl	NOUN
njb-29	52	13	for	for	ADP
njb-29	52	14	the	the	DET
njb-29	52	15	remaining	remain	VERB
njb-29	52	16	isolates	isolate	NOUN
njb-29	52	17	is	be	AUX
njb-29	52	18	not	not	PART
njb-29	52	19	known	know	VERB
njb-29	52	20	.	.	PUNCT
njb-29	53	1	the	the	DET
njb-29	53	2	clinical	clinical	ADJ
njb-29	53	3	isolates	isolate	NOUN
njb-29	53	4	were	be	AUX
njb-29	53	5	maintained	maintain	VERB
njb-29	53	6	in	in	ADP
njb-29	53	7	vitro	vitro	X
njb-29	53	8	in	in	ADP
njb-29	53	9	the	the	DET
njb-29	53	10	absence	absence	NOUN
njb-29	53	11	of	of	ADP
njb-29	53	12	the	the	DET
njb-29	53	13	drug	drug	NOUN
njb-29	53	14	pressure	pressure	NOUN
njb-29	53	15	.	.	PUNCT
njb-29	54	1	promastigotes	promastigote	NOUN
njb-29	54	2	were	be	AUX
njb-29	54	3	routinely	routinely	ADV
njb-29	54	4	cultured	cultured	ADJ
njb-29	54	5	at	at	ADP
njb-29	54	6	220c	220c	NUM
njb-29	54	7	in	in	ADP
njb-29	54	8	modified	modify	VERB
njb-29	54	9	m-199	m-199	PROPN
njb-29	54	10	medium	medium	NOUN
njb-29	54	11	(	(	PUNCT
njb-29	54	12	sigma	sigma	PROPN
njb-29	54	13	,	,	PUNCT
njb-29	54	14	usa	usa	PROPN
njb-29	54	15	)	)	PUNCT
njb-29	54	16	supplemented	supplement	VERB
njb-29	54	17	with	with	ADP
njb-29	54	18	10	10	NUM
njb-29	54	19	%	%	NOUN
njb-29	54	20	heat	heat	NOUN
njb-29	54	21	-	-	PUNCT
njb-29	54	22	inactivated	inactivate	VERB
njb-29	54	23	fetal	fetal	ADJ
njb-29	54	24	bovine	bovine	NOUN
njb-29	54	25	serum	serum	NOUN
njb-29	54	26	(	(	PUNCT
njb-29	54	27	fbs	fb	NOUN
njb-29	54	28	;	;	PUNCT
njb-29	54	29	gibco	gibco	PROPN
njb-29	54	30	/	/	SYM
njb-29	54	31	brl	brl	PROPN
njb-29	54	32	,	,	PUNCT
njb-29	54	33	life	life	NOUN
njb-29	54	34	technologies	technology	NOUN
njb-29	54	35	scotland	scotland	PROPN
njb-29	54	36	,	,	PUNCT
njb-29	54	37	uk	uk	PROPN
njb-29	54	38	)	)	PUNCT
njb-29	54	39	and	and	CCONJ
njb-29	54	40	0.13	0.13	NUM
njb-29	54	41	mg	mg	PROPN
njb-29	54	42	/	/	SYM
njb-29	54	43	ml	ml	PROPN
njb-29	54	44	penicillin	penicillin	PROPN
njb-29	54	45	and	and	CCONJ
njb-29	54	46	streptomycin	streptomycin	PROPN
njb-29	54	47	.	.	PUNCT
njb-29	55	1	this	this	DET
njb-29	55	2	study	study	NOUN
njb-29	55	3	has	have	VERB
njb-29	55	4	the	the	DET
njb-29	55	5	approval	approval	NOUN
njb-29	55	6	of	of	ADP
njb-29	55	7	the	the	DET
njb-29	55	8	institutional	institutional	ADJ
njb-29	55	9	level	level	NOUN
njb-29	55	10	ethics	ethic	NOUN
njb-29	55	11	committee	committee	NOUN
njb-29	55	12	.	.	PUNCT
njb-29	56	1	dna	dna	PROPN
njb-29	56	2	and	and	CCONJ
njb-29	56	3	rna	rna	PROPN
njb-29	56	4	manipulations	manipulation	NOUN
njb-29	56	5	chromosomes	chromosome	NOUN
njb-29	56	6	of	of	ADP
njb-29	56	7	the	the	DET
njb-29	56	8	clinical	clinical	ADJ
njb-29	56	9	isolates	isolate	NOUN
njb-29	56	10	were	be	AUX
njb-29	56	11	separated	separate	VERB
njb-29	56	12	by	by	ADP
njb-29	56	13	pulse	pulse	NOUN
njb-29	56	14	field	field	NOUN
njb-29	56	15	gel	gel	NOUN
njb-29	56	16	electrophoresis	electrophoresis	NOUN
njb-29	56	17	(	(	PUNCT
njb-29	56	18	pfge	pfge	NOUN
njb-29	56	19	)	)	PUNCT
njb-29	56	20	in	in	ADP
njb-29	56	21	which	which	PRON
njb-29	56	22	low	low	ADJ
njb-29	56	23	melting	melt	VERB
njb-29	56	24	agarose	agarose	NOUN
njb-29	56	25	blocks	block	NOUN
njb-29	56	26	,	,	PUNCT
njb-29	56	27	containing	contain	VERB
njb-29	56	28	embedded	embed	VERB
njb-29	56	29	cells	cell	NOUN
njb-29	56	30	(	(	PUNCT
njb-29	56	31	108	108	NUM
njb-29	56	32	/	/	SYM
njb-29	56	33	ml	ml	NOUN
njb-29	56	34	log	log	NOUN
njb-29	56	35	phase	phase	NOUN
njb-29	56	36	promastigotes	promastigote	NOUN
njb-29	56	37	)	)	PUNCT
njb-29	56	38	were	be	AUX
njb-29	56	39	electrophoresed	electrophorese	VERB
njb-29	56	40	in	in	ADP
njb-29	56	41	a	a	DET
njb-29	56	42	contour	contour	NOUN
njb-29	56	43	clamped	clamp	VERB
njb-29	56	44	homogeneous	homogeneous	ADJ
njb-29	56	45	electric	electric	ADJ
njb-29	56	46	field	field	NOUN
njb-29	56	47	apparatus	apparatus	NOUN
njb-29	56	48	(	(	PUNCT
njb-29	56	49	chef	chef	PROPN
njb-29	56	50	driii	driii	PROPN
njb-29	56	51	,	,	PUNCT
njb-29	56	52	bio	bio	PROPN
njb-29	56	53	-	-	PROPN
njb-29	56	54	rad	rad	ADJ
njb-29	56	55	)	)	PUNCT
njb-29	56	56	as	as	SCONJ
njb-29	56	57	reported	report	VERB
njb-29	56	58	earlier	early	ADV
njb-29	56	59	[	[	ADP
njb-29	56	60	20	20	NUM
njb-29	56	61	]	]	PUNCT
njb-29	56	62	.	.	PUNCT
njb-29	57	1	mid	mid	ADJ
njb-29	57	2	log	log	NOUN
njb-29	57	3	phase	phase	NOUN
njb-29	57	4	promastigotes	promastigote	NOUN
njb-29	57	5	(	(	PUNCT
njb-29	57	6	~2	~2	NUM
njb-29	57	7	x	x	SYM
njb-29	57	8	109	109	NUM
njb-29	57	9	cells	cell	NOUN
njb-29	57	10	)	)	PUNCT
njb-29	57	11	of	of	ADP
njb-29	57	12	all	all	DET
njb-29	57	13	the	the	DET
njb-29	57	14	field	field	NOUN
njb-29	57	15	isolates	isolate	NOUN
njb-29	57	16	were	be	AUX
njb-29	57	17	used	use	VERB
njb-29	57	18	for	for	ADP
njb-29	57	19	isolation	isolation	NOUN
njb-29	57	20	of	of	ADP
njb-29	57	21	genomic	genomic	ADJ
njb-29	57	22	dna	dna	PROPN
njb-29	57	23	.	.	PUNCT
njb-29	58	1	5	5	NUM
njb-29	58	2	µg	µg	NOUN
njb-29	58	3	of	of	ADP
njb-29	58	4	genomic	genomic	ADJ
njb-29	58	5	dna	dna	PROPN
njb-29	58	6	was	be	AUX
njb-29	58	7	digested	digest	VERB
njb-29	58	8	with	with	ADP
njb-29	58	9	hindiii	hindiii	ADJ
njb-29	58	10	enzyme	enzyme	NOUN
njb-29	58	11	and	and	CCONJ
njb-29	58	12	subjected	subject	VERB
njb-29	58	13	to	to	ADP
njb-29	58	14	electrophoresis	electrophoresis	NOUN
njb-29	58	15	.	.	PUNCT
njb-29	59	1	total	total	ADJ
njb-29	59	2	rna	rna	PROPN
njb-29	59	3	was	be	AUX
njb-29	59	4	isolated	isolate	VERB
njb-29	59	5	from	from	ADP
njb-29	59	6	promastigotes	promastigote	NOUN
njb-29	59	7	(	(	PUNCT
njb-29	59	8	2	2	NUM
njb-29	59	9	x	x	SYM
njb-29	59	10	108	108	NUM
njb-29	59	11	cells	cell	NOUN
njb-29	59	12	)	)	PUNCT
njb-29	59	13	using	use	VERB
njb-29	59	14	rnaeasy	rnaeasy	NOUN
njb-29	59	15	plus	plus	CCONJ
njb-29	59	16	mini	mini	NOUN
njb-29	59	17	kit	kit	NOUN
njb-29	59	18	(	(	PUNCT
njb-29	59	19	qiagen	qiagen	PROPN
njb-29	59	20	)	)	PUNCT
njb-29	59	21	.	.	PUNCT
njb-29	60	1	standard	standard	ADJ
njb-29	60	2	protocols	protocol	NOUN
njb-29	60	3	were	be	AUX
njb-29	60	4	followed	follow	VERB
njb-29	60	5	for	for	ADP
njb-29	60	6	southern	southern	ADJ
njb-29	60	7	hybridization	hybridization	NOUN
njb-29	60	8	[	[	PUNCT
njb-29	60	9	21	21	NUM
njb-29	60	10	]	]	PUNCT
njb-29	60	11	.	.	PUNCT
njb-29	61	1	dna	dna	PROPN
njb-29	61	2	probes	probe	NOUN
njb-29	61	3	used	use	VERB
njb-29	61	4	in	in	ADP
njb-29	61	5	the	the	DET
njb-29	61	6	present	present	ADJ
njb-29	61	7	study	study	NOUN
njb-29	61	8	included	include	VERB
njb-29	61	9	a	a	DET
njb-29	61	10	400	400	NUM
njb-29	61	11	-	-	PUNCT
njb-29	61	12	bp	bp	X
njb-29	61	13	mrpa	mrpa	PROPN
njb-29	61	14	fragment	fragment	PROPN
njb-29	61	15	(	(	PUNCT
njb-29	61	16	released	release	VERB
njb-29	61	17	from	from	ADP
njb-29	61	18	plasmid	plasmid	PROPN
njb-29	61	19	pm12	pm12	NOUN
njb-29	61	20	that	that	PRON
njb-29	61	21	was	be	AUX
njb-29	61	22	nepal	nepal	ADJ
njb-29	61	23	journal	journal	NOUN
njb-29	61	24	of	of	ADP
njb-29	61	25	biotechnology	biotechnology	NOUN
njb-29	61	26	.	.	PUNCT
njb-29	62	1	d	d	X
njb-29	62	2	e	e	PROPN
njb-29	62	3	c	c	PROPN
njb-29	62	4	.	.	PUNCT
njb-29	63	1	2	2	NUM
njb-29	63	2	0	0	NUM
njb-29	63	3	1	1	NUM
njb-29	63	4	6	6	NUM
njb-29	63	5	vol	vol	NOUN
njb-29	63	6	.	.	PROPN
njb-29	64	1	4	4	NUM
njb-29	64	2	,	,	PUNCT
njb-29	64	3	no	no	NOUN
njb-29	64	4	.	.	NOUN
njb-29	64	5	1	1	NUM
njb-29	64	6	:	:	SYM
njb-29	64	7	1	1	NUM
njb-29	64	8	-	-	SYM
njb-29	64	9	13	13	NUM
njb-29	64	10	maharjan	maharjan	NOUN
njb-29	64	11	et	et	NOUN
njb-29	64	12	al	al	PROPN
njb-29	64	13	.	.	PUNCT
njb-29	65	1	©	©	PROPN
njb-29	65	2	njb	njb	PROPN
njb-29	65	3	,	,	PUNCT
njb-29	65	4	biotechnology	biotechnology	NOUN
njb-29	65	5	society	society	NOUN
njb-29	65	6	of	of	ADP
njb-29	65	7	nepal	nepal	ADJ
njb-29	65	8	3	3	NUM
njb-29	65	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	PROPN
njb-29	65	10	digested	digest	VERB
njb-29	65	11	with	with	ADP
njb-29	65	12	bamhi	bamhi	PROPN
njb-29	65	13	and	and	CCONJ
njb-29	65	14	psti	psti	NOUN
njb-29	65	15	)	)	PUNCT
njb-29	65	16	,	,	PUNCT
njb-29	65	17	a	a	DET
njb-29	65	18	2.3	2.3	NUM
njb-29	65	19	-	-	PUNCT
njb-29	65	20	kb	kb	NOUN
njb-29	65	21	γgcs	γgcs	ADJ
njb-29	65	22	fragment	fragment	NOUN
njb-29	65	23	(	(	PUNCT
njb-29	65	24	derived	derive	VERB
njb-29	65	25	from	from	ADP
njb-29	65	26	plasmid	plasmid	PROPN
njb-29	65	27	pspαhygroαγgcs	pspαhygroαγgcs	NOUN
njb-29	65	28	digested	digest	VERB
njb-29	65	29	with	with	ADP
njb-29	65	30	hindiii	hindiii	PROPN
njb-29	65	31	and	and	CCONJ
njb-29	65	32	xbai	xbai	PROPN
njb-29	65	33	)	)	PUNCT
njb-29	65	34	,	,	PUNCT
njb-29	65	35	a	a	DET
njb-29	65	36	2.0	2.0	NUM
njb-29	65	37	-	-	PUNCT
njb-29	65	38	kb	kb	PROPN
njb-29	65	39	odc	odc	PROPN
njb-29	65	40	-	-	PUNCT
njb-29	65	41	full	full	ADJ
njb-29	65	42	length	length	NOUN
njb-29	65	43	probe	probe	NOUN
njb-29	65	44	(	(	PUNCT
njb-29	65	45	derived	derive	VERB
njb-29	65	46	from	from	ADP
njb-29	65	47	plasmid	plasmid	PROPN
njb-29	65	48	pspαhygroα	pspαhygroα	PROPN
njb-29	65	49	-	-	PUNCT
njb-29	65	50	odc	odc	PROPN
njb-29	65	51	digested	digest	VERB
njb-29	65	52	with	with	ADP
njb-29	65	53	hindiii	hindiii	PROPN
njb-29	65	54	and	and	CCONJ
njb-29	65	55	xbai	xbai	PROPN
njb-29	65	56	)	)	PUNCT
njb-29	65	57	and	and	CCONJ
njb-29	65	58	a	a	DET
njb-29	65	59	1.6	1.6	NUM
njb-29	65	60	-	-	PUNCT
njb-29	65	61	kb	kb	PROPN
njb-29	65	62	5’-ptr1	5’-ptr1	PROPN
njb-29	65	63	probe	probe	NOUN
njb-29	65	64	derived	derive	VERB
njb-29	65	65	from	from	ADP
njb-29	65	66	plasmid	plasmid	PROPN
njb-29	65	67	(	(	PUNCT
njb-29	65	68	psp72	psp72	PROPN
njb-29	65	69	-	-	PUNCT
njb-29	65	70	y	y	PROPN
njb-29	65	71	-	-	PUNCT
njb-29	65	72	hygro-5’-ptr1	hygro-5’-ptr1	PROPN
njb-29	65	73	)	)	PUNCT
njb-29	65	74	.	.	PUNCT
njb-29	66	1	cdna	cdna	PROPN
njb-29	66	2	synthesis	synthesis	PROPN
njb-29	66	3	and	and	CCONJ
njb-29	66	4	real	real	ADJ
njb-29	66	5	time	time	NOUN
njb-29	66	6	rtpcr	rtpcr	ADV
njb-29	66	7	total	total	ADJ
njb-29	66	8	rna	rna	PROPN
njb-29	66	9	was	be	AUX
njb-29	66	10	isolated	isolate	VERB
njb-29	66	11	from	from	ADP
njb-29	66	12	108	108	NUM
njb-29	66	13	leishmania	leishmania	NOUN
njb-29	66	14	cells	cell	NOUN
njb-29	66	15	in	in	ADP
njb-29	66	16	the	the	DET
njb-29	66	17	mid	mid	ADJ
njb-29	66	18	-	-	ADJ
njb-29	66	19	log	log	ADJ
njb-29	66	20	phase	phase	NOUN
njb-29	66	21	of	of	ADP
njb-29	66	22	growth	growth	NOUN
njb-29	66	23	using	use	VERB
njb-29	66	24	the	the	DET
njb-29	66	25	rneasy	rneasy	NOUN
njb-29	66	26	plus	plus	CCONJ
njb-29	66	27	mini	mini	NOUN
njb-29	66	28	kit	kit	NOUN
njb-29	66	29	(	(	PUNCT
njb-29	66	30	qiagen	qiagen	PROPN
njb-29	66	31	)	)	PUNCT
njb-29	66	32	as	as	SCONJ
njb-29	66	33	described	describe	VERB
njb-29	66	34	by	by	ADP
njb-29	66	35	the	the	DET
njb-29	66	36	manufacturer	manufacturer	NOUN
njb-29	66	37	.	.	PUNCT
njb-29	67	1	quality	quality	NOUN
njb-29	67	2	and	and	CCONJ
njb-29	67	3	quantity	quantity	NOUN
njb-29	67	4	of	of	ADP
njb-29	67	5	the	the	DET
njb-29	67	6	rna	rna	PROPN
njb-29	67	7	were	be	AUX
njb-29	67	8	determined	determine	VERB
njb-29	67	9	using	use	VERB
njb-29	67	10	the	the	DET
njb-29	67	11	rna	rna	PROPN
njb-29	67	12	6000	6000	NUM
njb-29	67	13	nano	nano	NOUN
njb-29	67	14	lab	lab	NOUN
njb-29	67	15	chip	chip	NOUN
njb-29	67	16	kit	kit	NOUN
njb-29	67	17	on	on	ADP
njb-29	67	18	the	the	DET
njb-29	67	19	bio	bio	NOUN
njb-29	67	20	-	-	PUNCT
njb-29	67	21	analyzer	analyzer	VERB
njb-29	67	22	2100	2100	NUM
njb-29	67	23	(	(	PUNCT
njb-29	67	24	agilent	agilent	ADJ
njb-29	67	25	technologies	technology	NOUN
njb-29	67	26	)	)	PUNCT
njb-29	67	27	.	.	PUNCT
njb-29	68	1	the	the	DET
njb-29	68	2	sequences	sequence	NOUN
njb-29	68	3	of	of	ADP
njb-29	68	4	the	the	DET
njb-29	68	5	primers	primer	NOUN
njb-29	68	6	for	for	ADP
njb-29	68	7	mrpa	mrpa	NOUN
njb-29	68	8	are	be	AUX
njb-29	68	9	forward	forward	ADV
njb-29	68	10	5’gcgcagccgtttgtgcttgtgg-3	5’gcgcagccgtttgtgcttgtgg-3	NUM
njb-29	68	11	’	'	PUNCT
njb-29	68	12	and	and	CCONJ
njb-29	68	13	reverse	reverse	VERB
njb-29	68	14	5’-ttgccgtacgtcgcgatggtgc-3	5’-ttgccgtacgtcgcgatggtgc-3	NUM
njb-29	68	15	’	'	PUNCT
njb-29	68	16	and	and	CCONJ
njb-29	68	17	for	for	ADP
njb-29	68	18	the	the	DET
njb-29	68	19	glyceraldehyde	glyceraldehyde	PROPN
njb-29	68	20	3	3	NUM
njb-29	68	21	-	-	PUNCT
njb-29	68	22	phosphate	phosphate	NOUN
njb-29	68	23	dehydrogenase	dehydrogenase	NOUN
njb-29	68	24	(	(	PUNCT
njb-29	68	25	gapdh	gapdh	NOUN
njb-29	68	26	)	)	PUNCT
njb-29	68	27	control	control	VERB
njb-29	68	28	forward	forward	ADV
njb-29	68	29	5’gaagtacacggtggaggctg	5’gaagtacacggtggaggctg	NUM
njb-29	68	30	and	and	CCONJ
njb-29	68	31	reverse	reverse	VERB
njb-29	68	32	5’cgctgatcacgaccttcttc	5’cgctgatcacgaccttcttc	NUM
njb-29	68	33	primers	primer	NOUN
njb-29	68	34	.	.	PUNCT
njb-29	69	1	the	the	DET
njb-29	69	2	sequences	sequence	NOUN
njb-29	69	3	of	of	ADP
njb-29	69	4	the	the	DET
njb-29	69	5	primers	primer	NOUN
njb-29	69	6	for	for	ADP
njb-29	69	7	odc	odc	PROPN
njb-29	69	8	are	be	AUX
njb-29	69	9	forward	forward	ADV
njb-29	69	10	5’gatggtgcgcccttactttgc-3’and	5’gatggtgcgcccttactttgc-3’and	NUM
njb-29	69	11	reverse	reverse	VERB
njb-29	69	12	5’-ttccatctccagcgggttgtcc-3	5’-ttccatctccagcgggttgtcc-3	PROPN
njb-29	69	13	’	'	PUNCT
njb-29	69	14	,	,	PUNCT
njb-29	69	15	and	and	CCONJ
njb-29	69	16	for	for	ADP
njb-29	69	17	the	the	DET
njb-29	69	18	γgcs	γgcs	NOUN
njb-29	69	19	,	,	PUNCT
njb-29	69	20	forward	forward	ADV
njb-29	69	21	5’cattggctggcgcgttgagttc-3	5’cattggctggcgcgttgagttc-3	PROPN
njb-29	69	22	’	'	PUNCT
njb-29	69	23	and	and	CCONJ
njb-29	69	24	reverse	reverse	VERB
njb-29	69	25	5’-atgtgcgcggcccatattctcg	5’-atgtgcgcggcccatattctcg	NUM
njb-29	69	26	-3	-3	PROPN
njb-29	69	27	’	'	PUNCT
njb-29	69	28	primer	primer	NOUN
njb-29	69	29	.	.	PUNCT
njb-29	70	1	complementary	complementary	ADJ
njb-29	70	2	dnas	dna	NOUN
njb-29	70	3	from	from	ADP
njb-29	70	4	promastigotes	promastigote	NOUN
njb-29	70	5	were	be	AUX
njb-29	70	6	synthesized	synthesize	VERB
njb-29	70	7	from	from	ADP
njb-29	70	8	500	500	NUM
njb-29	70	9	ng	ng	NOUN
njb-29	70	10	of	of	ADP
njb-29	70	11	total	total	ADJ
njb-29	70	12	rna	rna	PROPN
njb-29	70	13	using	use	VERB
njb-29	70	14	the	the	DET
njb-29	70	15	accusuperscript	accusuperscript	ADJ
njb-29	70	16	high	high	PROPN
njb-29	70	17	fidelity	fidelity	PROPN
njb-29	70	18	rt	rt	PROPN
njb-29	70	19	-	-	PUNCT
njb-29	70	20	pcr	pcr	PROPN
njb-29	70	21	kit	kit	NOUN
njb-29	70	22	(	(	PUNCT
njb-29	70	23	stratagene	stratagene	PROPN
njb-29	70	24	,	,	PUNCT
njb-29	70	25	la	la	PROPN
njb-29	70	26	jolla	jolla	X
njb-29	70	27	)	)	PUNCT
njb-29	70	28	and	and	CCONJ
njb-29	70	29	oligo	oligo	PROPN
njb-29	70	30	(	(	PUNCT
njb-29	70	31	dt)18	dt)18	PROPN
njb-29	70	32	primers	primer	NOUN
njb-29	70	33	following	follow	VERB
njb-29	70	34	manufacturer	manufacturer	NOUN
njb-29	70	35	’s	’s	PART
njb-29	70	36	instructions	instruction	NOUN
njb-29	70	37	.	.	PUNCT
njb-29	71	1	real	real	ADJ
njb-29	71	2	-	-	PUNCT
njb-29	71	3	time	time	NOUN
njb-29	71	4	pcr	pcr	NOUN
njb-29	71	5	was	be	AUX
njb-29	71	6	performed	perform	VERB
njb-29	71	7	in	in	ADP
njb-29	71	8	triplicate	triplicate	NOUN
njb-29	71	9	in	in	ADP
njb-29	71	10	25	25	NUM
njb-29	71	11	l	l	PROPN
njb-29	71	12	volumes	volume	NOUN
njb-29	71	13	using	use	VERB
njb-29	71	14	quantifast	quantifast	VERB
njb-29	71	15	sybr	sybr	PROPN
njb-29	71	16	green	green	PROPN
njb-29	71	17	pcr	pcr	PROPN
njb-29	71	18	master	master	NOUN
njb-29	71	19	mix	mix	PROPN
njb-29	71	20	(	(	PUNCT
njb-29	71	21	qiagen	qiagen	PROPN
njb-29	71	22	)	)	PUNCT
njb-29	71	23	in	in	ADP
njb-29	71	24	an	an	DET
njb-29	71	25	applied	applied	ADJ
njb-29	71	26	biosystem	biosystem	NOUN
njb-29	71	27	7500	7500	NUM
njb-29	71	28	.	.	PUNCT
njb-29	72	1	reactions	reaction	NOUN
njb-29	72	2	were	be	AUX
njb-29	72	3	run	run	VERB
njb-29	72	4	using	use	VERB
njb-29	72	5	the	the	DET
njb-29	72	6	following	follow	VERB
njb-29	72	7	thermal	thermal	ADJ
njb-29	72	8	profile	profile	NOUN
njb-29	72	9	:	:	PUNCT
njb-29	72	10	initial	initial	ADJ
njb-29	72	11	denaturation	denaturation	NOUN
njb-29	72	12	at	at	ADP
njb-29	72	13	95	95	NUM
njb-29	72	14	°	°	NOUN
njb-29	72	15	c	c	NOUN
njb-29	72	16	for	for	ADP
njb-29	72	17	5	5	NUM
njb-29	72	18	min	min	NOUN
njb-29	72	19	followed	follow	VERB
njb-29	72	20	by	by	ADP
njb-29	72	21	40	40	NUM
njb-29	72	22	cycles	cycle	NOUN
njb-29	72	23	with	with	ADP
njb-29	72	24	denaturation	denaturation	NOUN
njb-29	72	25	at	at	ADP
njb-29	72	26	95	95	NUM
njb-29	72	27	°	°	NOUN
njb-29	72	28	c	c	NOUN
njb-29	72	29	for	for	ADP
njb-29	72	30	30	30	NUM
njb-29	72	31	s	s	PROPN
njb-29	72	32	,	,	PUNCT
njb-29	72	33	annealing	anneal	VERB
njb-29	72	34	at	at	ADP
njb-29	72	35	62	62	NUM
njb-29	72	36	°	°	NOUN
njb-29	72	37	c	c	NOUN
njb-29	72	38	for	for	ADP
njb-29	72	39	1	1	NUM
njb-29	72	40	min	min	NOUN
njb-29	72	41	and	and	CCONJ
njb-29	72	42	extension	extension	NOUN
njb-29	72	43	at	at	ADP
njb-29	72	44	72	72	NUM
njb-29	72	45	°	°	NOUN
njb-29	72	46	c	c	NOUN
njb-29	72	47	for	for	ADP
njb-29	72	48	20	20	NUM
njb-29	72	49	s.	s.	PROPN
njb-29	72	50	the	the	DET
njb-29	72	51	pcr	pcr	PROPN
njb-29	72	52	was	be	AUX
njb-29	72	53	followed	follow	VERB
njb-29	72	54	by	by	ADP
njb-29	72	55	a	a	DET
njb-29	72	56	melt	melt	VERB
njb-29	72	57	curve	curve	NOUN
njb-29	72	58	analysis	analysis	NOUN
njb-29	72	59	to	to	PART
njb-29	72	60	ascertain	ascertain	VERB
njb-29	72	61	that	that	SCONJ
njb-29	72	62	the	the	DET
njb-29	72	63	expected	expected	ADJ
njb-29	72	64	products	product	NOUN
njb-29	72	65	were	be	AUX
njb-29	72	66	amplified	amplify	VERB
njb-29	72	67	.	.	PUNCT
njb-29	73	1	the	the	DET
njb-29	73	2	relative	relative	ADJ
njb-29	73	3	amount	amount	NOUN
njb-29	73	4	of	of	ADP
njb-29	73	5	pcr	pcr	NOUN
njb-29	73	6	products	product	NOUN
njb-29	73	7	generated	generate	VERB
njb-29	73	8	from	from	ADP
njb-29	73	9	each	each	DET
njb-29	73	10	primer	primer	NOUN
njb-29	73	11	set	set	NOUN
njb-29	73	12	was	be	AUX
njb-29	73	13	determined	determine	VERB
njb-29	73	14	based	base	VERB
njb-29	73	15	on	on	ADP
njb-29	73	16	the	the	DET
njb-29	73	17	threshold	threshold	NOUN
njb-29	73	18	cycle	cycle	NOUN
njb-29	73	19	(	(	PUNCT
njb-29	73	20	ct	ct	NOUN
njb-29	73	21	)	)	PUNCT
njb-29	73	22	value	value	NOUN
njb-29	73	23	and	and	CCONJ
njb-29	73	24	amplification	amplification	NOUN
njb-29	73	25	efficiencies	efficiency	NOUN
njb-29	73	26	and	and	CCONJ
njb-29	73	27	was	be	AUX
njb-29	73	28	normalized	normalize	VERB
njb-29	73	29	by	by	ADP
njb-29	73	30	dividing	divide	VERB
njb-29	73	31	the	the	DET
njb-29	73	32	values	value	NOUN
njb-29	73	33	by	by	ADP
njb-29	73	34	the	the	DET
njb-29	73	35	relative	relative	ADJ
njb-29	73	36	amount	amount	NOUN
njb-29	73	37	of	of	ADP
njb-29	73	38	the	the	DET
njb-29	73	39	gapdh	gapdh	NOUN
njb-29	73	40	gene	gene	NOUN
njb-29	73	41	used	use	VERB
njb-29	73	42	as	as	ADP
njb-29	73	43	a	a	DET
njb-29	73	44	control	control	NOUN
njb-29	73	45	.	.	PUNCT
njb-29	74	1	transfection	transfection	NOUN
njb-29	74	2	and	and	CCONJ
njb-29	74	3	overexpression	overexpression	NOUN
njb-29	74	4	of	of	ADP
njb-29	74	5	the	the	DET
njb-29	74	6	mrpa	mrpa	NOUN
njb-29	74	7	and	and	CCONJ
njb-29	74	8	γ	γ	PROPN
njb-29	74	9	-	-	PUNCT
njb-29	74	10	gcs	gcs	PROPN
njb-29	74	11	gene	gene	NOUN
njb-29	74	12	episomal	episomal	ADJ
njb-29	74	13	leishmania	leishmania	PROPN
njb-29	74	14	expression	expression	NOUN
njb-29	74	15	vectors	vector	NOUN
njb-29	74	16	,	,	PUNCT
njb-29	74	17	pglneoluc	pglneoluc	NOUN
njb-29	74	18	containing	contain	VERB
njb-29	74	19	luciferase	luciferase	NOUN
njb-29	74	20	encoding	encode	VERB
njb-29	74	21	dna	dna	PROPN
njb-29	74	22	and	and	CCONJ
njb-29	74	23	neomycin	neomycin	PROPN
njb-29	74	24	phosphotransferase	phosphotransferase	NOUN
njb-29	74	25	selectable	selectable	ADJ
njb-29	74	26	marker	marker	NOUN
njb-29	74	27	,	,	PUNCT
njb-29	74	28	psphygro-gcs	psphygro-gcs	NOUN
njb-29	74	29	containing	contain	VERB
njb-29	74	30	coding	code	VERB
njb-29	74	31	sequence	sequence	NOUN
njb-29	74	32	for	for	ADP
njb-29	74	33	heavy	heavy	ADJ
njb-29	74	34	subunit	subunit	NOUN
njb-29	74	35	of	of	ADP
njb-29	74	36	gcs	gcs	PROPN
njb-29	74	37	with	with	ADP
njb-29	74	38	hygromycin	hygromycin	PROPN
njb-29	74	39	phosphotransferase	phosphotransferase	PROPN
njb-29	74	40	as	as	ADP
njb-29	74	41	selectable	selectable	ADJ
njb-29	74	42	marker	marker	NOUN
njb-29	74	43	and	and	CCONJ
njb-29	74	44	pgem72f-neo-mrpa	pgem72f-neo-mrpa	PRON
njb-29	74	45	containing	contain	VERB
njb-29	74	46	mrpa	mrpa	ADV
njb-29	74	47	coding	code	VERB
njb-29	74	48	dna	dna	PROPN
njb-29	74	49	and	and	CCONJ
njb-29	74	50	neomycin	neomycin	PROPN
njb-29	74	51	phosphotransferase	phosphotransferase	NOUN
njb-29	74	52	as	as	ADP
njb-29	74	53	selectable	selectable	ADJ
njb-29	74	54	marker	marker	NOUN
njb-29	74	55	were	be	AUX
njb-29	74	56	obtained	obtain	VERB
njb-29	74	57	as	as	ADP
njb-29	74	58	gifts	gift	NOUN
njb-29	74	59	from	from	ADP
njb-29	74	60	prof	prof	PROPN
njb-29	74	61	.	.	PROPN
njb-29	74	62	marc	marc	PROPN
njb-29	74	63	ouellette	ouellette	PROPN
njb-29	74	64	,	,	PUNCT
njb-29	74	65	centre	centre	PROPN
njb-29	74	66	de	de	X
njb-29	74	67	recherche	recherche	X
njb-29	74	68	en	en	X
njb-29	74	69	infectiologie	infectiologie	X
njb-29	74	70	du	du	X
njb-29	74	71	centre	centre	PROPN
njb-29	74	72	de	de	X
njb-29	74	73	recherche	recherche	X
njb-29	74	74	du	du	X
njb-29	74	75	chul	chul	PROPN
njb-29	74	76	,	,	PUNCT
njb-29	74	77	universite	universite	ADJ
njb-29	74	78	laval	laval	PROPN
njb-29	74	79	,	,	PUNCT
njb-29	74	80	quebec	quebec	PROPN
njb-29	74	81	,	,	PUNCT
njb-29	74	82	canada	canada	PROPN
njb-29	74	83	.	.	PUNCT
njb-29	75	1	twenty	twenty	NUM
njb-29	75	2	µg	µg	NOUN
njb-29	75	3	of	of	ADP
njb-29	75	4	each	each	DET
njb-29	75	5	construct	construct	NOUN
njb-29	75	6	was	be	AUX
njb-29	75	7	transfected	transfecte	VERB
njb-29	75	8	into	into	ADP
njb-29	75	9	l.	l.	PROPN
njb-29	75	10	donovani	donovani	PROPN
njb-29	75	11	promastigotes	promastigote	NOUN
njb-29	75	12	by	by	ADP
njb-29	75	13	electroporation	electroporation	NOUN
njb-29	75	14	.	.	PUNCT
njb-29	76	1	electroporation	electroporation	NOUN
njb-29	76	2	was	be	AUX
njb-29	76	3	done	do	VERB
njb-29	76	4	with	with	ADP
njb-29	76	5	a	a	DET
njb-29	76	6	single	single	ADJ
njb-29	76	7	pulse	pulse	NOUN
njb-29	76	8	with	with	ADP
njb-29	76	9	the	the	DET
njb-29	76	10	following	follow	VERB
njb-29	76	11	parameters	parameter	NOUN
njb-29	76	12	450	450	NUM
njb-29	76	13	v	v	NOUN
njb-29	76	14	,	,	PUNCT
njb-29	76	15	500	500	NUM
njb-29	76	16	f	f	NOUN
njb-29	76	17	(	(	PUNCT
njb-29	76	18	bio	bio	NOUN
njb-29	76	19	-	-	ADJ
njb-29	76	20	rad	rad	ADJ
njb-29	76	21	)	)	PUNCT
njb-29	76	22	.	.	PUNCT
njb-29	77	1	transfectants	transfectant	NOUN
njb-29	77	2	were	be	AUX
njb-29	77	3	selected	select	VERB
njb-29	77	4	for	for	ADP
njb-29	77	5	resistance	resistance	NOUN
njb-29	77	6	to	to	ADP
njb-29	77	7	either	either	CCONJ
njb-29	77	8	g418	g418	PROPN
njb-29	77	9	(	(	PUNCT
njb-29	77	10	40	40	NUM
njb-29	77	11	μg	μg	NUM
njb-29	77	12	/	/	SYM
njb-29	77	13	ml	ml	PROPN
njb-29	77	14	)	)	PUNCT
njb-29	77	15	or	or	CCONJ
njb-29	77	16	hygromycin	hygromycin	PROPN
njb-29	77	17	b	b	PROPN
njb-29	77	18	(	(	PUNCT
njb-29	77	19	80	80	NUM
njb-29	77	20	μg	μg	NUM
njb-29	77	21	/	/	SYM
njb-29	77	22	ml	ml	PROPN
njb-29	77	23	)	)	PUNCT
njb-29	77	24	as	as	SCONJ
njb-29	77	25	described	describe	VERB
njb-29	77	26	earlier	early	ADV
njb-29	77	27	[	[	PROPN
njb-29	77	28	22	22	NUM
njb-29	77	29	]	]	PUNCT
njb-29	77	30	.	.	PUNCT
njb-29	78	1	chemosensitivity	chemosensitivity	NOUN
njb-29	78	2	profiles	profile	NOUN
njb-29	78	3	of	of	ADP
njb-29	78	4	sag	sag	PROPN
njb-29	78	5	-	-	PUNCT
njb-29	78	6	s	s	NOUN
njb-29	78	7	and	and	CCONJ
njb-29	78	8	sag	sag	ADJ
njb-29	78	9	-	-	PUNCT
njb-29	78	10	r	r	NOUN
njb-29	78	11	strains	strain	NOUN
njb-29	78	12	in	in	ADP
njb-29	78	13	an	an	DET
njb-29	78	14	amastigote	amastigote	NOUN
njb-29	78	15	macrophage	macrophage	NOUN
njb-29	78	16	model	model	NOUN
njb-29	78	17	stationary	stationary	ADJ
njb-29	78	18	phase	phase	NOUN
njb-29	78	19	leishmania	leishmania	PROPN
njb-29	78	20	promastigotes	promastigote	VERB
njb-29	78	21	expressing	express	VERB
njb-29	78	22	the	the	DET
njb-29	78	23	luciferase	luciferase	NOUN
njb-29	78	24	gene	gene	NOUN
njb-29	78	25	(	(	PUNCT
njb-29	78	26	pglneoluc	pglneoluc	NOUN
njb-29	78	27	)	)	PUNCT
njb-29	78	28	and	and	CCONJ
njb-29	78	29	psphygro-gcs	psphygro-gcs	NOUN
njb-29	78	30	containing	contain	VERB
njb-29	78	31	coding	code	VERB
njb-29	78	32	sequence	sequence	NOUN
njb-29	78	33	for	for	ADP
njb-29	78	34	heavy	heavy	ADJ
njb-29	78	35	subunit	subunit	NOUN
njb-29	78	36	of	of	ADP
njb-29	78	37	gcs	gcs	PROPN
njb-29	78	38	with	with	ADP
njb-29	78	39	hygromycin	hygromycin	PROPN
njb-29	78	40	phosphotransferase	phosphotransferase	PROPN
njb-29	78	41	as	as	ADP
njb-29	78	42	selectable	selectable	ADJ
njb-29	78	43	marker	marker	NOUN
njb-29	78	44	or	or	CCONJ
njb-29	78	45	pgem72f-neo-mrpa	pgem72f-neo-mrpa	PRON
njb-29	78	46	containing	contain	VERB
njb-29	78	47	mrpa	mrpa	ADV
njb-29	78	48	coding	code	VERB
njb-29	78	49	dna	dna	PROPN
njb-29	78	50	and	and	CCONJ
njb-29	78	51	neomycin	neomycin	PROPN
njb-29	78	52	phosphotransferase	phosphotransferase	NOUN
njb-29	78	53	as	as	ADP
njb-29	78	54	selectable	selectable	ADJ
njb-29	78	55	marker	marker	NOUN
njb-29	78	56	were	be	AUX
njb-29	78	57	infected	infect	VERB
njb-29	78	58	into	into	ADP
njb-29	78	59	j774a.1	j774a.1	NOUN
njb-29	78	60	macrophages	macrophage	NOUN
njb-29	78	61	.	.	PUNCT
njb-29	79	1	macrophage	macrophage	NOUN
njb-29	79	2	cell	cell	NOUN
njb-29	79	3	line	line	NOUN
njb-29	79	4	j774a.1	j774a.1	NOUN
njb-29	79	5	(	(	PUNCT
njb-29	79	6	american	american	ADJ
njb-29	79	7	type	type	NOUN
njb-29	79	8	culture	culture	NOUN
njb-29	79	9	collection	collection	NOUN
njb-29	79	10	)	)	PUNCT
njb-29	79	11	was	be	AUX
njb-29	79	12	maintained	maintain	VERB
njb-29	79	13	at	at	ADP
njb-29	79	14	37c	37c	NUM
njb-29	79	15	in	in	ADP
njb-29	79	16	rpmi1640	rpmi1640	PROPN
njb-29	79	17	medium	medium	NOUN
njb-29	79	18	(	(	PUNCT
njb-29	79	19	sigma	sigma	PROPN
njb-29	79	20	)	)	PUNCT
njb-29	79	21	containing	contain	VERB
njb-29	79	22	10	10	NUM
njb-29	79	23	%	%	NOUN
njb-29	79	24	heat	heat	NOUN
njb-29	79	25	inactivated	inactivate	VERB
njb-29	79	26	fetal	fetal	ADJ
njb-29	79	27	bovine	bovine	NOUN
njb-29	79	28	serum	serum	NOUN
njb-29	79	29	.	.	PUNCT
njb-29	80	1	briefly	briefly	ADV
njb-29	80	2	,	,	PUNCT
njb-29	80	3	j774a.1	j774a.1	VERB
njb-29	80	4	murine	murine	NOUN
njb-29	80	5	macrophages	macrophage	NOUN
njb-29	80	6	(	(	PUNCT
njb-29	80	7	1	1	NUM
njb-29	80	8	x	x	SYM
njb-29	80	9	105	105	NUM
njb-29	80	10	cells/	cells/	X
njb-29	80	11	petridish	petridish	ADJ
njb-29	80	12	)	)	PUNCT
njb-29	80	13	were	be	AUX
njb-29	80	14	infected	infect	VERB
njb-29	80	15	with	with	ADP
njb-29	80	16	1	1	NUM
njb-29	80	17	x	x	SYM
njb-29	80	18	106	106	NUM
njb-29	80	19	promastigotes	promastigote	NOUN
njb-29	80	20	(	(	PUNCT
njb-29	80	21	expressing	express	VERB
njb-29	80	22	the	the	DET
njb-29	80	23	luciferase	luciferase	NOUN
njb-29	80	24	gene	gene	NOUN
njb-29	80	25	(	(	PUNCT
njb-29	80	26	pglneoluc	pglneoluc	NOUN
njb-29	80	27	)	)	PUNCT
njb-29	80	28	in	in	ADP
njb-29	80	29	m199	m199	PROPN
njb-29	80	30	media	medium	NOUN
njb-29	80	31	with	with	ADP
njb-29	80	32	10	10	NUM
njb-29	80	33	%	%	NOUN
njb-29	80	34	fbs	fbs	ADJ
njb-29	80	35	.	.	PUNCT
njb-29	80	36	nepal	nepal	ADJ
njb-29	80	37	journal	journal	PROPN
njb-29	80	38	of	of	ADP
njb-29	80	39	biotechnology	biotechnology	NOUN
njb-29	80	40	.	.	PUNCT
njb-29	81	1	d	d	X
njb-29	81	2	e	e	PROPN
njb-29	81	3	c	c	PROPN
njb-29	81	4	.	.	PUNCT
njb-29	82	1	2	2	NUM
njb-29	82	2	0	0	NUM
njb-29	82	3	1	1	NUM
njb-29	82	4	6	6	NUM
njb-29	82	5	vol	vol	NOUN
njb-29	82	6	.	.	PROPN
njb-29	83	1	4	4	NUM
njb-29	83	2	,	,	PUNCT
njb-29	83	3	no	no	NOUN
njb-29	83	4	.	.	NOUN
njb-29	83	5	1	1	NUM
njb-29	83	6	:	:	SYM
njb-29	83	7	1	1	NUM
njb-29	83	8	-	-	SYM
njb-29	83	9	13	13	NUM
njb-29	83	10	maharjan	maharjan	NOUN
njb-29	83	11	et	et	NOUN
njb-29	83	12	al	al	PROPN
njb-29	83	13	.	.	PUNCT
njb-29	84	1	©	©	PROPN
njb-29	84	2	njb	njb	PROPN
njb-29	84	3	,	,	PUNCT
njb-29	84	4	biotechnology	biotechnology	NOUN
njb-29	84	5	society	society	NOUN
njb-29	84	6	of	of	ADP
njb-29	84	7	nepal	nepal	ADJ
njb-29	84	8	4	4	NUM
njb-29	84	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	NOUN
njb-29	84	10	after	after	ADP
njb-29	84	11	3	3	NUM
njb-29	84	12	h	h	NUM
njb-29	84	13	,	,	PUNCT
njb-29	84	14	the	the	DET
njb-29	84	15	non	non	ADJ
njb-29	84	16	-	-	ADJ
njb-29	84	17	internalized	internalized	ADJ
njb-29	84	18	parasites	parasite	NOUN
njb-29	84	19	were	be	AUX
njb-29	84	20	washed	wash	VERB
njb-29	84	21	off	off	ADP
njb-29	84	22	and	and	CCONJ
njb-29	84	23	sag	sag	PROPN
njb-29	84	24	was	be	AUX
njb-29	84	25	added	add	VERB
njb-29	84	26	at	at	ADP
njb-29	84	27	different	different	ADJ
njb-29	84	28	concentrations	concentration	NOUN
njb-29	84	29	(	(	PUNCT
njb-29	84	30	10	10	NUM
njb-29	84	31	–	–	PUNCT
njb-29	84	32	100	100	NUM
njb-29	84	33	g	g	NOUN
njb-29	84	34	/	/	SYM
njb-29	84	35	ml	ml	PROPN
njb-29	84	36	)	)	PUNCT
njb-29	84	37	.	.	PUNCT
njb-29	85	1	after	after	ADP
njb-29	85	2	5	5	NUM
njb-29	85	3	days	day	NOUN
njb-29	85	4	of	of	ADP
njb-29	85	5	drug	drug	NOUN
njb-29	85	6	exposure	exposure	NOUN
njb-29	85	7	,	,	PUNCT
njb-29	85	8	plates	plate	NOUN
njb-29	85	9	containing	contain	VERB
njb-29	85	10	adherent	adherent	NOUN
njb-29	85	11	macrophages	macrophage	NOUN
njb-29	85	12	were	be	AUX
njb-29	85	13	washed	wash	VERB
njb-29	85	14	and	and	CCONJ
njb-29	85	15	luciferase	luciferase	NOUN
njb-29	85	16	activity	activity	NOUN
njb-29	85	17	was	be	AUX
njb-29	85	18	determined	determine	VERB
njb-29	85	19	[	[	X
njb-29	85	20	22	22	NUM
njb-29	85	21	]	]	PUNCT
njb-29	85	22	.	.	PUNCT
njb-29	86	1	the	the	DET
njb-29	86	2	50	50	NUM
njb-29	86	3	%	%	NOUN
njb-29	86	4	inhibitory	inhibitory	ADJ
njb-29	86	5	concentration	concentration	NOUN
njb-29	86	6	(	(	PUNCT
njb-29	86	7	ic50	ic50	PROPN
njb-29	86	8	)	)	PUNCT
njb-29	86	9	was	be	AUX
njb-29	86	10	determined	determine	VERB
njb-29	86	11	from	from	ADP
njb-29	86	12	the	the	DET
njb-29	86	13	graph	graph	NOUN
njb-29	86	14	representing	represent	VERB
njb-29	86	15	different	different	ADJ
njb-29	86	16	concentrations	concentration	NOUN
njb-29	86	17	of	of	ADP
njb-29	86	18	sag	sag	NOUN
njb-29	86	19	plotted	plot	VERB
njb-29	86	20	against	against	ADP
njb-29	86	21	relative	relative	ADJ
njb-29	86	22	light	light	ADJ
njb-29	86	23	units	unit	NOUN
njb-29	86	24	(	(	PUNCT
njb-29	86	25	rlu	rlu	PROPN
njb-29	86	26	)	)	PUNCT
njb-29	86	27	produced	produce	VERB
njb-29	86	28	by	by	ADP
njb-29	86	29	luciferase	luciferase	PROPN
njb-29	86	30	expressing	express	VERB
njb-29	86	31	parasites	parasite	NOUN
njb-29	86	32	.	.	PUNCT
njb-29	87	1	thiol	thiol	PROPN
njb-29	87	2	analysis	analysis	PROPN
njb-29	87	3	thiols	thiols	PROPN
njb-29	87	4	were	be	AUX
njb-29	87	5	derivatized	derivatize	VERB
njb-29	87	6	with	with	ADP
njb-29	87	7	monobromobimane	monobromobimane	NOUN
njb-29	87	8	and	and	CCONJ
njb-29	87	9	separated	separate	VERB
njb-29	87	10	by	by	ADP
njb-29	87	11	highperfomance	highperfomance	PROPN
njb-29	87	12	liquid	liquid	PROPN
njb-29	87	13	chromatography	chromatography	NOUN
njb-29	87	14	(	(	PUNCT
njb-29	87	15	hplc	hplc	NOUN
njb-29	87	16	)	)	PUNCT
njb-29	87	17	as	as	SCONJ
njb-29	87	18	reported	report	VERB
njb-29	87	19	earlier	early	ADV
njb-29	87	20	[	[	ADP
njb-29	87	21	18	18	NUM
njb-29	87	22	]	]	PUNCT
njb-29	87	23	.	.	PUNCT
njb-29	88	1	statistical	statistical	ADJ
njb-29	88	2	analysis	analysis	NOUN
njb-29	88	3	data	datum	NOUN
njb-29	88	4	was	be	AUX
njb-29	88	5	analyzed	analyze	VERB
njb-29	88	6	by	by	ADP
njb-29	88	7	the	the	DET
njb-29	88	8	student	student	NOUN
njb-29	88	9	’s	’s	PART
njb-29	88	10	ttest	ttest	NOUN
njb-29	88	11	.	.	PUNCT
njb-29	89	1	the	the	DET
njb-29	89	2	data	datum	NOUN
njb-29	89	3	is	be	AUX
njb-29	89	4	represented	represent	VERB
njb-29	89	5	as	as	ADP
njb-29	89	6	mean	mean	ADJ
njb-29	89	7	±	±	PRON
njb-29	89	8	s.d	s.d	NOUN
njb-29	89	9	.	.	PUNCT
njb-29	90	1	the	the	DET
njb-29	90	2	results	result	NOUN
njb-29	90	3	are	be	AUX
njb-29	90	4	representative	representative	ADJ
njb-29	90	5	of	of	ADP
njb-29	90	6	three	three	NUM
njb-29	90	7	independent	independent	ADJ
njb-29	90	8	experiments	experiment	NOUN
njb-29	90	9	.	.	PUNCT
njb-29	91	1	a	a	DET
njb-29	91	2	p	p	NOUN
njb-29	91	3	value	value	NOUN
njb-29	91	4	of	of	ADP
njb-29	91	5	<	<	X
njb-29	91	6	0.05	0.05	NUM
njb-29	91	7	was	be	AUX
njb-29	91	8	considered	consider	VERB
njb-29	91	9	statistically	statistically	ADV
njb-29	91	10	significant	significant	ADJ
njb-29	91	11	.	.	PUNCT
njb-29	92	1	results	result	VERB
njb-29	92	2	intracellular	intracellular	ADJ
njb-29	92	3	thiol	thiol	ADJ
njb-29	92	4	levels	level	NOUN
njb-29	92	5	in	in	ADP
njb-29	92	6	sag	sag	PROPN
njb-29	92	7	-	-	PUNCT
njb-29	92	8	s	s	NOUN
njb-29	92	9	and	and	CCONJ
njb-29	92	10	sag	sag	ADJ
njb-29	92	11	-	-	PUNCT
njb-29	92	12	r	r	NOUN
njb-29	92	13	clinical	clinical	ADJ
njb-29	92	14	isolates	isolate	VERB
njb-29	92	15	resistance	resistance	NOUN
njb-29	92	16	to	to	ADP
njb-29	92	17	antimonials	antimonial	NOUN
njb-29	92	18	in	in	ADP
njb-29	92	19	clinical	clinical	ADJ
njb-29	92	20	isolates	isolate	NOUN
njb-29	92	21	is	be	AUX
njb-29	92	22	not	not	PART
njb-29	92	23	well	well	ADV
njb-29	92	24	defined	define	VERB
njb-29	92	25	.	.	PUNCT
njb-29	93	1	understanding	understand	VERB
njb-29	93	2	the	the	DET
njb-29	93	3	mechanism	mechanism	NOUN
njb-29	93	4	of	of	ADP
njb-29	93	5	resistance	resistance	NOUN
njb-29	93	6	to	to	ADP
njb-29	93	7	antimony	antimony	NOUN
njb-29	93	8	in	in	ADP
njb-29	93	9	clinical	clinical	ADJ
njb-29	93	10	isolates	isolate	NOUN
njb-29	93	11	of	of	ADP
njb-29	93	12	l.	l.	PROPN
njb-29	93	13	donovani	donovani	PROPN
njb-29	93	14	will	will	AUX
njb-29	93	15	aid	aid	VERB
njb-29	93	16	in	in	ADP
njb-29	93	17	the	the	DET
njb-29	93	18	development	development	NOUN
njb-29	93	19	of	of	ADP
njb-29	93	20	biomarkers	biomarker	NOUN
njb-29	93	21	for	for	ADP
njb-29	93	22	antimony	antimony	ADJ
njb-29	93	23	resistance	resistance	NOUN
njb-29	93	24	and	and	CCONJ
njb-29	93	25	this	this	PRON
njb-29	93	26	in	in	ADP
njb-29	93	27	turn	turn	NOUN
njb-29	93	28	will	will	AUX
njb-29	93	29	enable	enable	VERB
njb-29	93	30	the	the	DET
njb-29	93	31	clinicians	clinician	NOUN
njb-29	93	32	to	to	PART
njb-29	93	33	monitor	monitor	VERB
njb-29	93	34	the	the	DET
njb-29	93	35	treatment	treatment	NOUN
njb-29	93	36	of	of	ADP
njb-29	93	37	the	the	DET
njb-29	93	38	patients	patient	NOUN
njb-29	93	39	.	.	PUNCT
njb-29	94	1	with	with	ADP
njb-29	94	2	this	this	DET
njb-29	94	3	background	background	NOUN
njb-29	94	4	in	in	ADP
njb-29	94	5	mind	mind	NOUN
njb-29	94	6	,	,	PUNCT
njb-29	94	7	we	we	PRON
njb-29	94	8	used	use	VERB
njb-29	94	9	the	the	DET
njb-29	94	10	previously	previously	ADV
njb-29	94	11	characterized	characterize	VERB
njb-29	94	12	sag	sag	PROPN
njb-29	94	13	-	-	PUNCT
njb-29	94	14	s	s	NOUN
njb-29	94	15	and	and	CCONJ
njb-29	94	16	sag	sag	PROPN
njb-29	94	17	-	-	PUNCT
njb-29	94	18	r	r	NOUN
njb-29	94	19	,	,	PUNCT
njb-29	94	20	vl	vl	PROPN
njb-29	94	21	and	and	CCONJ
njb-29	94	22	pkdl	pkdl	PROPN
njb-29	94	23	clinical	clinical	ADJ
njb-29	94	24	isolates	isolate	NOUN
njb-29	94	25	for	for	ADP
njb-29	94	26	the	the	DET
njb-29	94	27	present	present	ADJ
njb-29	94	28	study	study	NOUN
njb-29	94	29	[	[	PUNCT
njb-29	94	30	20	20	NUM
njb-29	94	31	]	]	PUNCT
njb-29	94	32	.	.	PUNCT
njb-29	95	1	a	a	DET
njb-29	95	2	total	total	NOUN
njb-29	95	3	of	of	ADP
njb-29	95	4	fourteen	fourteen	NUM
njb-29	95	5	field	field	NOUN
njb-29	95	6	isolates	isolate	NOUN
njb-29	95	7	were	be	AUX
njb-29	95	8	used	use	VERB
njb-29	95	9	to	to	PART
njb-29	95	10	assess	assess	VERB
njb-29	95	11	the	the	DET
njb-29	95	12	putative	putative	ADJ
njb-29	95	13	role	role	NOUN
njb-29	95	14	of	of	ADP
njb-29	95	15	the	the	DET
njb-29	95	16	abc	abc	PROPN
njb-29	95	17	transporter	transporter	PROPN
njb-29	95	18	mrpa	mrpa	PROPN
njb-29	95	19	,	,	PUNCT
njb-29	95	20	ornithine	ornithine	ADJ
njb-29	95	21	decarboxylase	decarboxylase	NOUN
njb-29	95	22	and	and	CCONJ
njb-29	95	23	γglutamylcysteine	γglutamylcysteine	PROPN
njb-29	95	24	synthetase	synthetase	PROPN
njb-29	95	25	in	in	ADP
njb-29	95	26	antimony	antimony	NOUN
njb-29	95	27	susceptible	susceptible	ADJ
njb-29	95	28	and	and	CCONJ
njb-29	95	29	-resistant	-resistant	ADJ
njb-29	95	30	clinical	clinical	ADJ
njb-29	95	31	isolates	isolate	NOUN
njb-29	95	32	of	of	ADP
njb-29	95	33	l.	l.	PROPN
njb-29	95	34	donovani	donovani	PROPN
njb-29	95	35	from	from	ADP
njb-29	95	36	india	india	PROPN
njb-29	95	37	.	.	PUNCT
njb-29	96	1	as	as	SCONJ
njb-29	96	2	reported	report	VERB
njb-29	96	3	earlier	early	ADV
njb-29	96	4	,	,	PUNCT
njb-29	96	5	sag	sag	PROPN
njb-29	96	6	-	-	PUNCT
njb-29	96	7	s	s	NOUN
njb-29	96	8	isolates	isolate	NOUN
njb-29	96	9	,	,	PUNCT
njb-29	96	10	ag83	ag83	PROPN
njb-29	96	11	-	-	PUNCT
njb-29	96	12	s	s	PROPN
njb-29	96	13	,	,	PUNCT
njb-29	96	14	2001	2001	NUM
njb-29	96	15	-	-	PUNCT
njb-29	96	16	s	s	PROPN
njb-29	96	17	,	,	PUNCT
njb-29	96	18	mc7	mc7	PROPN
njb-29	96	19	-	-	PUNCT
njb-29	96	20	s	s	PROPN
njb-29	96	21	,	,	PUNCT
njb-29	96	22	rk1	rk1	PROPN
njb-29	96	23	-	-	PUNCT
njb-29	96	24	s	s	PROPN
njb-29	96	25	and	and	CCONJ
njb-29	96	26	ms2	ms2	PROPN
njb-29	96	27	-	-	PUNCT
njb-29	96	28	s	s	NOUN
njb-29	96	29	coming	come	VERB
njb-29	96	30	from	from	ADP
njb-29	96	31	sag	sag	ADJ
njb-29	96	32	responsive	responsive	ADJ
njb-29	96	33	patients	patient	NOUN
njb-29	96	34	had	have	AUX
njb-29	96	35	ic50	ic50	PROPN
njb-29	96	36	values	value	VERB
njb-29	96	37	6.2	6.2	NUM
njb-29	96	38	±	±	NOUN
njb-29	96	39	1.8	1.8	NUM
njb-29	96	40	,	,	PUNCT
njb-29	96	41	0.9	0.9	NUM
njb-29	96	42	±	±	NOUN
njb-29	96	43	0.12	0.12	NUM
njb-29	96	44	,	,	PUNCT
njb-29	96	45	8	8	NUM
njb-29	96	46	±	±	NOUN
njb-29	96	47	3.3	3.3	NUM
njb-29	96	48	,	,	PUNCT
njb-29	96	49	0.01	0.01	NUM
njb-29	96	50	±	±	NOUN
njb-29	96	51	0.02	0.02	NUM
njb-29	96	52	and	and	CCONJ
njb-29	96	53	4.75	4.75	NUM
njb-29	96	54	±	±	NOUN
njb-29	96	55	0.12	0.12	NUM
njb-29	96	56	µm	µm	NOUN
njb-29	96	57	respectively	respectively	ADV
njb-29	96	58	whereas	whereas	SCONJ
njb-29	96	59	the	the	DET
njb-29	96	60	sag	sag	ADJ
njb-29	96	61	-	-	PUNCT
njb-29	96	62	r	r	NOUN
njb-29	96	63	isolates	isolate	NOUN
njb-29	96	64	,	,	PUNCT
njb-29	96	65	mc4	mc4	PROPN
njb-29	96	66	-	-	PUNCT
njb-29	96	67	r	r	PROPN
njb-29	96	68	,	,	PUNCT
njb-29	96	69	mc8	mc8	PROPN
njb-29	96	70	-	-	PUNCT
njb-29	96	71	r	r	PROPN
njb-29	96	72	,	,	PUNCT
njb-29	96	73	mc9	mc9	PROPN
njb-29	96	74	-	-	PUNCT
njb-29	96	75	r	r	PROPN
njb-29	96	76	,	,	PUNCT
njb-29	96	77	nr3ar	nr3ar	PROPN
njb-29	96	78	,	,	PUNCT
njb-29	96	79	rmp8	rmp8	PROPN
njb-29	96	80	-	-	PUNCT
njb-29	96	81	r	r	PROPN
njb-29	96	82	,	,	PUNCT
njb-29	96	83	rmp19	rmp19	NOUN
njb-29	96	84	-	-	PUNCT
njb-29	96	85	r	r	NOUN
njb-29	96	86	,	,	PUNCT
njb-29	96	87	rmp142	rmp142	PROPN
njb-29	96	88	-	-	PUNCT
njb-29	96	89	r	r	PROPN
njb-29	96	90	,	,	PUNCT
njb-29	96	91	rmp155	rmp155	PROPN
njb-29	96	92	-	-	PUNCT
njb-29	96	93	r	r	PROPN
njb-29	96	94	,	,	PUNCT
njb-29	96	95	rmp240	rmp240	PROPN
njb-29	96	96	-	-	PUNCT
njb-29	96	97	r	r	NOUN
njb-29	96	98	coming	come	VERB
njb-29	96	99	from	from	ADP
njb-29	96	100	the	the	DET
njb-29	96	101	sag	sag	ADJ
njb-29	96	102	-	-	PUNCT
njb-29	96	103	unresponsive	unresponsive	ADJ
njb-29	96	104	patients	patient	NOUN
njb-29	96	105	had	have	VERB
njb-29	96	106	ic50s	ic50	NOUN
njb-29	96	107	that	that	PRON
njb-29	96	108	were	be	AUX
njb-29	96	109	2	2	PUNCT
njb-29	96	110	to	to	ADP
njb-29	96	111	>	>	X
njb-29	96	112	10	10	NUM
njb-29	96	113	fold	fold	VERB
njb-29	96	114	higher	high	ADJ
njb-29	96	115	than	than	ADP
njb-29	96	116	that	that	PRON
njb-29	96	117	of	of	ADP
njb-29	96	118	the	the	DET
njb-29	96	119	sensitive	sensitive	ADJ
njb-29	96	120	isolate	isolate	NOUN
njb-29	96	121	,	,	PUNCT
njb-29	96	122	ag83	ag83	PROPN
njb-29	96	123	-	-	PUNCT
njb-29	96	124	s.(20	s.(20	PROPN
njb-29	96	125	)	)	PUNCT
njb-29	96	126	rk1	rk1	PROPN
njb-29	96	127	-	-	PUNCT
njb-29	96	128	s	s	PROPN
njb-29	96	129	was	be	AUX
njb-29	96	130	the	the	DET
njb-29	96	131	most	most	ADV
njb-29	96	132	sensitive	sensitive	ADJ
njb-29	96	133	of	of	ADP
njb-29	96	134	all	all	DET
njb-29	96	135	the	the	DET
njb-29	96	136	isolates	isolate	NOUN
njb-29	96	137	with	with	ADP
njb-29	96	138	an	an	DET
njb-29	96	139	ic50	ic50	PROPN
njb-29	96	140	of	of	ADP
njb-29	96	141	0.01	0.01	NUM
njb-29	96	142	±	±	NOUN
njb-29	96	143	0.02	0.02	NUM
njb-29	96	144	µm	µm	PROPN
njb-29	96	145	.	.	PROPN
njb-29	96	146	intracellular	intracellular	PROPN
njb-29	96	147	thiol	thiol	PROPN
njb-29	96	148	levels	level	NOUN
njb-29	96	149	were	be	AUX
njb-29	96	150	quantified	quantify	VERB
njb-29	96	151	in	in	ADP
njb-29	96	152	the	the	DET
njb-29	96	153	sag	sag	PROPN
njb-29	96	154	-	-	PUNCT
njb-29	96	155	s	s	NOUN
njb-29	96	156	and	and	CCONJ
njb-29	96	157	sag	sag	ADJ
njb-29	96	158	-	-	PUNCT
njb-29	96	159	r	r	NOUN
njb-29	96	160	isolates	isolate	NOUN
njb-29	96	161	(	(	PUNCT
njb-29	96	162	figure	figure	NOUN
njb-29	96	163	1	1	NUM
njb-29	96	164	)	)	PUNCT
njb-29	96	165	.	.	PUNCT
njb-29	97	1	sag	sag	ADJ
njb-29	97	2	-	-	PUNCT
njb-29	97	3	r	r	NOUN
njb-29	97	4	isolates	isolate	NOUN
njb-29	97	5	maintained	maintain	VERB
njb-29	97	6	significantly	significantly	ADV
njb-29	97	7	higher	high	ADJ
njb-29	97	8	levels	level	NOUN
njb-29	97	9	of	of	ADP
njb-29	97	10	cysteine	cysteine	NOUN
njb-29	97	11	and	and	CCONJ
njb-29	97	12	glutathione	glutathione	NOUN
njb-29	97	13	as	as	ADP
njb-29	97	14	compared	compare	VERB
njb-29	97	15	to	to	ADP
njb-29	97	16	the	the	DET
njb-29	97	17	sag	sag	ADJ
njb-29	97	18	-	-	PUNCT
njb-29	97	19	s	s	NOUN
njb-29	97	20	isolates	isolate	NOUN
njb-29	97	21	.	.	PUNCT
njb-29	98	1	cysteine	cysteine	NOUN
njb-29	98	2	levels	level	NOUN
njb-29	98	3	in	in	ADP
njb-29	98	4	the	the	DET
njb-29	98	5	sag	sag	ADJ
njb-29	98	6	resistant	resistant	ADJ
njb-29	98	7	strains	strain	NOUN
njb-29	98	8	mc4	mc4	PROPN
njb-29	98	9	-	-	PUNCT
njb-29	98	10	r	r	PROPN
njb-29	98	11	,	,	PUNCT
njb-29	98	12	mc8	mc8	PROPN
njb-29	98	13	-	-	PUNCT
njb-29	98	14	r	r	PROPN
njb-29	98	15	,	,	PUNCT
njb-29	98	16	mc9	mc9	PROPN
njb-29	98	17	-	-	PUNCT
njb-29	98	18	r	r	PROPN
njb-29	98	19	,	,	PUNCT
njb-29	98	20	nr3ar	nr3ar	PROPN
njb-29	98	21	,	,	PUNCT
njb-29	98	22	rmp8	rmp8	PROPN
njb-29	98	23	-	-	PUNCT
njb-29	98	24	r	r	PROPN
njb-29	98	25	,	,	PUNCT
njb-29	98	26	rmp19	rmp19	NOUN
njb-29	98	27	-	-	PUNCT
njb-29	98	28	r	r	NOUN
njb-29	98	29	,	,	PUNCT
njb-29	98	30	rmp142	rmp142	PROPN
njb-29	98	31	-	-	PUNCT
njb-29	98	32	r	r	PROPN
njb-29	98	33	,	,	PUNCT
njb-29	98	34	rmp155	rmp155	PROPN
njb-29	98	35	-	-	PUNCT
njb-29	98	36	r	r	PROPN
njb-29	98	37	and	and	CCONJ
njb-29	98	38	rmp240	rmp240	PROPN
njb-29	98	39	-	-	PUNCT
njb-29	98	40	r	r	NOUN
njb-29	98	41	were	be	AUX
njb-29	98	42	~1.7	~1.7	X
njb-29	98	43	,	,	PUNCT
njb-29	98	44	~1.6	~1.6	NUM
njb-29	98	45	,	,	PUNCT
njb-29	98	46	~1.5	~1.5	NUM
njb-29	98	47	,	,	PUNCT
njb-29	98	48	~2.7	~2.7	PUNCT
njb-29	98	49	,	,	PUNCT
njb-29	98	50	~2.0	~2.0	PUNCT
njb-29	98	51	,	,	PUNCT
njb-29	98	52	~1.8	~1.8	PUNCT
njb-29	98	53	,	,	PUNCT
njb-29	98	54	~1.8	~1.8	X
njb-29	98	55	,	,	PUNCT
njb-29	98	56	~2.0	~2.0	X
njb-29	98	57	and	and	CCONJ
njb-29	98	58	~1.7	~1.7	PUNCT
njb-29	98	59	-fold	-fold	VERB
njb-29	98	60	higher	high	ADJ
njb-29	98	61	respectively	respectively	ADV
njb-29	98	62	when	when	SCONJ
njb-29	98	63	compared	compare	VERB
njb-29	98	64	to	to	ADP
njb-29	98	65	the	the	DET
njb-29	98	66	sag	sag	PROPN
njb-29	98	67	-	-	PUNCT
njb-29	98	68	s	s	NOUN
njb-29	98	69	isolate	isolate	PROPN
njb-29	98	70	,	,	PUNCT
njb-29	98	71	2001	2001	NUM
njb-29	98	72	-	-	PUNCT
njb-29	98	73	s	s	PROPN
njb-29	98	74	(	(	PUNCT
njb-29	98	75	figure	figure	NOUN
njb-29	98	76	1a	1a	NUM
njb-29	98	77	)	)	PUNCT
njb-29	98	78	.	.	PUNCT
njb-29	99	1	similarly	similarly	ADV
njb-29	99	2	gsh	gsh	PROPN
njb-29	99	3	levels	level	NOUN
njb-29	99	4	showed	show	VERB
njb-29	99	5	significant	significant	ADJ
njb-29	99	6	increase	increase	NOUN
njb-29	99	7	in	in	ADP
njb-29	99	8	the	the	DET
njb-29	99	9	sag	sag	ADJ
njb-29	99	10	-	-	PUNCT
njb-29	99	11	r	r	NOUN
njb-29	99	12	isolates	isolate	NOUN
njb-29	99	13	,	,	PUNCT
njb-29	99	14	mc4	mc4	PROPN
njb-29	99	15	-	-	PUNCT
njb-29	99	16	r	r	PROPN
njb-29	99	17	(	(	PUNCT
njb-29	99	18	~2.7	~2.7	PUNCT
njb-29	99	19	-	-	NOUN
njb-29	99	20	fold	fold	ADV
njb-29	99	21	)	)	PUNCT
njb-29	99	22	,	,	PUNCT
njb-29	99	23	mc8	mc8	PROPN
njb-29	99	24	-	-	PUNCT
njb-29	99	25	r	r	NOUN
njb-29	99	26	(	(	PUNCT
njb-29	99	27	~3.6	~3.6	PUNCT
njb-29	99	28	-fold	-fold	NOUN
njb-29	99	29	)	)	PUNCT
njb-29	99	30	,	,	PUNCT
njb-29	99	31	mc9	mc9	PROPN
njb-29	99	32	-	-	PUNCT
njb-29	99	33	r	r	NOUN
njb-29	99	34	(	(	PUNCT
njb-29	99	35	~3.0	~3.0	PUNCT
njb-29	99	36	-fold	-fold	NOUN
njb-29	99	37	)	)	PUNCT
njb-29	99	38	,	,	PUNCT
njb-29	99	39	nr3a	nr3a	ADV
njb-29	99	40	-	-	PUNCT
njb-29	99	41	r	r	NOUN
njb-29	99	42	(	(	PUNCT
njb-29	99	43	~2.0	~2.0	ADJ
njb-29	99	44	fold	fold	ADJ
njb-29	99	45	)	)	PUNCT
njb-29	99	46	,	,	PUNCT
njb-29	99	47	rmp8	rmp8	PROPN
njb-29	99	48	-	-	PUNCT
njb-29	99	49	r	r	NOUN
njb-29	99	50	(	(	PUNCT
njb-29	99	51	~3.2	~3.2	PUNCT
njb-29	99	52	-fold	-fold	ADJ
njb-29	99	53	)	)	PUNCT
njb-29	99	54	,	,	PUNCT
njb-29	99	55	rmp19	rmp19	NOUN
njb-29	99	56	-	-	PUNCT
njb-29	99	57	r	r	NOUN
njb-29	99	58	(	(	PUNCT
njb-29	99	59	~2.5	~2.5	NUM
njb-29	99	60	-fold	-fold	NOUN
njb-29	99	61	)	)	PUNCT
njb-29	99	62	,	,	PUNCT
njb-29	99	63	rmp142	rmp142	PROPN
njb-29	99	64	-	-	PUNCT
njb-29	99	65	r	r	NOUN
njb-29	99	66	(	(	PUNCT
njb-29	99	67	~3.1	~3.1	X
njb-29	99	68	-fold	-fold	NOUN
njb-29	99	69	)	)	PUNCT
njb-29	99	70	,	,	PUNCT
njb-29	99	71	rmp155	rmp155	PROPN
njb-29	99	72	-	-	PUNCT
njb-29	99	73	r	r	NOUN
njb-29	99	74	(	(	PUNCT
njb-29	99	75	~2.4	~2.4	PUNCT
njb-29	99	76	-fold	-fold	ADJ
njb-29	99	77	)	)	PUNCT
njb-29	99	78	and	and	CCONJ
njb-29	99	79	rmp240	rmp240	PROPN
njb-29	99	80	-	-	PUNCT
njb-29	99	81	r	r	NOUN
njb-29	99	82	(	(	PUNCT
njb-29	99	83	~3.0	~3.0	PUNCT
njb-29	99	84	-fold	-fold	NOUN
njb-29	99	85	)	)	PUNCT
njb-29	99	86	when	when	SCONJ
njb-29	99	87	compared	compare	VERB
njb-29	99	88	to	to	ADP
njb-29	99	89	the	the	DET
njb-29	99	90	sag	sag	PROPN
njb-29	99	91	sensitive	sensitive	PROPN
njb-29	99	92	isolate	isolate	PROPN
njb-29	99	93	,	,	PUNCT
njb-29	99	94	2001	2001	NUM
njb-29	99	95	-	-	PUNCT
njb-29	99	96	s	s	NOUN
njb-29	99	97	(	(	PUNCT
njb-29	99	98	figure	figure	NOUN
njb-29	99	99	1b	1b	NUM
njb-29	99	100	)	)	PUNCT
njb-29	99	101	.	.	PUNCT
njb-29	100	1	a	a	DET
njb-29	100	2	sag	sag	PROPN
njb-29	100	3	-	-	PUNCT
njb-29	100	4	s	s	NOUN
njb-29	100	5	strain	strain	NOUN
njb-29	100	6	,	,	PUNCT
njb-29	100	7	rk1	rk1	PROPN
njb-29	100	8	-	-	PUNCT
njb-29	100	9	s	s	PROPN
njb-29	100	10	had	have	VERB
njb-29	100	11	glutathione	glutathione	NOUN
njb-29	100	12	levels	level	NOUN
njb-29	100	13	that	that	PRON
njb-29	100	14	were	be	AUX
njb-29	100	15	~2.1	~2.1	ADV
njb-29	100	16	-fold	-fold	NOUN
njb-29	100	17	higher	high	ADJ
njb-29	100	18	when	when	SCONJ
njb-29	100	19	compared	compare	VERB
njb-29	100	20	to	to	ADP
njb-29	100	21	the	the	DET
njb-29	100	22	sag	sag	PROPN
njb-29	100	23	sensitive	sensitive	PROPN
njb-29	100	24	isolate	isolate	PROPN
njb-29	100	25	,	,	PUNCT
njb-29	100	26	2001	2001	NUM
njb-29	100	27	-	-	PUNCT
njb-29	100	28	s.	s.	PROPN
njb-29	100	29	interestingly	interestingly	ADV
njb-29	100	30	,	,	PUNCT
njb-29	100	31	no	no	DET
njb-29	100	32	significant	significant	ADJ
njb-29	100	33	difference	difference	NOUN
njb-29	100	34	was	be	AUX
njb-29	100	35	observed	observe	VERB
njb-29	100	36	in	in	ADP
njb-29	100	37	the	the	DET
njb-29	100	38	trypanothione	trypanothione	NOUN
njb-29	100	39	levels	level	NOUN
njb-29	100	40	between	between	ADP
njb-29	100	41	the	the	DET
njb-29	100	42	sag	sag	PROPN
njb-29	100	43	-	-	PUNCT
njb-29	100	44	s	s	NOUN
njb-29	100	45	and	and	CCONJ
njb-29	100	46	sag	sag	ADJ
njb-29	100	47	-	-	PUNCT
njb-29	100	48	r	r	NOUN
njb-29	100	49	isolates	isolate	NOUN
njb-29	100	50	(	(	PUNCT
njb-29	100	51	figure	figure	NOUN
njb-29	100	52	1c	1c	NUM
njb-29	100	53	)	)	PUNCT
njb-29	100	54	.	.	PUNCT
njb-29	101	1	similar	similar	ADJ
njb-29	101	2	observation	observation	NOUN
njb-29	101	3	was	be	AUX
njb-29	101	4	made	make	VERB
njb-29	101	5	in	in	ADP
njb-29	101	6	our	our	PRON
njb-29	101	7	earlier	early	ADJ
njb-29	101	8	study	study	NOUN
njb-29	101	9	using	use	VERB
njb-29	101	10	a	a	DET
njb-29	101	11	small	small	ADJ
njb-29	101	12	set	set	NOUN
njb-29	101	13	of	of	ADP
njb-29	101	14	clinical	clinical	ADJ
njb-29	101	15	isolates	isolate	NOUN
njb-29	101	16	[	[	PUNCT
njb-29	101	17	23	23	NUM
njb-29	101	18	]	]	PUNCT
njb-29	101	19	.	.	PUNCT
njb-29	102	1	gene	gene	NOUN
njb-29	102	2	copy	copy	NOUN
njb-29	102	3	number	number	NOUN
njb-29	102	4	and	and	CCONJ
njb-29	102	5	expression	expression	NOUN
njb-29	102	6	profiling	profiling	NOUN
njb-29	102	7	of	of	ADP
njb-29	102	8	the	the	DET
njb-29	102	9	abc	abc	PROPN
njb-29	102	10	transporter	transporter	PROPN
njb-29	102	11	mrpa	mrpa	NOUN
njb-29	102	12	in	in	ADP
njb-29	102	13	sag	sag	PROPN
njb-29	102	14	-	-	PUNCT
njb-29	102	15	s	s	NOUN
njb-29	102	16	and	and	CCONJ
njb-29	102	17	sag	sag	ADJ
njb-29	102	18	-	-	PUNCT
njb-29	102	19	r	r	NOUN
njb-29	102	20	clinical	clinical	ADJ
njb-29	102	21	isolates	isolate	VERB
njb-29	102	22	our	our	PRON
njb-29	102	23	earlier	early	ADJ
njb-29	102	24	work	work	NOUN
njb-29	102	25	on	on	ADP
njb-29	102	26	the	the	DET
njb-29	102	27	clinical	clinical	ADJ
njb-29	102	28	kala	kala	PROPN
njb-29	102	29	azar	azar	PROPN
njb-29	102	30	l.	l.	PROPN
njb-29	102	31	donovani	donovani	PROPN
njb-29	102	32	isolates	isolate	VERB
njb-29	102	33	from	from	ADP
njb-29	102	34	india	india	PROPN
njb-29	102	35	showed	show	VERB
njb-29	102	36	mrpa	mrpa	PROPN
njb-29	102	37	overexpression	overexpression	NOUN
njb-29	102	38	as	as	ADP
njb-29	102	39	an	an	DET
njb-29	102	40	important	important	ADJ
njb-29	102	41	sag	sag	ADJ
njb-29	102	42	resistance	resistance	NOUN
njb-29	102	43	factor	factor	NOUN
njb-29	102	44	[	[	PUNCT
njb-29	102	45	23	23	NUM
njb-29	102	46	]	]	PUNCT
njb-29	102	47	.	.	PUNCT
njb-29	103	1	to	to	PART
njb-29	103	2	further	far	ADV
njb-29	103	3	validate	validate	VERB
njb-29	103	4	,	,	PUNCT
njb-29	103	5	the	the	DET
njb-29	103	6	role	role	NOUN
njb-29	103	7	of	of	ADP
njb-29	103	8	mrpa	mrpa	NOUN
njb-29	103	9	gene	gene	NOUN
njb-29	103	10	in	in	ADP
njb-29	103	11	antimony	antimony	ADJ
njb-29	103	12	resistance	resistance	NOUN
njb-29	103	13	phenotype	phenotype	NOUN
njb-29	103	14	,	,	PUNCT
njb-29	103	15	we	we	PRON
njb-29	103	16	checked	check	VERB
njb-29	103	17	the	the	DET
njb-29	103	18	amplification	amplification	NOUN
njb-29	103	19	of	of	ADP
njb-29	103	20	mrpa	mrpa	PROPN
njb-29	103	21	gene	gene	NOUN
njb-29	103	22	by	by	ADP
njb-29	103	23	southern	southern	ADJ
njb-29	103	24	blot	blot	NOUN
njb-29	103	25	hybridization	hybridization	NOUN
njb-29	103	26	.	.	PUNCT
njb-29	104	1	southern	southern	ADJ
njb-29	104	2	blot	blot	PROPN
njb-29	104	3	hybridization	hybridization	NOUN
njb-29	104	4	of	of	ADP
njb-29	104	5	total	total	ADJ
njb-29	104	6	genomic	genomic	ADJ
njb-29	104	7	dna	dna	NOUN
njb-29	104	8	digested	digest	VERB
njb-29	104	9	with	with	ADP
njb-29	104	10	hindiii	hindiii	NOUN
njb-29	104	11	followed	follow	VERB
njb-29	104	12	by	by	ADP
njb-29	104	13	hybridization	hybridization	NOUN
njb-29	104	14	with	with	ADP
njb-29	104	15	nepal	nepal	ADJ
njb-29	104	16	journal	journal	NOUN
njb-29	104	17	of	of	ADP
njb-29	104	18	biotechnology	biotechnology	NOUN
njb-29	104	19	.	.	PUNCT
njb-29	105	1	d	d	X
njb-29	105	2	e	e	PROPN
njb-29	105	3	c	c	PROPN
njb-29	105	4	.	.	PUNCT
njb-29	106	1	2	2	NUM
njb-29	106	2	0	0	NUM
njb-29	106	3	1	1	NUM
njb-29	106	4	6	6	NUM
njb-29	106	5	vol	vol	NOUN
njb-29	106	6	.	.	PROPN
njb-29	107	1	4	4	NUM
njb-29	107	2	,	,	PUNCT
njb-29	107	3	no	no	NOUN
njb-29	107	4	.	.	NOUN
njb-29	107	5	1	1	NUM
njb-29	107	6	:	:	SYM
njb-29	107	7	1	1	NUM
njb-29	107	8	-	-	SYM
njb-29	107	9	13	13	NUM
njb-29	107	10	maharjan	maharjan	NOUN
njb-29	107	11	et	et	NOUN
njb-29	107	12	al	al	PROPN
njb-29	107	13	.	.	PUNCT
njb-29	108	1	©	©	PROPN
njb-29	108	2	njb	njb	PROPN
njb-29	108	3	,	,	PUNCT
njb-29	108	4	biotechnology	biotechnology	NOUN
njb-29	108	5	society	society	NOUN
njb-29	108	6	of	of	ADP
njb-29	108	7	nepal	nepal	ADJ
njb-29	108	8	5	5	NUM
njb-29	108	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	108	10	figure	figure	NOUN
njb-29	108	11	1	1	NUM
njb-29	108	12	:	:	PUNCT
njb-29	108	13	intracellular	intracellular	ADJ
njb-29	108	14	levels	level	NOUN
njb-29	108	15	of	of	ADP
njb-29	108	16	thiols	thiols	PROPN
njb-29	108	17	,	,	PUNCT
njb-29	108	18	cysteine	cysteine	NOUN
njb-29	108	19	,	,	PUNCT
njb-29	108	20	glutathione	glutathione	PROPN
njb-29	108	21	and	and	CCONJ
njb-29	108	22	trypanothione	trypanothione	PROPN
njb-29	108	23	in	in	ADP
njb-29	108	24	sag	sag	PROPN
njb-29	108	25	-	-	PUNCT
njb-29	108	26	s	s	NOUN
njb-29	108	27	and	and	CCONJ
njb-29	108	28	sag	sag	ADJ
njb-29	108	29	-	-	PUNCT
njb-29	108	30	r	r	NOUN
njb-29	108	31	l.	l.	PROPN
njb-29	108	32	donovani	donovani	PROPN
njb-29	108	33	vl	vl	PROPN
njb-29	108	34	and	and	CCONJ
njb-29	108	35	pkdl	pkdl	PROPN
njb-29	108	36	clinical	clinical	ADJ
njb-29	108	37	isolates	isolate	NOUN
njb-29	108	38	.	.	PUNCT
njb-29	109	1	a	a	DET
njb-29	109	2	:	:	PUNCT
njb-29	109	3	cysteine	cysteine	PROPN
njb-29	109	4	levels	levels	PROPN
njb-29	109	5	b	b	PROPN
njb-29	109	6	:	:	PUNCT
njb-29	109	7	glutathione	glutathione	PROPN
njb-29	109	8	levels	level	NOUN
njb-29	109	9	c	c	PROPN
njb-29	109	10	:	:	PUNCT
njb-29	109	11	trypanothione	trypanothione	PROPN
njb-29	109	12	levels	levels	PROPN
njb-29	109	13	.	.	PUNCT
njb-29	110	1	thiols	thiols	PROPN
njb-29	110	2	were	be	AUX
njb-29	110	3	derivatized	derivatize	VERB
njb-29	110	4	with	with	ADP
njb-29	110	5	monobromobimane	monobromobimane	NOUN
njb-29	110	6	and	and	CCONJ
njb-29	110	7	separated	separate	VERB
njb-29	110	8	by	by	ADP
njb-29	110	9	high	high	ADJ
njb-29	110	10	-	-	PUNCT
njb-29	110	11	perfomance	perfomance	NOUN
njb-29	110	12	liquid	liquid	NOUN
njb-29	110	13	chromatography	chromatography	NOUN
njb-29	110	14	(	(	PUNCT
njb-29	110	15	hplc	hplc	NOUN
njb-29	110	16	)	)	PUNCT
njb-29	110	17	.	.	PUNCT
njb-29	111	1	each	each	DET
njb-29	111	2	value	value	NOUN
njb-29	111	3	is	be	AUX
njb-29	111	4	the	the	DET
njb-29	111	5	mean	mean	NOUN
njb-29	111	6			PROPN
njb-29	111	7	sd	sd	NOUN
njb-29	111	8	of	of	ADP
njb-29	111	9	triplicates	triplicate	NOUN
njb-29	111	10	from	from	ADP
njb-29	111	11	two	two	NUM
njb-29	111	12	independent	independent	ADJ
njb-29	111	13	experiments	experiment	NOUN
njb-29	111	14	.	.	PUNCT
njb-29	112	1	a	a	PRON
njb-29	112	2	indicates	indicate	VERB
njb-29	112	3	p	p	X
njb-29	112	4	<	<	X
njb-29	112	5	0.01	0.01	NUM
njb-29	112	6	;	;	PUNCT
njb-29	112	7	b	b	X
njb-29	112	8	indicates	indicate	VERB
njb-29	112	9	p	p	X
njb-29	112	10	<	<	X
njb-29	112	11	0.001	0.001	NUM
njb-29	112	12	;	;	PUNCT
njb-29	112	13	c	c	X
njb-29	112	14	indicates	indicate	VERB
njb-29	112	15	p	p	X
njb-29	112	16	<	<	X
njb-29	112	17	0.0004	0.0004	NUM
njb-29	112	18	when	when	SCONJ
njb-29	112	19	compared	compare	VERB
njb-29	112	20	to	to	ADP
njb-29	112	21	2001	2001	NUM
njb-29	112	22	-	-	PUNCT
njb-29	112	23	s	s	NOUN
njb-29	112	24	respectively	respectively	ADV
njb-29	112	25	mrpa	mrpa	ADP
njb-29	112	26	specific	specific	ADJ
njb-29	112	27	probe	probe	NOUN
njb-29	112	28	was	be	AUX
njb-29	112	29	done	do	VERB
njb-29	112	30	.	.	PUNCT
njb-29	113	1	sag	sag	ADJ
njb-29	113	2	-	-	PUNCT
njb-29	113	3	sensitive	sensitive	ADJ
njb-29	113	4	and	and	CCONJ
njb-29	113	5	sag	sag	ADJ
njb-29	113	6	-	-	PUNCT
njb-29	113	7	resistant	resistant	ADJ
njb-29	113	8	field	field	NOUN
njb-29	113	9	isolates	isolate	NOUN
njb-29	113	10	showed	show	VERB
njb-29	113	11	a	a	DET
njb-29	113	12	single	single	ADJ
njb-29	113	13	hybridizing	hybridizing	NOUN
njb-29	113	14	fragment	fragment	NOUN
njb-29	113	15	of	of	ADP
njb-29	113	16	11	11	NUM
njb-29	113	17	-	-	PUNCT
njb-29	113	18	kb	kb	NOUN
njb-29	113	19	indicating	indicate	VERB
njb-29	113	20	that	that	SCONJ
njb-29	113	21	mrpa	mrpa	NOUN
njb-29	113	22	gene	gene	NOUN
njb-29	113	23	exist	exist	VERB
njb-29	113	24	as	as	ADP
njb-29	113	25	a	a	DET
njb-29	113	26	single	single	ADJ
njb-29	113	27	copy	copy	NOUN
njb-29	113	28	gene	gene	NOUN
njb-29	113	29	in	in	ADP
njb-29	113	30	all	all	DET
njb-29	113	31	the	the	DET
njb-29	113	32	isolates	isolate	NOUN
njb-29	113	33	(	(	PUNCT
njb-29	113	34	figure	figure	NOUN
njb-29	113	35	2a	2a	NUM
njb-29	113	36	)	)	PUNCT
njb-29	113	37	.	.	PUNCT
njb-29	114	1	quantitation	quantitation	NOUN
njb-29	114	2	of	of	ADP
njb-29	114	3	the	the	DET
njb-29	114	4	southern	southern	ADJ
njb-29	114	5	blot	blot	PROPN
njb-29	114	6	hybridization	hybridization	NOUN
njb-29	114	7	signal	signal	NOUN
njb-29	114	8	was	be	AUX
njb-29	114	9	done	do	VERB
njb-29	114	10	using	use	VERB
njb-29	114	11	imagequant	imagequant	ADJ
njb-29	114	12	5.2	5.2	NUM
njb-29	114	13	(	(	PUNCT
njb-29	114	14	molecular	molecular	ADJ
njb-29	114	15	dynamics	dynamic	NOUN
njb-29	114	16	)	)	PUNCT
njb-29	114	17	and	and	CCONJ
njb-29	114	18	the	the	DET
njb-29	114	19	fold	fold	ADJ
njb-29	114	20	difference	difference	NOUN
njb-29	114	21	in	in	ADP
njb-29	114	22	dna	dna	NOUN
njb-29	114	23	copy	copy	NOUN
njb-29	114	24	number	number	NOUN
njb-29	114	25	of	of	ADP
njb-29	114	26	the	the	DET
njb-29	114	27	isolates	isolate	NOUN
njb-29	114	28	with	with	ADP
njb-29	114	29	the	the	DET
njb-29	114	30	ag83	ag83	PROPN
njb-29	114	31	-	-	PUNCT
njb-29	114	32	s	s	PROPN
njb-29	114	33	or	or	CCONJ
njb-29	114	34	2001	2001	NUM
njb-29	114	35	-	-	PUNCT
njb-29	114	36	s	s	PROPN
njb-29	114	37	was	be	AUX
njb-29	114	38	calculated	calculate	VERB
njb-29	114	39	.	.	PUNCT
njb-29	115	1	amplification	amplification	NOUN
njb-29	115	2	of	of	ADP
njb-29	115	3	mrpa	mrpa	PROPN
njb-29	115	4	gene	gene	NOUN
njb-29	115	5	was	be	AUX
njb-29	115	6	observed	observe	VERB
njb-29	115	7	in	in	ADP
njb-29	115	8	the	the	DET
njb-29	115	9	resistant	resistant	ADJ
njb-29	115	10	isolates	isolate	NOUN
njb-29	115	11	,	,	PUNCT
njb-29	115	12	mc4	mc4	PROPN
njb-29	115	13	-	-	PUNCT
njb-29	115	14	r	r	PROPN
njb-29	115	15	,	,	PUNCT
njb-29	115	16	mc8r	mc8r	PROPN
njb-29	115	17	,	,	PUNCT
njb-29	115	18	mc9	mc9	PROPN
njb-29	115	19	-	-	PUNCT
njb-29	115	20	r	r	PROPN
njb-29	115	21	,	,	PUNCT
njb-29	115	22	rmp19	rmp19	NOUN
njb-29	115	23	-	-	PUNCT
njb-29	115	24	r	r	NOUN
njb-29	115	25	,	,	PUNCT
njb-29	115	26	rmp142	rmp142	PROPN
njb-29	115	27	-	-	PUNCT
njb-29	115	28	r	r	PROPN
njb-29	115	29	,	,	PUNCT
njb-29	115	30	rmp155	rmp155	PROPN
njb-29	115	31	-	-	PUNCT
njb-29	115	32	r	r	PROPN
njb-29	115	33	and	and	CCONJ
njb-29	115	34	nepal	nepal	ADJ
njb-29	115	35	journal	journal	NOUN
njb-29	115	36	of	of	ADP
njb-29	115	37	biotechnology	biotechnology	NOUN
njb-29	115	38	.	.	PUNCT
njb-29	116	1	d	d	X
njb-29	116	2	e	e	PROPN
njb-29	116	3	c	c	PROPN
njb-29	116	4	.	.	PUNCT
njb-29	117	1	2	2	NUM
njb-29	117	2	0	0	NUM
njb-29	117	3	1	1	NUM
njb-29	117	4	6	6	NUM
njb-29	117	5	vol	vol	NOUN
njb-29	117	6	.	.	PROPN
njb-29	118	1	4	4	NUM
njb-29	118	2	,	,	PUNCT
njb-29	118	3	no	no	NOUN
njb-29	118	4	.	.	NOUN
njb-29	118	5	1	1	NUM
njb-29	118	6	:	:	SYM
njb-29	118	7	1	1	NUM
njb-29	118	8	-	-	SYM
njb-29	118	9	13	13	NUM
njb-29	118	10	maharjan	maharjan	NOUN
njb-29	118	11	et	et	NOUN
njb-29	118	12	al	al	PROPN
njb-29	118	13	.	.	PUNCT
njb-29	119	1	©	©	PROPN
njb-29	119	2	njb	njb	PROPN
njb-29	119	3	,	,	PUNCT
njb-29	119	4	biotechnology	biotechnology	NOUN
njb-29	119	5	society	society	NOUN
njb-29	119	6	of	of	ADP
njb-29	119	7	nepal	nepal	ADJ
njb-29	119	8	6	6	NUM
njb-29	119	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	119	10	figure	figure	NOUN
njb-29	119	11	2	2	NUM
njb-29	119	12	:	:	PUNCT
njb-29	119	13	a	a	DET
njb-29	119	14	:	:	PUNCT
njb-29	119	15	southern	southern	ADJ
njb-29	119	16	blot	blot	NOUN
njb-29	119	17	analysis	analysis	NOUN
njb-29	119	18	of	of	ADP
njb-29	119	19	mrpa	mrpa	PROPN
njb-29	119	20	and	and	CCONJ
njb-29	119	21	ptr1	ptr1	PROPN
njb-29	119	22	genes	gene	NOUN
njb-29	119	23	in	in	ADP
njb-29	119	24	sag	sag	PROPN
njb-29	119	25	-	-	PUNCT
njb-29	119	26	s	s	NOUN
njb-29	119	27	and	and	CCONJ
njb-29	119	28	sag	sag	ADJ
njb-29	119	29	-	-	PUNCT
njb-29	119	30	r	r	NOUN
njb-29	119	31	l.	l.	PROPN
njb-29	119	32	donovani	donovani	PROPN
njb-29	119	33	vl	vl	PROPN
njb-29	119	34	and	and	CCONJ
njb-29	119	35	pkdl	pkdl	PROPN
njb-29	119	36	clinical	clinical	ADJ
njb-29	119	37	isolates	isolate	NOUN
njb-29	119	38	.	.	PUNCT
njb-29	120	1	total	total	ADJ
njb-29	120	2	genomic	genomic	ADJ
njb-29	120	3	dna	dna	NOUN
njb-29	120	4	of	of	ADP
njb-29	120	5	isolates	isolate	NOUN
njb-29	120	6	were	be	AUX
njb-29	120	7	digested	digest	VERB
njb-29	120	8	with	with	ADP
njb-29	120	9	hindiii	hindiii	PROPN
njb-29	120	10	,	,	PUNCT
njb-29	120	11	electrophoresed	electrophorese	VERB
njb-29	120	12	,	,	PUNCT
njb-29	120	13	blotted	blot	VERB
njb-29	120	14	and	and	CCONJ
njb-29	120	15	hybridized	hybridize	VERB
njb-29	120	16	with	with	ADP
njb-29	120	17	a	a	DET
njb-29	120	18	mrpa	mrpa	ADV
njb-29	120	19	specific	specific	ADJ
njb-29	120	20	probe	probe	NOUN
njb-29	120	21	of	of	ADP
njb-29	120	22	400	400	NUM
njb-29	120	23	-	-	PUNCT
njb-29	120	24	bp	bp	NOUN
njb-29	120	25	and	and	CCONJ
njb-29	120	26	6	6	NUM
njb-29	120	27	kb	kb	PROPN
njb-29	120	28	5’-ptr1	5’-ptr1	PROPN
njb-29	120	29	specific	specific	ADJ
njb-29	120	30	probe	probe	NOUN
njb-29	120	31	.	.	PUNCT
njb-29	121	1	the	the	DET
njb-29	121	2	size	size	NOUN
njb-29	121	3	of	of	ADP
njb-29	121	4	the	the	DET
njb-29	121	5	hybridizing	hybridize	VERB
njb-29	121	6	bands	band	NOUN
njb-29	121	7	was	be	AUX
njb-29	121	8	determined	determine	VERB
njb-29	121	9	using	use	VERB
njb-29	121	10	hindiii	hindiii	PROPN
njb-29	121	11	digested	digest	VERB
njb-29	121	12	lambda	lambda	PROPN
njb-29	121	13	dna	dna	PROPN
njb-29	121	14	.	.	PUNCT
njb-29	122	1	the	the	DET
njb-29	122	2	blot	blot	NOUN
njb-29	122	3	was	be	AUX
njb-29	122	4	rehybridized	rehybridize	VERB
njb-29	122	5	with	with	ADP
njb-29	122	6	α	α	PRON
njb-29	122	7	-	-	PUNCT
njb-29	122	8	tubulin	tubulin	NOUN
njb-29	122	9	probe	probe	NOUN
njb-29	122	10	to	to	PART
njb-29	122	11	monitor	monitor	VERB
njb-29	122	12	the	the	DET
njb-29	122	13	amount	amount	NOUN
njb-29	122	14	of	of	ADP
njb-29	122	15	digested	digested	ADJ
njb-29	122	16	dna	dna	NOUN
njb-29	122	17	layered	layer	VERB
njb-29	122	18	on	on	ADP
njb-29	122	19	the	the	DET
njb-29	122	20	gel	gel	NOUN
njb-29	122	21	.	.	PUNCT
njb-29	123	1	quantitation	quantitation	NOUN
njb-29	123	2	of	of	ADP
njb-29	123	3	southern	southern	ADJ
njb-29	123	4	blot	blot	NOUN
njb-29	123	5	was	be	AUX
njb-29	123	6	done	do	VERB
njb-29	123	7	by	by	ADP
njb-29	123	8	image	image	NOUN
njb-29	123	9	-	-	PUNCT
njb-29	123	10	quant	quant	ADJ
njb-29	123	11	software	software	NOUN
njb-29	123	12	5.2	5.2	NUM
njb-29	123	13	(	(	PUNCT
njb-29	123	14	molecular	molecular	ADJ
njb-29	123	15	dynamics	dynamic	NOUN
njb-29	123	16	)	)	PUNCT
njb-29	123	17	and	and	CCONJ
njb-29	123	18	the	the	DET
njb-29	123	19	fold	fold	ADJ
njb-29	123	20	difference	difference	NOUN
njb-29	123	21	in	in	ADP
njb-29	123	22	dna	dna	NOUN
njb-29	123	23	copy	copy	NOUN
njb-29	123	24	number	number	NOUN
njb-29	123	25	of	of	ADP
njb-29	123	26	mrpa	mrpa	NOUN
njb-29	123	27	is	be	AUX
njb-29	123	28	presented	present	VERB
njb-29	123	29	below	below	ADP
njb-29	123	30	each	each	DET
njb-29	123	31	blot	blot	NOUN
njb-29	123	32	.	.	PUNCT
njb-29	124	1	b	b	X
njb-29	124	2	:	:	PUNCT
njb-29	124	3	southern	southern	ADJ
njb-29	124	4	blot	blot	NOUN
njb-29	124	5	analysis	analysis	NOUN
njb-29	124	6	of	of	ADP
njb-29	124	7	the	the	DET
njb-29	124	8	pulse	pulse	NOUN
njb-29	124	9	field	field	NOUN
njb-29	124	10	gel	gel	NOUN
njb-29	124	11	electrophoresis	electrophoresis	NOUN
njb-29	124	12	of	of	ADP
njb-29	124	13	sag	sag	ADJ
njb-29	124	14	-	-	PUNCT
njb-29	124	15	sensitive	sensitive	ADJ
njb-29	124	16	(	(	PUNCT
njb-29	124	17	sag	sag	PROPN
njb-29	124	18	-	-	PUNCT
njb-29	124	19	s	s	PROPN
njb-29	124	20	)	)	PUNCT
njb-29	124	21	and	and	CCONJ
njb-29	124	22	sagresistant	sagresistant	ADJ
njb-29	124	23	(	(	PUNCT
njb-29	124	24	sag	sag	ADJ
njb-29	124	25	-	-	PUNCT
njb-29	124	26	r	r	NOUN
njb-29	124	27	)	)	PUNCT
njb-29	124	28	isolates	isolate	NOUN
njb-29	124	29	of	of	ADP
njb-29	124	30	leishmania	leishmania	PROPN
njb-29	124	31	donovani	donovani	PROPN
njb-29	124	32	chromosomes	chromosomes	PROPN
njb-29	124	33	.	.	PUNCT
njb-29	125	1	agarose	agarose	NOUN
njb-29	125	2	blocks	block	NOUN
njb-29	125	3	containing	contain	VERB
njb-29	125	4	chromosomal	chromosomal	ADJ
njb-29	125	5	dnas	dna	NOUN
njb-29	125	6	of	of	ADP
njb-29	125	7	promatigotes	promatigote	NOUN
njb-29	125	8	of	of	ADP
njb-29	125	9	l.	l.	PROPN
njb-29	125	10	donovani	donovani	PROPN
njb-29	125	11	clinical	clinical	ADJ
njb-29	125	12	isolates	isolate	NOUN
njb-29	125	13	were	be	AUX
njb-29	125	14	prepared	prepare	VERB
njb-29	125	15	and	and	CCONJ
njb-29	125	16	subjected	subject	VERB
njb-29	125	17	to	to	ADP
njb-29	125	18	pulsed	pulse	VERB
njb-29	125	19	field	field	NOUN
njb-29	125	20	gel	gel	NOUN
njb-29	125	21	electrophoresis	electrophoresis	NOUN
njb-29	125	22	for	for	ADP
njb-29	125	23	24	24	NUM
njb-29	125	24	hours	hour	NOUN
njb-29	125	25	run	run	VERB
njb-29	125	26	time	time	NOUN
njb-29	125	27	and	and	CCONJ
njb-29	125	28	hybridized	hybridize	VERB
njb-29	125	29	with	with	ADP
njb-29	125	30	a	a	DET
njb-29	125	31	mrpa	mrpa	ADV
njb-29	125	32	specific	specific	ADJ
njb-29	125	33	probe	probe	NOUN
njb-29	125	34	of	of	ADP
njb-29	125	35	400	400	NUM
njb-29	125	36	-	-	PUNCT
njb-29	125	37	bp	bp	PROPN
njb-29	125	38	.	.	PROPN
njb-29	125	39	c	c	X
njb-29	125	40	:	:	PUNCT
njb-29	125	41	real	real	ADJ
njb-29	125	42	time	time	NOUN
njb-29	125	43	rt	rt	PROPN
njb-29	125	44	-	-	PUNCT
njb-29	125	45	pcr	pcr	NOUN
njb-29	125	46	expression	expression	NOUN
njb-29	125	47	analysis	analysis	NOUN
njb-29	125	48	of	of	ADP
njb-29	125	49	mrpa	mrpa	PROPN
njb-29	125	50	gene	gene	NOUN
njb-29	125	51	in	in	ADP
njb-29	125	52	l.	l.	PROPN
njb-29	125	53	donovani	donovani	PROPN
njb-29	125	54	clinical	clinical	ADJ
njb-29	125	55	isolates	isolate	NOUN
njb-29	125	56	.	.	PUNCT
njb-29	126	1	mrpa	mrpa	PROPN
njb-29	126	2	rna	rna	NOUN
njb-29	126	3	expression	expression	NOUN
njb-29	126	4	ratios	ratio	NOUN
njb-29	126	5	in	in	ADP
njb-29	126	6	promastigotes	promastigote	NOUN
njb-29	126	7	of	of	ADP
njb-29	126	8	sag	sag	ADJ
njb-29	126	9	-resistant	-resistant	ADJ
njb-29	126	10	isolates	isolate	NOUN
njb-29	126	11	are	be	AUX
njb-29	126	12	relative	relative	ADJ
njb-29	126	13	to	to	ADP
njb-29	126	14	the	the	DET
njb-29	126	15	sag	sag	ADJ
njb-29	126	16	-	-	PUNCT
njb-29	126	17	sensitive	sensitive	ADJ
njb-29	126	18	isolate	isolate	NOUN
njb-29	126	19	(	(	PUNCT
njb-29	126	20	2001	2001	NUM
njb-29	126	21	-	-	PUNCT
njb-29	126	22	s	s	PROPN
njb-29	126	23	)	)	PUNCT
njb-29	126	24	.	.	PUNCT
njb-29	127	1	the	the	DET
njb-29	127	2	graph	graph	NOUN
njb-29	127	3	represents	represent	VERB
njb-29	127	4	mean	mean	NOUN
njb-29	127	5	of	of	ADP
njb-29	127	6	three	three	NUM
njb-29	127	7	independent	independent	ADJ
njb-29	127	8	experiments	experiment	NOUN
njb-29	127	9	performed	perform	VERB
njb-29	127	10	from	from	ADP
njb-29	127	11	three	three	NUM
njb-29	127	12	different	different	ADJ
njb-29	127	13	rna	rna	PROPN
njb-29	127	14	preparations	preparation	NOUN
njb-29	127	15	.	.	PUNCT
njb-29	128	1	nepal	nepal	ADJ
njb-29	128	2	journal	journal	PROPN
njb-29	128	3	of	of	ADP
njb-29	128	4	biotechnology	biotechnology	NOUN
njb-29	128	5	.	.	PUNCT
njb-29	129	1	d	d	X
njb-29	129	2	e	e	PROPN
njb-29	129	3	c	c	PROPN
njb-29	129	4	.	.	PUNCT
njb-29	130	1	2	2	NUM
njb-29	130	2	0	0	NUM
njb-29	130	3	1	1	NUM
njb-29	130	4	6	6	NUM
njb-29	130	5	vol	vol	NOUN
njb-29	130	6	.	.	PROPN
njb-29	131	1	4	4	NUM
njb-29	131	2	,	,	PUNCT
njb-29	131	3	no	no	NOUN
njb-29	131	4	.	.	NOUN
njb-29	131	5	1	1	NUM
njb-29	131	6	:	:	SYM
njb-29	131	7	1	1	NUM
njb-29	131	8	-	-	SYM
njb-29	131	9	13	13	NUM
njb-29	131	10	maharjan	maharjan	NOUN
njb-29	131	11	et	et	NOUN
njb-29	131	12	al	al	PROPN
njb-29	131	13	.	.	PUNCT
njb-29	132	1	©	©	PROPN
njb-29	132	2	njb	njb	PROPN
njb-29	132	3	,	,	PUNCT
njb-29	132	4	biotechnology	biotechnology	NOUN
njb-29	132	5	society	society	NOUN
njb-29	132	6	of	of	ADP
njb-29	132	7	nepal	nepal	ADJ
njb-29	132	8	7	7	NUM
njb-29	132	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	132	10	figure	figure	NOUN
njb-29	132	11	3	3	NUM
njb-29	132	12	:	:	PUNCT
njb-29	132	13	a	a	PRON
njb-29	132	14	:	:	PUNCT
njb-29	132	15	characterization	characterization	NOUN
njb-29	132	16	of	of	ADP
njb-29	132	17	odc	odc	PROPN
njb-29	132	18	gene	gene	NOUN
njb-29	132	19	in	in	ADP
njb-29	132	20	sag	sag	PROPN
njb-29	132	21	-	-	PUNCT
njb-29	132	22	s	s	NOUN
njb-29	132	23	and	and	CCONJ
njb-29	132	24	sag	sag	ADJ
njb-29	132	25	-	-	PUNCT
njb-29	132	26	r	r	NOUN
njb-29	132	27	isolates	isolate	NOUN
njb-29	132	28	l.	l.	PROPN
njb-29	132	29	donovani	donovani	PROPN
njb-29	132	30	vl	vl	PROPN
njb-29	132	31	and	and	CCONJ
njb-29	132	32	pkdl	pkdl	PROPN
njb-29	132	33	clinical	clinical	ADJ
njb-29	132	34	isolates	isolate	NOUN
njb-29	132	35	.	.	PUNCT
njb-29	133	1	genomic	genomic	ADJ
njb-29	133	2	dnas	dna	NOUN
njb-29	133	3	were	be	AUX
njb-29	133	4	isolated	isolate	VERB
njb-29	133	5	and	and	CCONJ
njb-29	133	6	digested	digest	VERB
njb-29	133	7	with	with	ADP
njb-29	133	8	hindiii	hindiii	NOUN
njb-29	133	9	and	and	CCONJ
njb-29	133	10	hybridized	hybridize	VERB
njb-29	133	11	with	with	ADP
njb-29	133	12	a	a	DET
njb-29	133	13	full	full	ADJ
njb-29	133	14	-	-	PUNCT
njb-29	133	15	length	length	NOUN
njb-29	133	16	odc	odc	VERB
njb-29	133	17	specific	specific	ADJ
njb-29	133	18	probe	probe	NOUN
njb-29	133	19	,	,	PUNCT
njb-29	133	20	derived	derive	VERB
njb-29	133	21	from	from	ADP
njb-29	133	22	the	the	DET
njb-29	133	23	l.	l.	PROPN
njb-29	133	24	donovani	donovani	PROPN
njb-29	133	25	odc	odc	PROPN
njb-29	133	26	gene	gene	NOUN
njb-29	133	27	.	.	PUNCT
njb-29	134	1	the	the	DET
njb-29	134	2	sizes	size	NOUN
njb-29	134	3	of	of	ADP
njb-29	134	4	the	the	DET
njb-29	134	5	hybridizing	hybridize	VERB
njb-29	134	6	bands	band	NOUN
njb-29	134	7	were	be	AUX
njb-29	134	8	determined	determine	VERB
njb-29	134	9	using	use	VERB
njb-29	134	10	hindiii	hindiii	PROPN
njb-29	134	11	digested	digest	VERB
njb-29	134	12	lambda	lambda	PROPN
njb-29	134	13	dna	dna	NOUN
njb-29	134	14	marker	marker	NOUN
njb-29	134	15	.	.	PUNCT
njb-29	135	1	the	the	DET
njb-29	135	2	blot	blot	NOUN
njb-29	135	3	was	be	AUX
njb-29	135	4	rehybridized	rehybridize	VERB
njb-29	135	5	with	with	ADP
njb-29	135	6	α	α	PRON
njb-29	135	7	-	-	PUNCT
njb-29	135	8	tubulin	tubulin	NOUN
njb-29	135	9	probe	probe	NOUN
njb-29	135	10	to	to	PART
njb-29	135	11	monitor	monitor	VERB
njb-29	135	12	the	the	DET
njb-29	135	13	amount	amount	NOUN
njb-29	135	14	of	of	ADP
njb-29	135	15	digested	digested	ADJ
njb-29	135	16	dna	dna	NOUN
njb-29	135	17	layered	layer	VERB
njb-29	135	18	on	on	ADP
njb-29	135	19	the	the	DET
njb-29	135	20	gel	gel	NOUN
njb-29	135	21	.	.	PUNCT
njb-29	136	1	b	b	X
njb-29	136	2	:	:	PUNCT
njb-29	136	3	real	real	ADJ
njb-29	136	4	time	time	NOUN
njb-29	136	5	rt	rt	PROPN
njb-29	136	6	-	-	PUNCT
njb-29	136	7	pcr	pcr	NOUN
njb-29	136	8	expression	expression	NOUN
njb-29	136	9	analysis	analysis	NOUN
njb-29	136	10	of	of	ADP
njb-29	136	11	odc	odc	PROPN
njb-29	136	12	in	in	ADP
njb-29	136	13	l.	l.	PROPN
njb-29	136	14	donovani	donovani	PROPN
njb-29	136	15	clinical	clinical	ADJ
njb-29	136	16	isolates	isolate	NOUN
njb-29	136	17	.	.	PUNCT
njb-29	137	1	odc	odc	PROPN
njb-29	137	2	rna	rna	PROPN
njb-29	137	3	expression	expression	NOUN
njb-29	137	4	ratios	ratio	NOUN
njb-29	137	5	in	in	ADP
njb-29	137	6	the	the	DET
njb-29	137	7	sagresistant	sagresistant	ADJ
njb-29	137	8	isolates	isolate	NOUN
njb-29	137	9	are	be	AUX
njb-29	137	10	relative	relative	ADJ
njb-29	137	11	to	to	ADP
njb-29	137	12	the	the	DET
njb-29	137	13	sag	sag	ADJ
njb-29	137	14	-	-	PUNCT
njb-29	137	15	sensitive	sensitive	ADJ
njb-29	137	16	isolate	isolate	NOUN
njb-29	137	17	,	,	PUNCT
njb-29	137	18	2001	2001	NUM
njb-29	137	19	-	-	PUNCT
njb-29	137	20	s.	s.	PROPN
njb-29	137	21	results	result	NOUN
njb-29	137	22	are	be	AUX
njb-29	137	23	mean	mean	ADJ
njb-29	137	24	of	of	ADP
njb-29	137	25	three	three	NUM
njb-29	137	26	independent	independent	ADJ
njb-29	137	27	experiments	experiment	NOUN
njb-29	137	28	performed	perform	VERB
njb-29	137	29	from	from	ADP
njb-29	137	30	three	three	NUM
njb-29	137	31	different	different	ADJ
njb-29	137	32	rna	rna	PROPN
njb-29	137	33	preparations	preparation	NOUN
njb-29	137	34	.	.	PUNCT
njb-29	138	1	rmp240	rmp240	PROPN
njb-29	138	2	-	-	PUNCT
njb-29	138	3	r	r	NOUN
njb-29	138	4	(	(	PUNCT
njb-29	138	5	figure	figure	NOUN
njb-29	138	6	2a	2a	NUM
njb-29	138	7	)	)	PUNCT
njb-29	138	8	.	.	PUNCT
njb-29	139	1	no	no	DET
njb-29	139	2	amplification	amplification	NOUN
njb-29	139	3	was	be	AUX
njb-29	139	4	observed	observe	VERB
njb-29	139	5	in	in	ADP
njb-29	139	6	the	the	DET
njb-29	139	7	resistant	resistant	ADJ
njb-29	139	8	isolates	isolate	NOUN
njb-29	139	9	,	,	PUNCT
njb-29	139	10	nr3a	nr3a	ADV
njb-29	139	11	-	-	PUNCT
njb-29	139	12	r	r	NOUN
njb-29	139	13	and	and	CCONJ
njb-29	139	14	rmp8	rmp8	PROPN
njb-29	139	15	-	-	PUNCT
njb-29	139	16	r	r	NOUN
njb-29	139	17	(	(	PUNCT
njb-29	139	18	figure	figure	NOUN
njb-29	139	19	2a	2a	NUM
njb-29	139	20	)	)	PUNCT
njb-29	139	21	.	.	PUNCT
njb-29	140	1	the	the	DET
njb-29	140	2	amplification	amplification	NOUN
njb-29	140	3	observed	observe	VERB
njb-29	140	4	in	in	ADP
njb-29	140	5	the	the	DET
njb-29	140	6	resistant	resistant	ADJ
njb-29	140	7	isolates	isolate	NOUN
njb-29	140	8	was	be	AUX
njb-29	140	9	further	far	ADV
njb-29	140	10	analyzed	analyze	VERB
njb-29	140	11	by	by	ADP
njb-29	140	12	pfge	pfge	NOUN
njb-29	140	13	(	(	PUNCT
njb-29	140	14	figure	figure	NOUN
njb-29	140	15	2b	2b	NUM
njb-29	140	16	)	)	PUNCT
njb-29	140	17	.	.	PUNCT
njb-29	141	1	none	none	NOUN
njb-29	141	2	of	of	ADP
njb-29	141	3	the	the	DET
njb-29	141	4	resistant	resistant	ADJ
njb-29	141	5	isolates	isolate	NOUN
njb-29	141	6	showed	show	VERB
njb-29	141	7	circular	circular	ADJ
njb-29	141	8	amplification	amplification	NOUN
njb-29	141	9	as	as	SCONJ
njb-29	141	10	was	be	AUX
njb-29	141	11	observed	observe	VERB
njb-29	141	12	in	in	ADP
njb-29	141	13	our	our	PRON
njb-29	141	14	earlier	early	ADJ
njb-29	141	15	studies	study	NOUN
njb-29	141	16	with	with	ADP
njb-29	141	17	limited	limit	VERB
njb-29	141	18	number	number	NOUN
njb-29	141	19	of	of	ADP
njb-29	141	20	isolates	isolate	NOUN
njb-29	141	21	[	[	PUNCT
njb-29	141	22	23	23	NUM
njb-29	141	23	]	]	PUNCT
njb-29	141	24	.	.	PUNCT
njb-29	142	1	interestingly	interestingly	ADV
njb-29	142	2	,	,	PUNCT
njb-29	142	3	two	two	NUM
njb-29	142	4	sensitive	sensitive	ADJ
njb-29	142	5	pkdl	pkdl	NOUN
njb-29	142	6	isolates	isolate	NOUN
njb-29	142	7	,	,	PUNCT
njb-29	142	8	rk1	rk1	PROPN
njb-29	142	9	-	-	PUNCT
njb-29	142	10	s	s	PROPN
njb-29	142	11	and	and	CCONJ
njb-29	142	12	ms2	ms2	PROPN
njb-29	142	13	-	-	PUNCT
njb-29	142	14	s	s	PROPN
njb-29	142	15	and	and	CCONJ
njb-29	142	16	one	one	NUM
njb-29	142	17	resistant	resistant	ADJ
njb-29	142	18	pkdl	pkdl	NOUN
njb-29	142	19	isolate	isolate	VERB
njb-29	142	20	,	,	PUNCT
njb-29	142	21	nr3a	nr3a	ADV
njb-29	142	22	-	-	PUNCT
njb-29	142	23	r	r	NOUN
njb-29	142	24	had	have	VERB
njb-29	142	25	the	the	DET
njb-29	142	26	presence	presence	NOUN
njb-29	142	27	of	of	ADP
njb-29	142	28	mrpa	mrpa	NOUN
njb-29	142	29	on	on	ADP
njb-29	142	30	two	two	NUM
njb-29	142	31	chromosomes	chromosome	NOUN
njb-29	142	32	as	as	SCONJ
njb-29	142	33	indicated	indicate	VERB
njb-29	142	34	by	by	ADP
njb-29	142	35	their	their	PRON
njb-29	142	36	characteristic	characteristic	ADJ
njb-29	142	37	migration	migration	NOUN
njb-29	142	38	in	in	ADP
njb-29	142	39	pfge	pfge	NOUN
njb-29	142	40	(	(	PUNCT
njb-29	142	41	figure	figure	NOUN
njb-29	142	42	2b	2b	NUM
njb-29	142	43	)	)	PUNCT
njb-29	142	44	.	.	PUNCT
njb-29	143	1	we	we	PRON
njb-29	143	2	had	have	AUX
njb-29	143	3	earlier	early	ADV
njb-29	143	4	reported	report	VERB
njb-29	143	5	co	co	NOUN
njb-29	143	6	-	-	NOUN
njb-29	143	7	amplification	amplification	NOUN
njb-29	143	8	of	of	ADP
njb-29	143	9	pterin	pterin	NOUN
njb-29	143	10	reductase	reductase	NOUN
njb-29	143	11	gene	gene	NOUN
njb-29	143	12	(	(	PUNCT
njb-29	143	13	ptr1	ptr1	PROPN
njb-29	143	14	)	)	PUNCT
njb-29	143	15	with	with	ADP
njb-29	143	16	mrpa	mrpa	NOUN
njb-29	143	17	in	in	ADP
njb-29	143	18	the	the	DET
njb-29	143	19	clinical	clinical	ADJ
njb-29	143	20	isolates	isolate	NOUN
njb-29	143	21	[	[	PUNCT
njb-29	143	22	23	23	NUM
njb-29	143	23	]	]	PUNCT
njb-29	143	24	.	.	PUNCT
njb-29	144	1	in	in	ADP
njb-29	144	2	the	the	DET
njb-29	144	3	present	present	ADJ
njb-29	144	4	study	study	NOUN
njb-29	144	5	,	,	PUNCT
njb-29	144	6	coamplification	coamplification	NOUN
njb-29	144	7	of	of	ADP
njb-29	144	8	ptr1	ptr1	PROPN
njb-29	144	9	gene	gene	NOUN
njb-29	144	10	with	with	ADP
njb-29	144	11	mrpa	mrpa	PROPN
njb-29	144	12	gene	gene	NOUN
njb-29	144	13	was	be	AUX
njb-29	144	14	not	not	PART
njb-29	144	15	observed	observe	VERB
njb-29	144	16	in	in	ADP
njb-29	144	17	any	any	PRON
njb-29	144	18	of	of	ADP
njb-29	144	19	the	the	DET
njb-29	144	20	clinical	clinical	ADJ
njb-29	144	21	isolates	isolate	NOUN
njb-29	144	22	as	as	ADP
njb-29	144	23	nepal	nepal	ADJ
njb-29	144	24	journal	journal	NOUN
njb-29	144	25	of	of	ADP
njb-29	144	26	biotechnology	biotechnology	NOUN
njb-29	144	27	.	.	PUNCT
njb-29	145	1	d	d	X
njb-29	145	2	e	e	PROPN
njb-29	145	3	c	c	PROPN
njb-29	145	4	.	.	PUNCT
njb-29	146	1	2	2	NUM
njb-29	146	2	0	0	NUM
njb-29	146	3	1	1	NUM
njb-29	146	4	6	6	NUM
njb-29	146	5	vol	vol	NOUN
njb-29	146	6	.	.	PROPN
njb-29	147	1	4	4	NUM
njb-29	147	2	,	,	PUNCT
njb-29	147	3	no	no	NOUN
njb-29	147	4	.	.	NOUN
njb-29	147	5	1	1	NUM
njb-29	147	6	:	:	SYM
njb-29	147	7	1	1	NUM
njb-29	147	8	-	-	SYM
njb-29	147	9	13	13	NUM
njb-29	147	10	maharjan	maharjan	NOUN
njb-29	147	11	et	et	NOUN
njb-29	147	12	al	al	PROPN
njb-29	147	13	.	.	PUNCT
njb-29	148	1	©	©	PROPN
njb-29	148	2	njb	njb	PROPN
njb-29	148	3	,	,	PUNCT
njb-29	148	4	biotechnology	biotechnology	NOUN
njb-29	148	5	society	society	NOUN
njb-29	148	6	of	of	ADP
njb-29	148	7	nepal	nepal	ADJ
njb-29	148	8	8	8	NUM
njb-29	148	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	148	10	figure	figure	NOUN
njb-29	148	11	4	4	NUM
njb-29	148	12	:	:	PUNCT
njb-29	148	13	a	a	DET
njb-29	148	14	:	:	PUNCT
njb-29	148	15	southern	southern	ADJ
njb-29	148	16	blot	blot	NOUN
njb-29	148	17	analysis	analysis	NOUN
njb-29	148	18	of	of	ADP
njb-29	148	19	the	the	DET
njb-29	148	20	-gcs	-gcs	PROPN
njb-29	148	21	gene	gene	NOUN
njb-29	148	22	in	in	ADP
njb-29	148	23	the	the	DET
njb-29	148	24	sag	sag	ADJ
njb-29	148	25	-	-	PUNCT
njb-29	148	26	sensitive	sensitive	ADJ
njb-29	148	27	and	and	CCONJ
njb-29	148	28	the	the	DET
njb-29	148	29	sag	sag	ADJ
njb-29	148	30	-	-	PUNCT
njb-29	148	31	resistant	resistant	ADJ
njb-29	148	32	leishmania	leishmania	PROPN
njb-29	148	33	donovani	donovani	PROPN
njb-29	148	34	vl	vl	PROPN
njb-29	148	35	and	and	CCONJ
njb-29	148	36	pkdl	pkdl	PROPN
njb-29	148	37	field	field	PROPN
njb-29	148	38	isolates	isolate	NOUN
njb-29	148	39	.	.	PUNCT
njb-29	149	1	total	total	ADJ
njb-29	149	2	genomic	genomic	ADJ
njb-29	149	3	dna	dna	PROPN
njb-29	149	4	was	be	AUX
njb-29	149	5	isolated	isolate	VERB
njb-29	149	6	and	and	CCONJ
njb-29	149	7	digested	digest	VERB
njb-29	149	8	with	with	ADP
njb-29	149	9	hindiii	hindiii	PROPN
njb-29	149	10	.	.	PUNCT
njb-29	150	1	the	the	DET
njb-29	150	2	digested	digested	ADJ
njb-29	150	3	dna	dna	PROPN
njb-29	150	4	was	be	AUX
njb-29	150	5	electrophoresed	electrophorese	VERB
njb-29	150	6	,	,	PUNCT
njb-29	150	7	blotted	blot	VERB
njb-29	150	8	and	and	CCONJ
njb-29	150	9	hybridized	hybridize	VERB
njb-29	150	10	with	with	ADP
njb-29	150	11	-gcs	-gcs	DET
njb-29	150	12	probe	probe	NOUN
njb-29	150	13	.	.	PUNCT
njb-29	151	1	the	the	DET
njb-29	151	2	sizes	size	NOUN
njb-29	151	3	of	of	ADP
njb-29	151	4	the	the	DET
njb-29	151	5	hybridizing	hybridize	VERB
njb-29	151	6	bands	band	NOUN
njb-29	151	7	were	be	AUX
njb-29	151	8	determined	determine	VERB
njb-29	151	9	using	use	VERB
njb-29	151	10	hindiii	hindiii	PROPN
njb-29	151	11	digested	digest	VERB
njb-29	151	12	λdna	λdna	ADV
njb-29	151	13	.	.	PUNCT
njb-29	152	1	the	the	DET
njb-29	152	2	blot	blot	NOUN
njb-29	152	3	was	be	AUX
njb-29	152	4	rehybridized	rehybridize	VERB
njb-29	152	5	with	with	ADP
njb-29	152	6	α	α	PRON
njb-29	152	7	-	-	PUNCT
njb-29	152	8	tubulin	tubulin	NOUN
njb-29	152	9	probe	probe	NOUN
njb-29	152	10	to	to	PART
njb-29	152	11	monitor	monitor	VERB
njb-29	152	12	the	the	DET
njb-29	152	13	amount	amount	NOUN
njb-29	152	14	of	of	ADP
njb-29	152	15	digested	digested	ADJ
njb-29	152	16	dna	dna	NOUN
njb-29	152	17	layered	layer	VERB
njb-29	152	18	on	on	ADP
njb-29	152	19	the	the	DET
njb-29	152	20	gel	gel	NOUN
njb-29	152	21	.	.	PUNCT
njb-29	153	1	b	b	X
njb-29	153	2	:	:	PUNCT
njb-29	153	3	real	real	ADJ
njb-29	153	4	time	time	NOUN
njb-29	153	5	rt	rt	PROPN
njb-29	153	6	-	-	PUNCT
njb-29	153	7	pcr	pcr	NOUN
njb-29	153	8	expression	expression	NOUN
njb-29	153	9	analysis	analysis	NOUN
njb-29	153	10	of	of	ADP
njb-29	153	11	-gcs	-gcs	DET
njb-29	153	12	gene	gene	NOUN
njb-29	153	13	in	in	ADP
njb-29	153	14	l.	l.	PROPN
njb-29	153	15	donovani	donovani	PROPN
njb-29	153	16	clinical	clinical	ADJ
njb-29	153	17	isolates	isolate	NOUN
njb-29	153	18	.	.	PUNCT
njb-29	154	1	-gcs	-gcs	NUM
njb-29	154	2	gene	gene	NOUN
njb-29	154	3	expression	expression	NOUN
njb-29	154	4	ratios	ratio	NOUN
njb-29	154	5	in	in	ADP
njb-29	154	6	the	the	DET
njb-29	154	7	sag	sag	ADJ
njb-29	154	8	-	-	PUNCT
njb-29	154	9	resistant	resistant	ADJ
njb-29	154	10	isolates	isolate	NOUN
njb-29	154	11	are	be	AUX
njb-29	154	12	relative	relative	ADJ
njb-29	154	13	to	to	ADP
njb-29	154	14	the	the	DET
njb-29	154	15	sagsensitive	sagsensitive	PROPN
njb-29	154	16	isolate	isolate	PROPN
njb-29	154	17	,	,	PUNCT
njb-29	154	18	2001	2001	NUM
njb-29	154	19	-	-	PUNCT
njb-29	154	20	s.	s.	PROPN
njb-29	154	21	results	result	NOUN
njb-29	154	22	are	be	AUX
njb-29	154	23	mean	mean	ADJ
njb-29	154	24	of	of	ADP
njb-29	154	25	three	three	NUM
njb-29	154	26	independent	independent	ADJ
njb-29	154	27	experiments	experiment	NOUN
njb-29	154	28	performed	perform	VERB
njb-29	154	29	from	from	ADP
njb-29	154	30	three	three	NUM
njb-29	154	31	different	different	ADJ
njb-29	154	32	rna	rna	PROPN
njb-29	154	33	preparations	preparation	NOUN
njb-29	154	34	.	.	PUNCT
njb-29	155	1	determined	determine	VERB
njb-29	155	2	by	by	ADP
njb-29	155	3	southern	southern	ADJ
njb-29	155	4	-	-	PUNCT
njb-29	155	5	blot	blot	NOUN
njb-29	155	6	analysis	analysis	NOUN
njb-29	155	7	using	use	VERB
njb-29	155	8	ptr1	ptr1	PROPN
njb-29	155	9	-	-	PUNCT
njb-29	155	10	specific	specific	ADJ
njb-29	155	11	probe	probe	NOUN
njb-29	155	12	(	(	PUNCT
njb-29	155	13	figure	figure	NOUN
njb-29	155	14	2a	2a	NUM
njb-29	155	15	)	)	PUNCT
njb-29	155	16	.	.	PUNCT
njb-29	156	1	comparison	comparison	NOUN
njb-29	156	2	of	of	ADP
njb-29	156	3	mrpa	mrpa	NOUN
njb-29	156	4	gene	gene	NOUN
njb-29	156	5	expression	expression	NOUN
njb-29	156	6	in	in	ADP
njb-29	156	7	sag	sag	PROPN
njb-29	156	8	-	-	PUNCT
njb-29	156	9	s	s	NOUN
njb-29	156	10	versus	versus	X
njb-29	156	11	sag	sag	ADJ
njb-29	156	12	-	-	PUNCT
njb-29	156	13	r	r	NOUN
njb-29	156	14	field	field	NOUN
njb-29	156	15	isolates	isolate	NOUN
njb-29	156	16	was	be	AUX
njb-29	156	17	done	do	VERB
njb-29	156	18	to	to	PART
njb-29	156	19	verify	verify	VERB
njb-29	156	20	if	if	SCONJ
njb-29	156	21	there	there	PRON
njb-29	156	22	is	be	VERB
njb-29	156	23	any	any	DET
njb-29	156	24	correlation	correlation	NOUN
njb-29	156	25	between	between	ADP
njb-29	156	26	mrpa	mrpa	PROPN
njb-29	156	27	gene	gene	NOUN
njb-29	156	28	expression	expression	NOUN
njb-29	156	29	and	and	CCONJ
njb-29	156	30	sag	sag	ADJ
njb-29	156	31	susceptibility	susceptibility	NOUN
njb-29	156	32	profile	profile	NOUN
njb-29	156	33	of	of	ADP
njb-29	156	34	the	the	DET
njb-29	156	35	clinical	clinical	ADJ
njb-29	156	36	isolates	isolate	NOUN
njb-29	156	37	.	.	PUNCT
njb-29	157	1	total	total	ADJ
njb-29	157	2	rna	rna	PROPN
njb-29	157	3	from	from	ADP
njb-29	157	4	promastigotes	promastigote	NOUN
njb-29	157	5	of	of	ADP
njb-29	157	6	the	the	DET
njb-29	157	7	clinical	clinical	ADJ
njb-29	157	8	isolates	isolate	NOUN
njb-29	157	9	was	be	AUX
njb-29	157	10	isolated	isolate	VERB
njb-29	157	11	and	and	CCONJ
njb-29	157	12	complementary	complementary	ADJ
njb-29	157	13	dnas	dna	NOUN
njb-29	157	14	were	be	AUX
njb-29	157	15	synthesized	synthesize	VERB
njb-29	157	16	.	.	PUNCT
njb-29	158	1	realtime	realtime	NOUN
njb-29	158	2	-pcr	-pcr	PROPN
njb-29	158	3	using	use	VERB
njb-29	158	4	quantifast	quantifast	VERB
njb-29	158	5	sybr	sybr	PROPN
njb-29	158	6	green	green	PROPN
njb-29	158	7	pcr	pcr	PROPN
njb-29	158	8	master	master	NOUN
njb-29	158	9	mix	mix	PROPN
njb-29	158	10	(	(	PUNCT
njb-29	158	11	qiagen	qiagen	PROPN
njb-29	158	12	)	)	PUNCT
njb-29	158	13	with	with	ADP
njb-29	158	14	mrpa	mrpa	PROPN
njb-29	158	15	(	(	PUNCT
njb-29	158	16	gene	gene	NOUN
njb-29	158	17	specific	specific	ADJ
njb-29	158	18	)	)	PUNCT
njb-29	158	19	and	and	CCONJ
njb-29	158	20	gapdh	gapdh	NOUN
njb-29	158	21	(	(	PUNCT
njb-29	158	22	internal	internal	ADJ
njb-29	158	23	control	control	NOUN
njb-29	158	24	)	)	PUNCT
njb-29	158	25	primers	primer	NOUN
njb-29	158	26	was	be	AUX
njb-29	158	27	performed	perform	VERB
njb-29	158	28	.	.	PUNCT
njb-29	159	1	up	up	ADP
njb-29	159	2	-	-	PUNCT
njb-29	159	3	regulation	regulation	NOUN
njb-29	159	4	of	of	ADP
njb-29	159	5	mrpa	mrpa	PROPN
njb-29	159	6	expression	expression	NOUN
njb-29	159	7	was	be	AUX
njb-29	159	8	observed	observe	VERB
njb-29	159	9	in	in	ADP
njb-29	159	10	the	the	DET
njb-29	159	11	resistant	resistant	ADJ
njb-29	159	12	clinical	clinical	ADJ
njb-29	159	13	isolates	isolate	NOUN
njb-29	159	14	.	.	PUNCT
njb-29	160	1	mrpa	mrpa	PROPN
njb-29	160	2	expression	expression	NOUN
njb-29	160	3	in	in	ADP
njb-29	160	4	the	the	DET
njb-29	160	5	resistant	resistant	ADJ
njb-29	160	6	strains	strain	NOUN
njb-29	160	7	,	,	PUNCT
njb-29	160	8	mc4r	mc4r	PROPN
njb-29	160	9	,	,	PUNCT
njb-29	160	10	mc8	mc8	PROPN
njb-29	160	11	-	-	PUNCT
njb-29	160	12	r	r	PROPN
njb-29	160	13	,	,	PUNCT
njb-29	160	14	mc9	mc9	PROPN
njb-29	160	15	-	-	PUNCT
njb-29	160	16	r	r	PROPN
njb-29	160	17	,	,	PUNCT
njb-29	160	18	nr3a	nr3a	ADV
njb-29	160	19	-	-	PUNCT
njb-29	160	20	r	r	ADJ
njb-29	160	21	,	,	PUNCT
njb-29	160	22	rmp8	rmp8	PROPN
njb-29	160	23	-	-	PUNCT
njb-29	160	24	r	r	PROPN
njb-29	160	25	,	,	PUNCT
njb-29	160	26	rmp19	rmp19	NOUN
njb-29	160	27	-	-	PUNCT
njb-29	160	28	r	r	NOUN
njb-29	160	29	,	,	PUNCT
njb-29	160	30	nepal	nepal	ADJ
njb-29	160	31	journal	journal	NOUN
njb-29	160	32	of	of	ADP
njb-29	160	33	biotechnology	biotechnology	NOUN
njb-29	160	34	.	.	PUNCT
njb-29	161	1	d	d	X
njb-29	161	2	e	e	PROPN
njb-29	161	3	c	c	PROPN
njb-29	161	4	.	.	PUNCT
njb-29	162	1	2	2	NUM
njb-29	162	2	0	0	NUM
njb-29	162	3	1	1	NUM
njb-29	162	4	6	6	NUM
njb-29	162	5	vol	vol	NOUN
njb-29	162	6	.	.	PROPN
njb-29	163	1	4	4	NUM
njb-29	163	2	,	,	PUNCT
njb-29	163	3	no	no	NOUN
njb-29	163	4	.	.	NOUN
njb-29	163	5	1	1	NUM
njb-29	163	6	:	:	SYM
njb-29	163	7	1	1	NUM
njb-29	163	8	-	-	SYM
njb-29	163	9	13	13	NUM
njb-29	163	10	maharjan	maharjan	NOUN
njb-29	163	11	et	et	NOUN
njb-29	163	12	al	al	PROPN
njb-29	163	13	.	.	PUNCT
njb-29	164	1	©	©	PROPN
njb-29	164	2	njb	njb	PROPN
njb-29	164	3	,	,	PUNCT
njb-29	164	4	biotechnology	biotechnology	NOUN
njb-29	164	5	society	society	NOUN
njb-29	164	6	of	of	ADP
njb-29	164	7	nepal	nepal	ADJ
njb-29	164	8	9	9	NUM
njb-29	164	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	164	10	rmp142	rmp142	PROPN
njb-29	164	11	-	-	PUNCT
njb-29	164	12	r	r	PROPN
njb-29	164	13	,	,	PUNCT
njb-29	164	14	rmp155	rmp155	PROPN
njb-29	164	15	-	-	PUNCT
njb-29	164	16	r	r	PROPN
njb-29	164	17	and	and	CCONJ
njb-29	164	18	rmp240	rmp240	PROPN
njb-29	164	19	-	-	PUNCT
njb-29	164	20	r	r	NOUN
njb-29	164	21	was	be	AUX
njb-29	164	22	~4-	~4-	PROPN
njb-29	164	23	,	,	PUNCT
njb-29	164	24	~4.2-	~4.2-	PUNCT
njb-29	164	25	,	,	PUNCT
njb-29	164	26	~9.6-	~9.6-	NUM
njb-29	164	27	,	,	PUNCT
njb-29	164	28	~7.2-	~7.2-	DET
njb-29	164	29	,	,	PUNCT
njb-29	164	30	~6.1-	~6.1-	PUNCT
njb-29	164	31	,	,	PUNCT
njb-29	164	32	~6.8-	~6.8-	NUM
njb-29	164	33	,	,	PUNCT
njb-29	164	34	~6.0-	~6.0-	X
njb-29	164	35	,	,	PUNCT
njb-29	164	36	~7.5	~7.5	NUM
njb-29	164	37	and	and	CCONJ
njb-29	164	38	~4.4fold	~4.4fold	VERB
njb-29	164	39	more	more	ADV
njb-29	164	40	respectively	respectively	ADV
njb-29	164	41	when	when	SCONJ
njb-29	164	42	compared	compare	VERB
njb-29	164	43	to	to	ADP
njb-29	164	44	the	the	DET
njb-29	164	45	expression	expression	NOUN
njb-29	164	46	in	in	ADP
njb-29	164	47	the	the	DET
njb-29	164	48	sensitive	sensitive	ADJ
njb-29	164	49	isolate	isolate	NOUN
njb-29	164	50	,	,	PUNCT
njb-29	164	51	2001	2001	NUM
njb-29	164	52	-	-	PUNCT
njb-29	164	53	s	s	NOUN
njb-29	164	54	(	(	PUNCT
njb-29	164	55	figure	figure	NOUN
njb-29	164	56	2c	2c	NUM
njb-29	164	57	)	)	PUNCT
njb-29	164	58	.	.	PUNCT
njb-29	165	1	gene	gene	NOUN
njb-29	165	2	copy	copy	NOUN
njb-29	165	3	number	number	NOUN
njb-29	165	4	and	and	CCONJ
njb-29	165	5	expression	expression	NOUN
njb-29	165	6	profiling	profiling	NOUN
njb-29	165	7	of	of	ADP
njb-29	165	8	the	the	DET
njb-29	165	9	ornithine	ornithine	ADJ
njb-29	165	10	decarboxylase	decarboxylase	NOUN
njb-29	165	11	(	(	PUNCT
njb-29	165	12	odc	odc	PROPN
njb-29	165	13	)	)	PUNCT
njb-29	165	14	gene	gene	NOUN
njb-29	165	15	in	in	ADP
njb-29	165	16	sag	sag	PROPN
njb-29	165	17	-	-	PUNCT
njb-29	165	18	s	s	NOUN
njb-29	165	19	and	and	CCONJ
njb-29	165	20	sag	sag	ADJ
njb-29	165	21	-	-	PUNCT
njb-29	165	22	r	r	NOUN
njb-29	165	23	clinical	clinical	ADJ
njb-29	165	24	isolates	isolate	NOUN
njb-29	165	25	.	.	PUNCT
njb-29	166	1	ornithine	ornithine	PROPN
njb-29	166	2	decarboxylase	decarboxylase	NOUN
njb-29	166	3	(	(	PUNCT
njb-29	166	4	odc	odc	PROPN
njb-29	166	5	)	)	PUNCT
njb-29	166	6	is	be	AUX
njb-29	166	7	the	the	DET
njb-29	166	8	ratelimiting	ratelimite	VERB
njb-29	166	9	enzyme	enzyme	NOUN
njb-29	166	10	of	of	ADP
njb-29	166	11	the	the	DET
njb-29	166	12	polyamine	polyamine	NOUN
njb-29	166	13	biosynthetic	biosynthetic	ADJ
njb-29	166	14	pathway	pathway	NOUN
njb-29	166	15	.	.	PUNCT
njb-29	167	1	in	in	ADP
njb-29	167	2	addition	addition	NOUN
njb-29	167	3	to	to	ADP
njb-29	167	4	mrpa	mrpa	PROPN
njb-29	167	5	,	,	PUNCT
njb-29	167	6	overexpression	overexpression	NOUN
njb-29	167	7	of	of	ADP
njb-29	167	8	the	the	DET
njb-29	167	9	odc	odc	PROPN
njb-29	167	10	gene	gene	NOUN
njb-29	167	11	has	have	AUX
njb-29	167	12	been	be	AUX
njb-29	167	13	reported	report	VERB
njb-29	167	14	in	in	ADP
njb-29	167	15	the	the	DET
njb-29	167	16	antimony	antimony	NOUN
njb-29	167	17	resistant	resistant	ADJ
njb-29	167	18	mutants	mutant	NOUN
njb-29	167	19	[	[	X
njb-29	167	20	23	23	NUM
njb-29	167	21	-	-	SYM
njb-29	167	22	25	25	NUM
njb-29	167	23	]	]	PUNCT
njb-29	167	24	.	.	PUNCT
njb-29	168	1	these	these	DET
njb-29	168	2	observations	observation	NOUN
njb-29	168	3	prompted	prompt	VERB
njb-29	168	4	us	we	PRON
njb-29	168	5	to	to	PART
njb-29	168	6	determine	determine	VERB
njb-29	168	7	if	if	SCONJ
njb-29	168	8	amplification	amplification	NOUN
njb-29	168	9	of	of	ADP
njb-29	168	10	the	the	DET
njb-29	168	11	odc	odc	PROPN
njb-29	168	12	gene	gene	NOUN
njb-29	168	13	occured	occur	VERB
njb-29	168	14	in	in	ADP
njb-29	168	15	our	our	PRON
njb-29	168	16	clinical	clinical	ADJ
njb-29	168	17	isolates	isolate	NOUN
njb-29	168	18	.	.	PUNCT
njb-29	169	1	southern	southern	ADJ
njb-29	169	2	-	-	PUNCT
njb-29	169	3	blot	blot	NOUN
njb-29	169	4	analysis	analysis	NOUN
njb-29	169	5	of	of	ADP
njb-29	169	6	the	the	DET
njb-29	169	7	total	total	ADJ
njb-29	169	8	genomic	genomic	ADJ
njb-29	169	9	dna	dna	NOUN
njb-29	169	10	digested	digest	VERB
njb-29	169	11	with	with	ADP
njb-29	169	12	hindiii	hindiii	NOUN
njb-29	169	13	and	and	CCONJ
njb-29	169	14	hybridized	hybridize	VERB
njb-29	169	15	with	with	ADP
njb-29	169	16	the	the	DET
njb-29	169	17	odc	odc	PROPN
njb-29	169	18	specific	specific	ADJ
njb-29	169	19	probe	probe	NOUN
njb-29	169	20	was	be	AUX
njb-29	169	21	done	do	VERB
njb-29	169	22	.	.	PUNCT
njb-29	170	1	sag	sag	PROPN
njb-29	170	2	-	-	PUNCT
njb-29	170	3	s	s	PROPN
njb-29	170	4	and	and	CCONJ
njb-29	170	5	sag	sag	ADJ
njb-29	170	6	-	-	PUNCT
njb-29	170	7	r	r	NOUN
njb-29	170	8	isolates	isolate	NOUN
njb-29	170	9	showed	show	VERB
njb-29	170	10	a	a	DET
njb-29	170	11	single	single	ADJ
njb-29	170	12	copy	copy	NOUN
njb-29	170	13	of	of	ADP
njb-29	170	14	the	the	DET
njb-29	170	15	odc	odc	PROPN
njb-29	170	16	gene	gene	NOUN
njb-29	170	17	(	(	PUNCT
njb-29	170	18	figure	figure	NOUN
njb-29	170	19	3a	3a	NUM
njb-29	170	20	)	)	PUNCT
njb-29	170	21	with	with	ADP
njb-29	170	22	the	the	DET
njb-29	170	23	exception	exception	NOUN
njb-29	170	24	of	of	ADP
njb-29	170	25	three	three	NUM
njb-29	170	26	pkdl	pkdl	NOUN
njb-29	170	27	isolates	isolate	NOUN
njb-29	170	28	,	,	PUNCT
njb-29	170	29	rk1	rk1	PROPN
njb-29	170	30	-	-	PUNCT
njb-29	170	31	s	s	PROPN
njb-29	170	32	,	,	PUNCT
njb-29	170	33	ms2	ms2	PROPN
njb-29	170	34	-	-	PUNCT
njb-29	170	35	s	s	PROPN
njb-29	170	36	and	and	CCONJ
njb-29	170	37	nr3a	nr3a	ADJ
njb-29	170	38	-	-	PUNCT
njb-29	170	39	r.	r.	PROPN
njb-29	170	40	interestingly	interestingly	ADV
njb-29	170	41	,	,	PUNCT
njb-29	170	42	two	two	NUM
njb-29	170	43	copies	copy	NOUN
njb-29	170	44	of	of	ADP
njb-29	170	45	the	the	DET
njb-29	170	46	odc	odc	PROPN
njb-29	170	47	gene	gene	NOUN
njb-29	170	48	were	be	AUX
njb-29	170	49	observed	observe	VERB
njb-29	170	50	in	in	ADP
njb-29	170	51	these	these	DET
njb-29	170	52	three	three	NUM
njb-29	170	53	pkdl	pkdl	NOUN
njb-29	170	54	isolates	isolate	NOUN
njb-29	170	55	(	(	PUNCT
njb-29	170	56	figure	figure	NOUN
njb-29	170	57	3a	3a	NUM
njb-29	170	58	)	)	PUNCT
njb-29	170	59	.	.	PUNCT
njb-29	171	1	comparison	comparison	NOUN
njb-29	171	2	of	of	ADP
njb-29	171	3	odc	odc	ADJ
njb-29	171	4	gene	gene	NOUN
njb-29	171	5	expression	expression	NOUN
njb-29	171	6	in	in	ADP
njb-29	171	7	sag	sag	PROPN
njb-29	171	8	-	-	PUNCT
njb-29	171	9	s	s	NOUN
njb-29	171	10	versus	versus	X
njb-29	171	11	sag	sag	ADJ
njb-29	171	12	-	-	PUNCT
njb-29	171	13	r	r	NOUN
njb-29	171	14	field	field	NOUN
njb-29	171	15	isolates	isolate	NOUN
njb-29	171	16	was	be	AUX
njb-29	171	17	done	do	VERB
njb-29	171	18	to	to	PART
njb-29	171	19	verify	verify	VERB
njb-29	171	20	if	if	SCONJ
njb-29	171	21	there	there	PRON
njb-29	171	22	is	be	VERB
njb-29	171	23	any	any	DET
njb-29	171	24	correlation	correlation	NOUN
njb-29	171	25	between	between	ADP
njb-29	171	26	the	the	DET
njb-29	171	27	gene	gene	NOUN
njb-29	171	28	expression	expression	NOUN
njb-29	171	29	and	and	CCONJ
njb-29	171	30	sag	sag	ADJ
njb-29	171	31	susceptibility	susceptibility	NOUN
njb-29	171	32	profile	profile	NOUN
njb-29	171	33	of	of	ADP
njb-29	171	34	the	the	DET
njb-29	171	35	clinical	clinical	ADJ
njb-29	171	36	isolates	isolate	NOUN
njb-29	171	37	.	.	PUNCT
njb-29	172	1	real	real	ADJ
njb-29	172	2	-	-	PUNCT
njb-29	172	3	time	time	NOUN
njb-29	172	4	pcr	pcr	NOUN
njb-29	172	5	with	with	ADP
njb-29	172	6	the	the	DET
njb-29	172	7	odc	odc	PROPN
njb-29	172	8	(	(	PUNCT
njb-29	172	9	gene	gene	NOUN
njb-29	172	10	specific	specific	NOUN
njb-29	172	11	)	)	PUNCT
njb-29	172	12	and	and	CCONJ
njb-29	172	13	the	the	DET
njb-29	172	14	gapdh	gapdh	NOUN
njb-29	172	15	(	(	PUNCT
njb-29	172	16	internal	internal	ADJ
njb-29	172	17	control	control	NOUN
njb-29	172	18	)	)	PUNCT
njb-29	172	19	primers	primer	NOUN
njb-29	172	20	was	be	AUX
njb-29	172	21	performed	perform	VERB
njb-29	172	22	.	.	PUNCT
njb-29	173	1	up	up	ADP
njb-29	173	2	-	-	PUNCT
njb-29	173	3	regulation	regulation	NOUN
njb-29	173	4	of	of	ADP
njb-29	173	5	the	the	DET
njb-29	173	6	odc	odc	PROPN
njb-29	173	7	expression	expression	NOUN
njb-29	173	8	was	be	AUX
njb-29	173	9	observed	observe	VERB
njb-29	173	10	in	in	ADP
njb-29	173	11	the	the	DET
njb-29	173	12	resistant	resistant	ADJ
njb-29	173	13	clinical	clinical	ADJ
njb-29	173	14	isolates	isolate	NOUN
njb-29	173	15	.	.	PUNCT
njb-29	174	1	odc	odc	VERB
njb-29	174	2	expression	expression	NOUN
njb-29	174	3	in	in	ADP
njb-29	174	4	the	the	DET
njb-29	174	5	resistant	resistant	ADJ
njb-29	174	6	strains	strain	NOUN
njb-29	174	7	,	,	PUNCT
njb-29	174	8	mc4	mc4	PROPN
njb-29	174	9	-	-	PUNCT
njb-29	174	10	r	r	PROPN
njb-29	174	11	,	,	PUNCT
njb-29	174	12	mc8	mc8	PROPN
njb-29	174	13	-	-	PUNCT
njb-29	174	14	r	r	PROPN
njb-29	174	15	,	,	PUNCT
njb-29	174	16	mc9	mc9	PROPN
njb-29	174	17	-	-	PUNCT
njb-29	174	18	r	r	PROPN
njb-29	174	19	,	,	PUNCT
njb-29	174	20	nr3a	nr3a	ADV
njb-29	174	21	-	-	PUNCT
njb-29	174	22	r	r	PROPN
njb-29	174	23	,	,	PUNCT
njb-29	174	24	rmp8r	rmp8r	PROPN
njb-29	174	25	,	,	PUNCT
njb-29	174	26	rmp19	rmp19	NOUN
njb-29	174	27	-	-	PUNCT
njb-29	174	28	r	r	NOUN
njb-29	174	29	,	,	PUNCT
njb-29	174	30	rmp142	rmp142	PROPN
njb-29	174	31	-	-	PUNCT
njb-29	174	32	r	r	PROPN
njb-29	174	33	,	,	PUNCT
njb-29	174	34	rmp155	rmp155	PROPN
njb-29	174	35	-	-	PUNCT
njb-29	174	36	r	r	PROPN
njb-29	174	37	and	and	CCONJ
njb-29	174	38	rmp240	rmp240	PROPN
njb-29	174	39	-	-	PUNCT
njb-29	174	40	r	r	NOUN
njb-29	174	41	was	be	AUX
njb-29	174	42	~3.6-	~3.6-	PUNCT
njb-29	174	43	,	,	PUNCT
njb-29	174	44	~7.4-	~7.4-	PUNCT
njb-29	174	45	,	,	PUNCT
njb-29	174	46	~3.1-	~3.1-	PUNCT
njb-29	174	47	,	,	PUNCT
njb-29	174	48	~2.7-	~2.7-	X
njb-29	174	49	,	,	PUNCT
njb-29	174	50	~2.3-	~2.3-	NUM
njb-29	174	51	,	,	PUNCT
njb-29	174	52	~3.3-	~3.3-	PUNCT
njb-29	174	53	,	,	PUNCT
njb-29	174	54	~3.5-	~3.5-	PUNCT
njb-29	174	55	,	,	PUNCT
njb-29	174	56	~2.8	~2.8	X
njb-29	174	57	and	and	CCONJ
njb-29	174	58	~3.0fold	~3.0fold	NOUN
njb-29	174	59	more	more	ADV
njb-29	174	60	respectively	respectively	ADV
njb-29	174	61	when	when	SCONJ
njb-29	174	62	compared	compare	VERB
njb-29	174	63	to	to	ADP
njb-29	174	64	the	the	DET
njb-29	174	65	sensitive	sensitive	ADJ
njb-29	174	66	isolate	isolate	PROPN
njb-29	174	67	,	,	PUNCT
njb-29	174	68	2001	2001	NUM
njb-29	174	69	-	-	PUNCT
njb-29	174	70	s	s	NOUN
njb-29	174	71	(	(	PUNCT
njb-29	174	72	figure	figure	NOUN
njb-29	174	73	3b	3b	NUM
njb-29	174	74	)	)	PUNCT
njb-29	174	75	.	.	PUNCT
njb-29	175	1	sag	sag	PROPN
njb-29	175	2	-	-	PUNCT
njb-29	175	3	s	s	NOUN
njb-29	175	4	isolate	isolate	NOUN
njb-29	176	1	,	,	PUNCT
njb-29	176	2	rk1	rk1	PROPN
njb-29	176	3	-	-	PUNCT
njb-29	176	4	s	s	PROPN
njb-29	176	5	was	be	AUX
njb-29	176	6	an	an	DET
njb-29	176	7	exception	exception	NOUN
njb-29	176	8	since	since	SCONJ
njb-29	176	9	it	it	PRON
njb-29	176	10	was	be	AUX
njb-29	176	11	the	the	DET
njb-29	176	12	only	only	ADJ
njb-29	176	13	sensitive	sensitive	ADJ
njb-29	176	14	isolate	isolate	NOUN
njb-29	176	15	that	that	PRON
njb-29	176	16	showed	show	VERB
njb-29	176	17	2.9	2.9	NUM
njb-29	176	18	-	-	ADJ
njb-29	176	19	fold	fold	ADJ
njb-29	176	20	up	up	NOUN
njb-29	176	21	-	-	PUNCT
njb-29	176	22	regulation	regulation	NOUN
njb-29	176	23	when	when	SCONJ
njb-29	176	24	compared	compare	VERB
njb-29	176	25	to	to	ADP
njb-29	176	26	the	the	DET
njb-29	176	27	reference	reference	NOUN
njb-29	176	28	strain	strain	NOUN
njb-29	176	29	,	,	PUNCT
njb-29	176	30	2001	2001	NUM
njb-29	176	31	-	-	PUNCT
njb-29	176	32	s	s	PROPN
njb-29	176	33	and	and	CCONJ
njb-29	176	34	also	also	ADV
njb-29	176	35	in	in	ADP
njb-29	176	36	comparison	comparison	NOUN
njb-29	176	37	with	with	ADP
njb-29	176	38	all	all	DET
njb-29	176	39	other	other	ADJ
njb-29	176	40	sag	sag	PROPN
njb-29	176	41	-	-	PUNCT
njb-29	176	42	s	s	NOUN
njb-29	176	43	isolates	isolate	NOUN
njb-29	176	44	(	(	PUNCT
njb-29	176	45	figure	figure	NOUN
njb-29	176	46	3b	3b	NUM
njb-29	176	47	)	)	PUNCT
njb-29	176	48	.	.	PUNCT
njb-29	177	1	no	no	DET
njb-29	177	2	uniform	uniform	ADJ
njb-29	177	3	correlation	correlation	NOUN
njb-29	177	4	was	be	AUX
njb-29	177	5	observed	observe	VERB
njb-29	177	6	between	between	ADP
njb-29	177	7	gene	gene	NOUN
njb-29	177	8	amplification	amplification	NOUN
njb-29	177	9	and	and	CCONJ
njb-29	177	10	odc	odc	VERB
njb-29	177	11	gene	gene	NOUN
njb-29	177	12	expression	expression	NOUN
njb-29	177	13	in	in	ADP
njb-29	177	14	these	these	DET
njb-29	177	15	isolates	isolate	NOUN
njb-29	177	16	.	.	PUNCT
njb-29	178	1	gene	gene	NOUN
njb-29	178	2	copy	copy	NOUN
njb-29	178	3	number	number	NOUN
njb-29	178	4	and	and	CCONJ
njb-29	178	5	expression	expression	NOUN
njb-29	178	6	profiling	profiling	NOUN
njb-29	178	7	of	of	ADP
njb-29	178	8	the	the	DET
njb-29	178	9	γ	γ	PROPN
njb-29	178	10	-	-	PUNCT
njb-29	178	11	glutamylcysteine	glutamylcysteine	NOUN
njb-29	178	12	synthetase	synthetase	PROPN
njb-29	178	13	(	(	PUNCT
njb-29	178	14	γ	γ	PROPN
njb-29	178	15	-	-	PROPN
njb-29	178	16	gcs	gcs	PROPN
njb-29	178	17	)	)	PUNCT
njb-29	178	18	gene	gene	NOUN
njb-29	178	19	in	in	ADP
njb-29	178	20	sag	sag	PROPN
njb-29	178	21	-	-	PUNCT
njb-29	178	22	s	s	NOUN
njb-29	178	23	and	and	CCONJ
njb-29	178	24	sag	sag	ADJ
njb-29	178	25	-	-	PUNCT
njb-29	178	26	r	r	NOUN
njb-29	178	27	clinical	clinical	ADJ
njb-29	178	28	isolates	isolate	NOUN
njb-29	178	29	in	in	ADP
njb-29	178	30	addition	addition	NOUN
njb-29	178	31	to	to	ADP
njb-29	178	32	mrpa	mrpa	PROPN
njb-29	178	33	and	and	CCONJ
njb-29	178	34	odc	odc	PROPN
njb-29	178	35	,	,	PUNCT
njb-29	178	36	another	another	DET
njb-29	178	37	locus	locus	NOUN
njb-29	178	38	that	that	PRON
njb-29	178	39	has	have	AUX
njb-29	178	40	been	be	AUX
njb-29	178	41	reported	report	VERB
njb-29	178	42	to	to	PART
njb-29	178	43	be	be	AUX
njb-29	178	44	amplified	amplify	VERB
njb-29	178	45	in	in	ADP
njb-29	178	46	the	the	DET
njb-29	178	47	antimony	antimony	NOUN
njb-29	178	48	-	-	PUNCT
njb-29	178	49	resistant	resistant	ADJ
njb-29	178	50	isolates	isolate	NOUN
njb-29	178	51	is	be	AUX
njb-29	178	52	the	the	DET
njb-29	178	53	gsh1	gsh1	PROPN
njb-29	178	54	gene	gene	NOUN
njb-29	178	55	coding	coding	NOUN
njb-29	178	56	for	for	ADP
njb-29	178	57	the	the	DET
njb-29	178	58	heavy	heavy	ADJ
njb-29	178	59	subunit	subunit	NOUN
njb-29	178	60	of	of	ADP
njb-29	178	61	-gcs	-gcs	PROPN
njb-29	178	62	.	.	PUNCT
njb-29	179	1	-gcs	-gcs	NUM
njb-29	179	2	is	be	AUX
njb-29	179	3	the	the	DET
njb-29	179	4	rate	rate	NOUN
njb-29	179	5	limiting	limit	VERB
njb-29	179	6	enzyme	enzyme	NOUN
njb-29	179	7	for	for	ADP
njb-29	179	8	gsh	gsh	PROPN
njb-29	179	9	synthesis	synthesis	NOUN
njb-29	180	1	[	[	X
njb-29	180	2	14,23	14,23	NUM
njb-29	180	3	]	]	PUNCT
njb-29	180	4	.	.	PUNCT
njb-29	181	1	we	we	PRON
njb-29	181	2	performed	perform	VERB
njb-29	181	3	southern	southern	ADJ
njb-29	181	4	blot	blot	NOUN
njb-29	181	5	analysis	analysis	NOUN
njb-29	181	6	of	of	ADP
njb-29	181	7	the	the	DET
njb-29	181	8	total	total	ADJ
njb-29	181	9	genomic	genomic	ADJ
njb-29	181	10	dna	dna	NOUN
njb-29	181	11	digested	digest	VERB
njb-29	181	12	with	with	ADP
njb-29	181	13	hindiii	hindiii	NOUN
njb-29	181	14	and	and	CCONJ
njb-29	181	15	hybridized	hybridize	VERB
njb-29	181	16	with	with	ADP
njb-29	181	17	the	the	DET
njb-29	181	18	-gcs	-gcs	PRON
njb-29	181	19	specific	specific	ADJ
njb-29	181	20	probe	probe	NOUN
njb-29	181	21	.	.	PUNCT
njb-29	182	1	southern	southern	ADJ
njb-29	182	2	blot	blot	NOUN
njb-29	182	3	analysis	analysis	NOUN
njb-29	182	4	of	of	ADP
njb-29	182	5	the	the	DET
njb-29	182	6	-gcs	-gcs	PROPN
njb-29	182	7	gene	gene	NOUN
njb-29	182	8	showed	show	VERB
njb-29	182	9	two	two	NUM
njb-29	182	10	copies	copy	NOUN
njb-29	182	11	in	in	ADP
njb-29	182	12	a	a	DET
njb-29	182	13	resistant	resistant	ADJ
njb-29	182	14	isolate	isolate	NOUN
njb-29	182	15	mc4	mc4	PROPN
njb-29	182	16	-	-	PUNCT
njb-29	182	17	r	r	NOUN
njb-29	182	18	but	but	CCONJ
njb-29	182	19	in	in	ADP
njb-29	182	20	all	all	DET
njb-29	182	21	other	other	ADJ
njb-29	182	22	isolates	isolate	NOUN
njb-29	182	23	,	,	PUNCT
njb-29	182	24	-gcs	-gcs	DET
njb-29	182	25	probe	probe	NOUN
njb-29	182	26	hybridized	hybridize	VERB
njb-29	182	27	to	to	ADP
njb-29	182	28	a	a	DET
njb-29	182	29	single	single	ADJ
njb-29	182	30	hybridizing	hybridize	VERB
njb-29	182	31	fragment	fragment	NOUN
njb-29	182	32	of	of	ADP
njb-29	182	33	10	10	NUM
njb-29	182	34	-	-	PUNCT
njb-29	182	35	kb	kb	NOUN
njb-29	182	36	(	(	PUNCT
njb-29	182	37	figure	figure	NOUN
njb-29	182	38	4a	4a	NUM
njb-29	182	39	)	)	PUNCT
njb-29	182	40	.	.	PUNCT
njb-29	183	1	sag	sag	PROPN
njb-29	183	2	-	-	PUNCT
njb-29	183	3	s	s	NOUN
njb-29	183	4	isolate	isolate	NOUN
njb-29	184	1	,	,	PUNCT
njb-29	184	2	rk1	rk1	PROPN
njb-29	184	3	-	-	PUNCT
njb-29	184	4	s	s	PROPN
njb-29	184	5	was	be	AUX
njb-29	184	6	again	again	ADV
njb-29	184	7	an	an	DET
njb-29	184	8	exception	exception	NOUN
njb-29	184	9	since	since	SCONJ
njb-29	184	10	it	it	PRON
njb-29	184	11	showed	show	VERB
njb-29	184	12	amplification	amplification	NOUN
njb-29	184	13	of	of	ADP
njb-29	184	14	the	the	DET
njb-29	184	15	-gcs	-gcs	PROPN
njb-29	184	16	gene	gene	NOUN
njb-29	184	17	(	(	PUNCT
njb-29	184	18	figure	figure	NOUN
njb-29	184	19	4a	4a	NUM
njb-29	184	20	)	)	PUNCT
njb-29	184	21	.	.	PUNCT
njb-29	185	1	comparison	comparison	NOUN
njb-29	185	2	of	of	ADP
njb-29	185	3	gcs	gcs	ADJ
njb-29	185	4	gene	gene	NOUN
njb-29	185	5	expression	expression	NOUN
njb-29	185	6	in	in	ADP
njb-29	185	7	sag	sag	PROPN
njb-29	185	8	-	-	PUNCT
njb-29	185	9	s	s	NOUN
njb-29	185	10	versus	versus	X
njb-29	185	11	sag	sag	ADJ
njb-29	185	12	-	-	PUNCT
njb-29	185	13	r	r	NOUN
njb-29	185	14	field	field	NOUN
njb-29	185	15	isolates	isolate	NOUN
njb-29	185	16	was	be	AUX
njb-29	185	17	done	do	VERB
njb-29	185	18	to	to	PART
njb-29	185	19	verify	verify	VERB
njb-29	185	20	if	if	SCONJ
njb-29	185	21	there	there	PRON
njb-29	185	22	is	be	VERB
njb-29	185	23	any	any	DET
njb-29	185	24	correlation	correlation	NOUN
njb-29	185	25	between	between	ADP
njb-29	185	26	gene	gene	NOUN
njb-29	185	27	expression	expression	NOUN
njb-29	185	28	and	and	CCONJ
njb-29	185	29	sag	sag	ADJ
njb-29	185	30	sensitivity	sensitivity	NOUN
njb-29	185	31	profile	profile	NOUN
njb-29	185	32	of	of	ADP
njb-29	185	33	the	the	DET
njb-29	185	34	clinical	clinical	ADJ
njb-29	185	35	isolates	isolate	NOUN
njb-29	185	36	.	.	PUNCT
njb-29	186	1	real	real	ADJ
njb-29	186	2	-	-	PUNCT
njb-29	186	3	time	time	NOUN
njb-29	186	4	pcr	pcr	NOUN
njb-29	186	5	using	use	VERB
njb-29	186	6	-gcs	-gcs	PUNCT
njb-29	186	7	(	(	PUNCT
njb-29	186	8	gene	gene	NOUN
njb-29	186	9	specific	specific	NOUN
njb-29	186	10	)	)	PUNCT
njb-29	186	11	and	and	CCONJ
njb-29	186	12	gapdh	gapdh	NOUN
njb-29	186	13	(	(	PUNCT
njb-29	186	14	internal	internal	ADJ
njb-29	186	15	control	control	NOUN
njb-29	186	16	)	)	PUNCT
njb-29	186	17	primers	primer	NOUN
njb-29	186	18	was	be	AUX
njb-29	186	19	performed	perform	VERB
njb-29	186	20	.	.	PUNCT
njb-29	187	1	up	up	ADP
njb-29	187	2	-	-	PUNCT
njb-29	187	3	regulation	regulation	NOUN
njb-29	187	4	of	of	ADP
njb-29	187	5	-gcs	-gcs	DET
njb-29	187	6	expression	expression	NOUN
njb-29	187	7	was	be	AUX
njb-29	187	8	observed	observe	VERB
njb-29	187	9	in	in	ADP
njb-29	187	10	the	the	DET
njb-29	187	11	resistant	resistant	ADJ
njb-29	187	12	clinical	clinical	ADJ
njb-29	187	13	isolates	isolate	NOUN
njb-29	187	14	.	.	PUNCT
njb-29	188	1	-gcs	-gcs	NUM
njb-29	188	2	expression	expression	NOUN
njb-29	188	3	in	in	ADP
njb-29	188	4	the	the	DET
njb-29	188	5	resistant	resistant	ADJ
njb-29	188	6	strains	strain	NOUN
njb-29	188	7	,	,	PUNCT
njb-29	188	8	mc4	mc4	PROPN
njb-29	188	9	-	-	PUNCT
njb-29	188	10	r	r	PROPN
njb-29	188	11	,	,	PUNCT
njb-29	188	12	mc8	mc8	PROPN
njb-29	188	13	-	-	PUNCT
njb-29	188	14	r	r	PROPN
njb-29	188	15	,	,	PUNCT
njb-29	188	16	mc9	mc9	PROPN
njb-29	188	17	-	-	PUNCT
njb-29	188	18	r	r	PROPN
njb-29	188	19	,	,	PUNCT
njb-29	188	20	nr3a	nr3a	ADV
njb-29	188	21	-	-	PUNCT
njb-29	188	22	r	r	ADJ
njb-29	188	23	,	,	PUNCT
njb-29	188	24	rmp8	rmp8	PROPN
njb-29	188	25	-	-	PUNCT
njb-29	188	26	r	r	PROPN
njb-29	188	27	,	,	PUNCT
njb-29	188	28	rmp19	rmp19	NOUN
njb-29	188	29	-	-	PUNCT
njb-29	188	30	r	r	NOUN
njb-29	188	31	,	,	PUNCT
njb-29	188	32	rmp142	rmp142	PROPN
njb-29	188	33	-	-	PUNCT
njb-29	188	34	r	r	PROPN
njb-29	188	35	,	,	PUNCT
njb-29	188	36	rmp155	rmp155	PROPN
njb-29	188	37	-	-	PUNCT
njb-29	188	38	r	r	PROPN
njb-29	188	39	and	and	CCONJ
njb-29	188	40	rmp240	rmp240	PROPN
njb-29	188	41	-	-	PUNCT
njb-29	188	42	r	r	NOUN
njb-29	188	43	was	be	AUX
njb-29	188	44	4.3-	4.3-	NUM
njb-29	188	45	,	,	PUNCT
njb-29	188	46	5.2-	5.2-	NUM
njb-29	188	47	,	,	PUNCT
njb-29	188	48	6.4-	6.4-	NUM
njb-29	188	49	,	,	PUNCT
njb-29	188	50	5.5-	5.5-	NUM
njb-29	188	51	,	,	PUNCT
njb-29	188	52	3.0-	3.0-	NUM
njb-29	188	53	,	,	PUNCT
njb-29	188	54	5.0-	5.0-	NUM
njb-29	188	55	,	,	PUNCT
njb-29	188	56	5.3-	5.3-	NUM
njb-29	188	57	,	,	PUNCT
njb-29	188	58	4.2	4.2	NUM
njb-29	188	59	and	and	CCONJ
njb-29	188	60	8.8fold	8.8fold	NUM
njb-29	188	61	more	more	ADV
njb-29	188	62	respectively	respectively	ADV
njb-29	188	63	compared	compare	VERB
njb-29	188	64	to	to	ADP
njb-29	188	65	the	the	DET
njb-29	188	66	expression	expression	NOUN
njb-29	188	67	in	in	ADP
njb-29	188	68	the	the	DET
njb-29	188	69	sensitive	sensitive	ADJ
njb-29	188	70	isolate	isolate	NOUN
njb-29	188	71	,	,	PUNCT
njb-29	188	72	2001	2001	NUM
njb-29	188	73	-	-	PUNCT
njb-29	188	74	s	s	NOUN
njb-29	188	75	(	(	PUNCT
njb-29	188	76	figure	figure	NOUN
njb-29	188	77	4b	4b	NUM
njb-29	188	78	)	)	PUNCT
njb-29	188	79	.	.	PUNCT
njb-29	189	1	in	in	ADP
njb-29	189	2	the	the	DET
njb-29	189	3	present	present	ADJ
njb-29	189	4	study	study	NOUN
njb-29	189	5	though	though	SCONJ
njb-29	189	6	upregulation	upregulation	NOUN
njb-29	189	7	of	of	ADP
njb-29	189	8	-gcs	-gcs	NUM
njb-29	189	9	was	be	AUX
njb-29	189	10	observed	observe	VERB
njb-29	189	11	in	in	ADP
njb-29	189	12	all	all	DET
njb-29	189	13	sag	sag	ADJ
njb-29	189	14	-	-	PUNCT
njb-29	189	15	r	r	NOUN
njb-29	189	16	isolates	isolate	NOUN
njb-29	189	17	,	,	PUNCT
njb-29	189	18	interestingly	interestingly	ADV
njb-29	189	19	one	one	NUM
njb-29	189	20	sag	sag	PROPN
njb-29	189	21	-	-	PUNCT
njb-29	189	22	s	s	NOUN
njb-29	189	23	isolate	isolate	NOUN
njb-29	189	24	,	,	PUNCT
njb-29	189	25	rk1	rk1	PROPN
njb-29	189	26	-	-	PUNCT
njb-29	189	27	s	s	PROPN
njb-29	189	28	showed	show	VERB
njb-29	189	29	5.5	5.5	NUM
njb-29	189	30	-	-	PUNCT
njb-29	189	31	fold	fold	VERB
njb-29	189	32	up	up	NOUN
njb-29	189	33	-	-	PUNCT
njb-29	189	34	regulation	regulation	NOUN
njb-29	189	35	of	of	ADP
njb-29	189	36	gcs	gcs	ADJ
njb-29	189	37	expression	expression	NOUN
njb-29	189	38	when	when	SCONJ
njb-29	189	39	compared	compare	VERB
njb-29	189	40	to	to	ADP
njb-29	189	41	a	a	DET
njb-29	189	42	sag	sag	PROPN
njb-29	189	43	-	-	PUNCT
njb-29	189	44	s	s	NOUN
njb-29	189	45	isolate	isolate	PROPN
njb-29	189	46	,	,	PUNCT
njb-29	189	47	2001	2001	NUM
njb-29	189	48	-	-	PUNCT
njb-29	189	49	s	s	NOUN
njb-29	189	50	(	(	PUNCT
njb-29	189	51	figure	figure	NOUN
njb-29	189	52	4b	4b	NUM
njb-29	189	53	)	)	PUNCT
njb-29	189	54	.	.	PUNCT
njb-29	190	1	l	l	NOUN
njb-29	190	2	-	-	PUNCT
njb-29	190	3	butathione	butathione	NOUN
njb-29	190	4	-	-	PUNCT
njb-29	190	5	sulfoxamine	sulfoxamine	PROPN
njb-29	190	6	(	(	PUNCT
njb-29	190	7	bso	bso	PROPN
njb-29	190	8	)	)	PUNCT
njb-29	190	9	,	,	PUNCT
njb-29	190	10	an	an	DET
njb-29	190	11	inhibitor	inhibitor	NOUN
njb-29	190	12	of	of	ADP
njb-29	190	13	-gcs	-gcs	NUM
njb-29	190	14	was	be	AUX
njb-29	190	15	used	use	VERB
njb-29	190	16	to	to	PART
njb-29	190	17	compare	compare	VERB
njb-29	190	18	its	its	PRON
njb-29	190	19	effect	effect	NOUN
njb-29	190	20	on	on	ADP
njb-29	190	21	the	the	DET
njb-29	190	22	sag	sag	PROPN
njb-29	190	23	-	-	PUNCT
njb-29	190	24	s	s	NOUN
njb-29	190	25	isolate	isolate	NOUN
njb-29	190	26	,	,	PUNCT
njb-29	190	27	rk1	rk1	PROPN
njb-29	190	28	-	-	PUNCT
njb-29	190	29	s	s	PROPN
njb-29	190	30	and	and	CCONJ
njb-29	190	31	2001	2001	NUM
njb-29	190	32	-	-	PUNCT
njb-29	190	33	s.	s.	PROPN
njb-29	190	34	rk1	rk1	PROPN
njb-29	190	35	-	-	PUNCT
njb-29	190	36	s	s	PART
njb-29	190	37	promastigotes	promastigote	NOUN
njb-29	190	38	overexpressing	overexpresse	VERB
njb-29	190	39	-gcs	-gcs	NUM
njb-29	190	40	were	be	AUX
njb-29	190	41	~5	~5	ADJ
njb-29	190	42	fold	fold	ADV
njb-29	190	43	more	more	ADV
njb-29	190	44	resistant	resistant	ADJ
njb-29	190	45	to	to	ADP
njb-29	190	46	bso	bso	PROPN
njb-29	190	47	when	when	SCONJ
njb-29	190	48	compared	compare	VERB
njb-29	190	49	to	to	ADP
njb-29	190	50	the	the	DET
njb-29	190	51	ic50	ic50	PROPN
njb-29	190	52	of	of	ADP
njb-29	190	53	promastigotes	promastigote	NOUN
njb-29	190	54	of	of	ADP
njb-29	190	55	the	the	DET
njb-29	190	56	2001	2001	NUM
njb-29	190	57	-	-	PUNCT
njb-29	190	58	s	s	PROPN
njb-29	190	59	,	,	PUNCT
njb-29	190	60	the	the	DET
njb-29	190	61	ic50	ic50	PROPN
njb-29	190	62	being	be	AUX
njb-29	190	63	6.5	6.5	NUM
njb-29	190	64	±	±	NOUN
njb-29	190	65	0.5	0.5	NUM
njb-29	190	66	mm	mm	NOUN
njb-29	190	67	and	and	CCONJ
njb-29	190	68	1.3	1.3	NUM
njb-29	190	69	±	±	NOUN
njb-29	190	70	0.3	0.3	NUM
njb-29	190	71	mm	mm	NOUN
njb-29	190	72	respectively	respectively	ADV
njb-29	190	73	.	.	PUNCT
njb-29	191	1	nepal	nepal	ADJ
njb-29	191	2	journal	journal	PROPN
njb-29	191	3	of	of	ADP
njb-29	191	4	biotechnology	biotechnology	NOUN
njb-29	191	5	.	.	PUNCT
njb-29	192	1	d	d	X
njb-29	192	2	e	e	PROPN
njb-29	192	3	c	c	PROPN
njb-29	192	4	.	.	PUNCT
njb-29	193	1	2	2	NUM
njb-29	193	2	0	0	NUM
njb-29	193	3	1	1	NUM
njb-29	193	4	6	6	NUM
njb-29	193	5	vol	vol	NOUN
njb-29	193	6	.	.	PROPN
njb-29	194	1	4	4	NUM
njb-29	194	2	,	,	PUNCT
njb-29	194	3	no	no	NOUN
njb-29	194	4	.	.	NOUN
njb-29	194	5	1	1	NUM
njb-29	194	6	:	:	SYM
njb-29	194	7	1	1	NUM
njb-29	194	8	-	-	SYM
njb-29	194	9	13	13	NUM
njb-29	194	10	maharjan	maharjan	NOUN
njb-29	194	11	et	et	NOUN
njb-29	194	12	al	al	PROPN
njb-29	194	13	.	.	PUNCT
njb-29	195	1	©	©	PROPN
njb-29	195	2	njb	njb	PROPN
njb-29	195	3	,	,	PUNCT
njb-29	195	4	biotechnology	biotechnology	NOUN
njb-29	195	5	society	society	NOUN
njb-29	195	6	of	of	ADP
njb-29	195	7	nepal	nepal	ADJ
njb-29	195	8	10	10	NUM
njb-29	195	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	195	10	figure	figure	NOUN
njb-29	195	11	5	5	NUM
njb-29	195	12	:	:	PUNCT
njb-29	195	13	over	over	ADP
njb-29	195	14	-	-	PUNCT
njb-29	195	15	expression	expression	NOUN
njb-29	195	16	of	of	ADP
njb-29	195	17	mrpa	mrpa	NOUN
njb-29	195	18	and	and	CCONJ
njb-29	195	19	γ	γ	PROPN
njb-29	195	20	-	-	PUNCT
njb-29	195	21	gcs	gcs	PROPN
njb-29	195	22	gene	gene	NOUN
njb-29	195	23	in	in	ADP
njb-29	195	24	a	a	DET
njb-29	195	25	sensitive	sensitive	PROPN
njb-29	195	26	l.	l.	PROPN
njb-29	195	27	donovani	donovani	PROPN
njb-29	195	28	isolate	isolate	PROPN
njb-29	195	29	.	.	PUNCT
njb-29	196	1	a	a	DET
njb-29	196	2	:	:	PUNCT
njb-29	196	3	transfection	transfection	NOUN
njb-29	196	4	of	of	ADP
njb-29	196	5	mrpa	mrpa	PROPN
njb-29	196	6	in	in	ADP
njb-29	196	7	sag	sag	ADJ
njb-29	196	8	-	-	PUNCT
njb-29	196	9	sensitive	sensitive	ADJ
njb-29	196	10	isolate	isolate	VERB
njb-29	196	11	leads	lead	NOUN
njb-29	196	12	to	to	ADP
njb-29	196	13	resistance	resistance	NOUN
njb-29	196	14	to	to	ADP
njb-29	196	15	antimony	antimony	NOUN
njb-29	196	16	in	in	ADP
njb-29	196	17	amastigotes	amastigote	NOUN
njb-29	196	18	.	.	PUNCT
njb-29	197	1	ag83	ag83	PROPN
njb-29	197	2	-	-	PUNCT
njb-29	197	3	s	s	NOUN
njb-29	197	4	(	(	PUNCT
njb-29	197	5	-	-	PUNCT
njb-29	197	6	■	■	NOUN
njb-29	197	7	-	-	PUNCT
njb-29	197	8	)	)	PUNCT
njb-29	197	9	was	be	AUX
njb-29	197	10	transfected	transfecte	VERB
njb-29	197	11	with	with	ADP
njb-29	197	12	pgl-neoluc	pgl-neoluc	NOUN
njb-29	197	13	,	,	PUNCT
njb-29	197	14	ag83	ag83	PROPN
njb-29	197	15	-	-	PUNCT
njb-29	197	16	s	s	NOUN
njb-29	197	17	+	+	CCONJ
njb-29	197	18	ldmrpa	ldmrpa	NOUN
njb-29	197	19	(	(	PUNCT
njb-29	197	20	-	-	PUNCT
njb-29	197	21	□	□	NUM
njb-29	197	22	-	-	NUM
njb-29	197	23	)	)	PUNCT
njb-29	197	24	was	be	AUX
njb-29	197	25	transfected	transfecte	VERB
njb-29	197	26	with	with	ADP
njb-29	197	27	pgem72f-neo-mrpa	pgem72f-neo-mrpa	NOUN
njb-29	197	28	+	+	CCONJ
njb-29	197	29	pglneoluc	pglneoluc	NOUN
njb-29	197	30	and	and	CCONJ
njb-29	197	31	sensitivity	sensitivity	NOUN
njb-29	197	32	to	to	PART
njb-29	197	33	sag	sag	VERB
njb-29	197	34	in	in	ADP
njb-29	197	35	the	the	DET
njb-29	197	36	j774a.1	j774a.1	NOUN
njb-29	197	37	line	line	NOUN
njb-29	197	38	was	be	AUX
njb-29	197	39	measured	measure	VERB
njb-29	197	40	as	as	SCONJ
njb-29	197	41	described	describe	VERB
njb-29	197	42	in	in	ADP
njb-29	197	43	materials	material	NOUN
njb-29	197	44	and	and	CCONJ
njb-29	197	45	methods	method	NOUN
njb-29	197	46	.	.	PUNCT
njb-29	198	1	each	each	DET
njb-29	198	2	data	data	NOUN
njb-29	198	3	point	point	NOUN
njb-29	198	4	represents	represent	VERB
njb-29	198	5	the	the	DET
njb-29	198	6	mean	mean	NOUN
njb-29	198	7			PROPN
njb-29	198	8	sd	sd	NOUN
njb-29	198	9	of	of	ADP
njb-29	198	10	three	three	NUM
njb-29	198	11	determinations	determination	NOUN
njb-29	198	12	.	.	PUNCT
njb-29	199	1	northern	northern	ADJ
njb-29	199	2	blot	blot	NOUN
njb-29	199	3	analysis	analysis	NOUN
njb-29	199	4	(	(	PUNCT
njb-29	199	5	insets	inset	NOUN
njb-29	199	6	in	in	ADP
njb-29	199	7	a	a	PRON
njb-29	199	8	)	)	PUNCT
njb-29	199	9	of	of	ADP
njb-29	199	10	vector	vector	NOUN
njb-29	199	11	transfected	transfecte	VERB
njb-29	199	12	controls	control	NOUN
njb-29	199	13	and	and	CCONJ
njb-29	199	14	mrpa	mrpa	ADV
njb-29	199	15	transfected	transfecte	VERB
njb-29	199	16	lines	line	NOUN
njb-29	199	17	was	be	AUX
njb-29	199	18	performed	perform	VERB
njb-29	199	19	as	as	SCONJ
njb-29	199	20	described	describe	VERB
njb-29	199	21	under	under	ADP
njb-29	199	22	methods	method	NOUN
njb-29	199	23	section	section	PROPN
njb-29	199	24	b	b	PROPN
njb-29	199	25	:	:	PUNCT
njb-29	199	26	transfection	transfection	NOUN
njb-29	199	27	of	of	ADP
njb-29	199	28	γ	γ	PROPN
njb-29	199	29	-	-	PUNCT
njb-29	199	30	gcs	gcs	PROPN
njb-29	199	31	gene	gene	NOUN
njb-29	199	32	in	in	ADP
njb-29	199	33	sagsensitive	sagsensitive	PROPN
njb-29	199	34	isolate	isolate	NOUN
njb-29	199	35	leads	lead	VERB
njb-29	199	36	to	to	ADP
njb-29	199	37	antimony	antimony	NOUN
njb-29	199	38	resistance	resistance	NOUN
njb-29	199	39	in	in	ADP
njb-29	199	40	intracellular	intracellular	ADJ
njb-29	199	41	amastigotes	amastigote	NOUN
njb-29	199	42	.	.	PUNCT
njb-29	200	1	ag83	ag83	PROPN
njb-29	200	2	-	-	PUNCT
njb-29	200	3	s	s	NOUN
njb-29	200	4	(	(	PUNCT
njb-29	200	5	-	-	PUNCT
njb-29	200	6	■	■	NOUN
njb-29	200	7	-	-	NOUN
njb-29	200	8	)	)	PUNCT
njb-29	200	9	transfected	transfecte	VERB
njb-29	200	10	with	with	ADP
njb-29	200	11	pgl-neoluc	pgl-neoluc	NOUN
njb-29	200	12	,	,	PUNCT
njb-29	200	13	ag83	ag83	PROPN
njb-29	200	14	-	-	PUNCT
njb-29	200	15	s	s	NOUN
njb-29	200	16	+	+	SYM
njb-29	200	17	γ	γ	NOUN
njb-29	200	18	-	-	PUNCT
njb-29	200	19	gcs	gcs	PROPN
njb-29	200	20	(	(	PUNCT
njb-29	200	21	-	-	PUNCT
njb-29	200	22	□	□	NUM
njb-29	200	23	-	-	NUM
njb-29	200	24	)	)	PUNCT
njb-29	200	25	transfected	transfecte	VERB
njb-29	200	26	with	with	ADP
njb-29	200	27	psphygro-gcs	psphygro-gcs	NOUN
njb-29	200	28	+	+	CCONJ
njb-29	200	29	pglneoluc	pglneoluc	NOUN
njb-29	200	30	and	and	CCONJ
njb-29	200	31	sensitivity	sensitivity	NOUN
njb-29	200	32	to	to	PART
njb-29	200	33	sag	sag	VERB
njb-29	200	34	measured	measure	VERB
njb-29	200	35	as	as	SCONJ
njb-29	200	36	described	describe	VERB
njb-29	200	37	in	in	ADP
njb-29	200	38	materials	material	NOUN
njb-29	200	39	and	and	CCONJ
njb-29	200	40	methods	method	NOUN
njb-29	200	41	.	.	PUNCT
njb-29	201	1	each	each	DET
njb-29	201	2	data	data	NOUN
njb-29	201	3	point	point	NOUN
njb-29	201	4	represents	represent	VERB
njb-29	201	5	the	the	DET
njb-29	201	6	mean	mean	NOUN
njb-29	201	7			PROPN
njb-29	201	8	sd	sd	NOUN
njb-29	201	9	of	of	ADP
njb-29	201	10	three	three	NUM
njb-29	201	11	determinations	determination	NOUN
njb-29	201	12	.	.	PUNCT
njb-29	202	1	northern	northern	ADJ
njb-29	202	2	blot	blot	NOUN
njb-29	202	3	analysis	analysis	NOUN
njb-29	202	4	(	(	PUNCT
njb-29	202	5	insets	inset	NOUN
njb-29	202	6	in	in	ADP
njb-29	202	7	b	b	NOUN
njb-29	202	8	)	)	PUNCT
njb-29	202	9	of	of	ADP
njb-29	202	10	vector	vector	NOUN
njb-29	202	11	transfected	transfecte	VERB
njb-29	202	12	controls	control	NOUN
njb-29	202	13	and	and	CCONJ
njb-29	202	14	γ	γ	PROPN
njb-29	202	15	-	-	PUNCT
njb-29	202	16	gcs	gcs	PROPN
njb-29	202	17	transfected	transfecte	VERB
njb-29	202	18	lines	line	NOUN
njb-29	202	19	was	be	AUX
njb-29	202	20	performed	perform	VERB
njb-29	202	21	as	as	SCONJ
njb-29	202	22	described	describe	VERB
njb-29	202	23	under	under	ADP
njb-29	202	24	methods	method	NOUN
njb-29	202	25	section	section	NOUN
njb-29	202	26	.	.	PUNCT
njb-29	203	1	overexpression	overexpression	NOUN
njb-29	203	2	of	of	ADP
njb-29	203	3	mrpa	mrpa	NOUN
njb-29	203	4	or	or	CCONJ
njb-29	203	5	-gcs	-gcs	NUM
njb-29	203	6	in	in	ADP
njb-29	203	7	an	an	DET
njb-29	203	8	antimony	antimony	NOUN
njb-29	203	9	-	-	PUNCT
njb-29	203	10	sensitive	sensitive	ADJ
njb-29	203	11	isolate	isolate	VERB
njb-29	203	12	conferred	confer	VERB
njb-29	203	13	increased	increase	VERB
njb-29	203	14	expression	expression	NOUN
njb-29	203	15	and	and	CCONJ
njb-29	203	16	resistance	resistance	NOUN
njb-29	203	17	to	to	ADP
njb-29	203	18	antimony	antimony	NOUN
njb-29	203	19	to	to	PART
njb-29	203	20	determine	determine	VERB
njb-29	203	21	whether	whether	SCONJ
njb-29	203	22	overexpression	overexpression	NOUN
njb-29	203	23	of	of	ADP
njb-29	203	24	mrpa	mrpa	NOUN
njb-29	203	25	and	and	CCONJ
njb-29	203	26	-gcs	-gcs	PUNCT
njb-29	203	27	conferred	confer	VERB
njb-29	203	28	antimony	antimony	NOUN
njb-29	203	29	resistance	resistance	NOUN
njb-29	203	30	in	in	ADP
njb-29	203	31	a	a	DET
njb-29	203	32	sensitive	sensitive	ADJ
njb-29	203	33	isolate	isolate	NOUN
njb-29	203	34	,	,	PUNCT
njb-29	203	35	we	we	PRON
njb-29	203	36	transfected	transfecte	VERB
njb-29	203	37	mrpa	mrpa	NOUN
njb-29	203	38	or	or	CCONJ
njb-29	203	39	-gcs	-gcs	NUM
njb-29	203	40	constructs	construct	VERB
njb-29	203	41	into	into	ADP
njb-29	203	42	a	a	DET
njb-29	203	43	sag	sag	PROPN
njb-29	203	44	-	-	PUNCT
njb-29	203	45	s	s	NOUN
njb-29	203	46	isolate	isolate	NOUN
njb-29	203	47	,	,	PUNCT
njb-29	203	48	ag83	ag83	PROPN
njb-29	203	49	-	-	PUNCT
njb-29	203	50	s.	s.	PROPN
njb-29	203	51	these	these	DET
njb-29	203	52	mrpa	mrpa	NOUN
njb-29	203	53	and	and	CCONJ
njb-29	203	54	-gcs	-gcs	PUNCT
njb-29	203	55	recombinant	recombinant	ADJ
njb-29	203	56	parasites	parasite	NOUN
njb-29	203	57	were	be	AUX
njb-29	203	58	co	co	VERB
njb-29	203	59	-	-	VERB
njb-29	203	60	transfected	transfecte	VERB
njb-29	203	61	with	with	ADP
njb-29	203	62	pgl-neoluc	pgl-neoluc	NOUN
njb-29	203	63	,	,	PUNCT
njb-29	203	64	encoding	encode	VERB
njb-29	203	65	luc	luc	PROPN
njb-29	203	66	.	.	PUNCT
njb-29	204	1	intracellular	intracellular	PROPN
njb-29	204	2	amastigotes	amastigote	VERB
njb-29	204	3	over	over	ADP
njb-29	204	4	-	-	PUNCT
njb-29	204	5	expressing	express	VERB
njb-29	204	6	mrpa	mrpa	NOUN
njb-29	204	7	(	(	PUNCT
njb-29	204	8	ic50	ic50	PROPN
njb-29	204	9	,	,	PUNCT
njb-29	204	10	32.3	32.3	NUM
njb-29	204	11	±	±	NOUN
njb-29	204	12	6.4	6.4	NUM
njb-29	204	13	g	g	NUM
njb-29	204	14	/	/	SYM
njb-29	204	15	ml	ml	PROPN
njb-29	204	16	)	)	PUNCT
njb-29	204	17	were	be	AUX
njb-29	204	18	3.6	3.6	NUM
njb-29	204	19	-	-	ADJ
njb-29	204	20	fold	fold	ADV
njb-29	204	21	more	more	ADV
njb-29	204	22	resistant	resistant	ADJ
njb-29	204	23	to	to	PART
njb-29	204	24	sag	sag	VERB
njb-29	204	25	when	when	SCONJ
njb-29	204	26	compared	compare	VERB
njb-29	204	27	to	to	ADP
njb-29	204	28	amastigotes	amastigote	NOUN
njb-29	204	29	of	of	ADP
njb-29	204	30	the	the	DET
njb-29	204	31	parent	parent	NOUN
njb-29	204	32	strain	strain	NOUN
njb-29	204	33	transfected	transfecte	VERB
njb-29	204	34	with	with	ADP
njb-29	204	35	the	the	DET
njb-29	204	36	control	control	NOUN
njb-29	204	37	vector	vector	NOUN
njb-29	204	38	(	(	PUNCT
njb-29	204	39	ic50	ic50	PROPN
njb-29	204	40	,	,	PUNCT
njb-29	204	41	9	9	NUM
njb-29	204	42	±	±	NOUN
njb-29	204	43	0.5	0.5	NUM
njb-29	204	44	g	g	NUM
njb-29	204	45	/	/	SYM
njb-29	204	46	ml	ml	PROPN
njb-29	204	47	)	)	PUNCT
njb-29	204	48	(	(	PUNCT
njb-29	204	49	figure	figure	NOUN
njb-29	204	50	5a	5a	NUM
njb-29	204	51	)	)	PUNCT
njb-29	204	52	.	.	PUNCT
njb-29	205	1	intracellular	intracellular	PROPN
njb-29	205	2	amastigotes	amastigote	VERB
njb-29	205	3	over	over	ADP
njb-29	205	4	-	-	PUNCT
njb-29	205	5	expressing	express	VERB
njb-29	205	6	gcs	gcs	NOUN
njb-29	205	7	were	be	AUX
njb-29	205	8	3.3	3.3	NUM
njb-29	205	9	-	-	ADJ
njb-29	205	10	fold	fold	ADJ
njb-29	205	11	resistant	resistant	ADJ
njb-29	205	12	to	to	PART
njb-29	205	13	sag	sag	VERB
njb-29	205	14	when	when	SCONJ
njb-29	205	15	compared	compare	VERB
njb-29	205	16	to	to	ADP
njb-29	205	17	the	the	DET
njb-29	205	18	sensitive	sensitive	PROPN
njb-29	205	19	l.	l.	PROPN
njb-29	205	20	donovani	donovani	PROPN
njb-29	205	21	the	the	DET
njb-29	205	22	ic50	ic50	PROPN
njb-29	205	23	value	value	NOUN
njb-29	205	24	being	be	AUX
njb-29	205	25	(	(	PUNCT
njb-29	205	26	29.7	29.7	NUM
njb-29	205	27	±	±	NOUN
njb-29	205	28	1.5	1.5	NUM
njb-29	205	29	g	g	NUM
njb-29	205	30	/	/	SYM
njb-29	205	31	ml	ml	PROPN
njb-29	205	32	)	)	PUNCT
njb-29	205	33	respectively	respectively	ADV
njb-29	205	34	(	(	PUNCT
njb-29	205	35	figure	figure	VERB
njb-29	205	36	5b	5b	NUM
njb-29	205	37	)	)	PUNCT
njb-29	205	38	.	.	PUNCT
njb-29	206	1	in	in	ADP
njb-29	206	2	our	our	PRON
njb-29	206	3	previous	previous	ADJ
njb-29	206	4	studies	study	NOUN
njb-29	206	5	we	we	PRON
njb-29	206	6	had	have	AUX
njb-29	206	7	demonstrated	demonstrate	VERB
njb-29	206	8	that	that	SCONJ
njb-29	206	9	the	the	DET
njb-29	206	10	odc	odc	PROPN
njb-29	206	11	overexpressors	overexpressor	NOUN
njb-29	206	12	exhibited	exhibit	VERB
njb-29	206	13	significant	significant	ADJ
njb-29	206	14	resistance	resistance	NOUN
njb-29	206	15	to	to	ADP
njb-29	206	16	pentostam	pentostam	NOUN
njb-29	206	17	compared	compare	VERB
njb-29	206	18	to	to	ADP
njb-29	206	19	the	the	DET
njb-29	206	20	wild	wild	ADJ
njb-29	206	21	type	type	NOUN
njb-29	206	22	cells	cell	NOUN
njb-29	206	23	(	(	PUNCT
njb-29	206	24	26	26	NUM
njb-29	206	25	)	)	PUNCT
njb-29	206	26	.	.	PUNCT
njb-29	207	1	intracellular	intracellular	PROPN
njb-29	207	2	amastigotes	amastigote	VERB
njb-29	207	3	over	over	ADP
njb-29	207	4	-	-	PUNCT
njb-29	207	5	expressing	express	VERB
njb-29	207	6	odc	odc	PROPN
njb-29	207	7	(	(	PUNCT
njb-29	207	8	ic50	ic50	PROPN
njb-29	207	9	,	,	PUNCT
njb-29	207	10	>	>	X
njb-29	207	11	80	80	NUM
njb-29	207	12	g	g	NUM
njb-29	207	13	/	/	SYM
njb-29	207	14	ml	ml	PROPN
njb-29	207	15	)	)	PUNCT
njb-29	207	16	were	be	AUX
njb-29	207	17	>	>	X
njb-29	207	18	8.8	8.8	NUM
njb-29	207	19	-	-	PUNCT
njb-29	207	20	fold	fold	VERB
njb-29	207	21	more	more	ADV
njb-29	207	22	resistant	resistant	ADJ
njb-29	207	23	to	to	PART
njb-29	207	24	sag	sag	VERB
njb-29	207	25	when	when	SCONJ
njb-29	207	26	compared	compare	VERB
njb-29	207	27	to	to	ADP
njb-29	207	28	amastigotes	amastigote	NOUN
njb-29	207	29	of	of	ADP
njb-29	207	30	the	the	DET
njb-29	207	31	parent	parent	NOUN
njb-29	207	32	strain	strain	NOUN
njb-29	207	33	transfected	transfecte	VERB
njb-29	207	34	with	with	ADP
njb-29	207	35	the	the	DET
njb-29	207	36	control	control	NOUN
njb-29	207	37	vector	vector	NOUN
njb-29	207	38	[	[	PUNCT
njb-29	207	39	26	26	NUM
njb-29	207	40	]	]	PUNCT
njb-29	207	41	.	.	PUNCT
njb-29	208	1	discussion	discussion	NOUN
njb-29	208	2	currently	currently	ADV
njb-29	208	3	,	,	PUNCT
njb-29	208	4	chemotherapy	chemotherapy	NOUN
njb-29	208	5	is	be	AUX
njb-29	208	6	the	the	DET
njb-29	208	7	only	only	ADJ
njb-29	208	8	effective	effective	ADJ
njb-29	208	9	way	way	NOUN
njb-29	208	10	to	to	PART
njb-29	208	11	control	control	VERB
njb-29	208	12	leishmania	leishmania	PROPN
njb-29	208	13	infection	infection	NOUN
njb-29	208	14	.	.	PUNCT
njb-29	209	1	pentavalent	pentavalent	NOUN
njb-29	209	2	antimonials	antimonial	NOUN
njb-29	209	3	are	be	AUX
njb-29	209	4	the	the	DET
njb-29	209	5	mainstay	mainstay	NOUN
njb-29	209	6	of	of	ADP
njb-29	209	7	therapy	therapy	NOUN
njb-29	209	8	in	in	ADP
njb-29	209	9	the	the	DET
njb-29	209	10	treatment	treatment	NOUN
njb-29	209	11	of	of	ADP
njb-29	209	12	visceral	visceral	NOUN
njb-29	209	13	leishmaniasis	leishmaniasis	NOUN
njb-29	209	14	[	[	PUNCT
njb-29	209	15	27	27	NUM
njb-29	209	16	]	]	PUNCT
njb-29	209	17	.	.	PUNCT
njb-29	210	1	increase	increase	NOUN
njb-29	210	2	in	in	ADP
njb-29	210	3	resistance	resistance	NOUN
njb-29	210	4	to	to	ADP
njb-29	210	5	sag	sag	PROPN
njb-29	210	6	has	have	AUX
njb-29	210	7	led	lead	VERB
njb-29	210	8	to	to	ADP
njb-29	210	9	an	an	DET
njb-29	210	10	upsurge	upsurge	NOUN
njb-29	210	11	in	in	ADP
njb-29	210	12	therapeutic	therapeutic	ADJ
njb-29	210	13	failure	failure	NOUN
njb-29	210	14	and	and	CCONJ
njb-29	210	15	in	in	ADP
njb-29	210	16	the	the	DET
njb-29	210	17	absence	absence	NOUN
njb-29	210	18	of	of	ADP
njb-29	210	19	limited	limited	ADJ
njb-29	210	20	chemotherapeutic	chemotherapeutic	NOUN
njb-29	210	21	alternatives	alternative	NOUN
njb-29	210	22	,	,	PUNCT
njb-29	210	23	it	it	PRON
njb-29	210	24	is	be	AUX
njb-29	210	25	extremely	extremely	ADV
njb-29	210	26	necessary	necessary	ADJ
njb-29	210	27	to	to	PART
njb-29	210	28	identify	identify	VERB
njb-29	210	29	biomarkers	biomarker	NOUN
njb-29	210	30	for	for	ADP
njb-29	210	31	monitoring	monitor	VERB
njb-29	210	32	antimony	antimony	ADJ
njb-29	210	33	resistance	resistance	NOUN
njb-29	210	34	.	.	PUNCT
njb-29	211	1	trivalent	trivalent	ADJ
njb-29	211	2	form	form	NOUN
njb-29	211	3	of	of	ADP
njb-29	211	4	the	the	DET
njb-29	211	5	antimonial	antimonial	ADJ
njb-29	211	6	drug	drug	NOUN
njb-29	211	7	(	(	PUNCT
njb-29	211	8	sbiii	sbiii	NOUN
njb-29	211	9	)	)	PUNCT
njb-29	211	10	is	be	AUX
njb-29	211	11	the	the	DET
njb-29	211	12	prodrug	prodrug	NOUN
njb-29	211	13	that	that	PRON
njb-29	211	14	is	be	AUX
njb-29	211	15	formed	form	VERB
njb-29	211	16	by	by	ADP
njb-29	211	17	conversion	conversion	NOUN
njb-29	211	18	of	of	ADP
njb-29	211	19	pentavalent	pentavalent	NOUN
njb-29	211	20	antimony	antimony	NOUN
njb-29	211	21	(	(	PUNCT
njb-29	211	22	sbv	sbv	PROPN
njb-29	211	23	)	)	PUNCT
njb-29	211	24	by	by	ADP
njb-29	211	25	a	a	DET
njb-29	211	26	putative	putative	ADJ
njb-29	211	27	metalloid	metalloid	NOUN
njb-29	211	28	reductase	reductase	NOUN
njb-29	211	29	present	present	ADJ
njb-29	211	30	in	in	ADP
njb-29	211	31	the	the	DET
njb-29	211	32	macrophages	macrophage	NOUN
njb-29	211	33	[	[	PUNCT
njb-29	211	34	28	28	NUM
njb-29	211	35	]	]	PUNCT
njb-29	211	36	.	.	PUNCT
njb-29	212	1	antimonial	antimonial	ADJ
njb-29	212	2	resistance	resistance	NOUN
njb-29	212	3	in	in	ADP
njb-29	212	4	both	both	DET
njb-29	212	5	laboratory	laboratory	NOUN
njb-29	212	6	mutants	mutant	NOUN
njb-29	212	7	and	and	CCONJ
njb-29	212	8	clinical	clinical	ADJ
njb-29	212	9	isolates	isolate	NOUN
njb-29	212	10	has	have	AUX
njb-29	212	11	been	be	AUX
njb-29	212	12	associated	associate	VERB
njb-29	212	13	with	with	ADP
njb-29	212	14	(	(	PUNCT
njb-29	212	15	a	a	X
njb-29	212	16	)	)	PUNCT
njb-29	212	17	decreased	decrease	VERB
njb-29	212	18	uptake	uptake	NOUN
njb-29	212	19	of	of	ADP
njb-29	212	20	the	the	DET
njb-29	212	21	drug	drug	NOUN
njb-29	212	22	through	through	ADP
njb-29	212	23	aquaglyceroporin	aquaglyceroporin	PROPN
njb-29	212	24	(	(	PUNCT
njb-29	212	25	aqp1	aqp1	PROPN
njb-29	212	26	)	)	PUNCT
njb-29	212	27	that	that	SCONJ
njb-29	212	28	codes	code	NOUN
njb-29	212	29	for	for	ADP
njb-29	212	30	the	the	DET
njb-29	212	31	protein	protein	NOUN
njb-29	212	32	responsible	responsible	ADJ
njb-29	212	33	for	for	ADP
njb-29	212	34	sbiii	sbiii	PROPN
njb-29	212	35	transport	transport	NOUN
njb-29	212	36	nepal	nepal	ADJ
njb-29	212	37	journal	journal	NOUN
njb-29	212	38	of	of	ADP
njb-29	212	39	biotechnology	biotechnology	NOUN
njb-29	212	40	.	.	PUNCT
njb-29	213	1	d	d	X
njb-29	213	2	e	e	PROPN
njb-29	213	3	c	c	PROPN
njb-29	213	4	.	.	PUNCT
njb-29	214	1	2	2	NUM
njb-29	214	2	0	0	NUM
njb-29	214	3	1	1	NUM
njb-29	214	4	6	6	NUM
njb-29	214	5	vol	vol	NOUN
njb-29	214	6	.	.	PROPN
njb-29	215	1	4	4	NUM
njb-29	215	2	,	,	PUNCT
njb-29	215	3	no	no	NOUN
njb-29	215	4	.	.	NOUN
njb-29	215	5	1	1	NUM
njb-29	215	6	:	:	SYM
njb-29	215	7	1	1	NUM
njb-29	215	8	-	-	SYM
njb-29	215	9	13	13	NUM
njb-29	215	10	maharjan	maharjan	NOUN
njb-29	215	11	et	et	NOUN
njb-29	215	12	al	al	PROPN
njb-29	215	13	.	.	PUNCT
njb-29	216	1	©	©	PROPN
njb-29	216	2	njb	njb	PROPN
njb-29	216	3	,	,	PUNCT
njb-29	216	4	biotechnology	biotechnology	NOUN
njb-29	216	5	society	society	NOUN
njb-29	216	6	of	of	ADP
njb-29	216	7	nepal	nepal	ADJ
njb-29	216	8	11	11	NUM
njb-29	216	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	NOUN
njb-29	216	10	[	[	PUNCT
njb-29	216	11	11,12,20,29	11,12,20,29	NUM
njb-29	216	12	]	]	X
njb-29	216	13	(	(	PUNCT
njb-29	216	14	b	b	NOUN
njb-29	216	15	)	)	PUNCT
njb-29	216	16	over	over	ADP
njb-29	216	17	expression	expression	NOUN
njb-29	216	18	of	of	ADP
njb-29	216	19	odc	odc	PROPN
njb-29	216	20	and	and	CCONJ
njb-29	216	21	γgcs	γgcs	ADJ
njb-29	216	22	enzymes	enzyme	NOUN
njb-29	216	23	of	of	ADP
njb-29	216	24	the	the	DET
njb-29	216	25	trypanothione	trypanothione	NOUN
njb-29	216	26	biosynthetic	biosynthetic	ADJ
njb-29	216	27	pathway	pathway	NOUN
njb-29	216	28	[	[	X
njb-29	216	29	2,25	2,25	NUM
njb-29	216	30	]	]	PUNCT
njb-29	216	31	and	and	CCONJ
njb-29	216	32	(	(	PUNCT
njb-29	216	33	c	c	X
njb-29	216	34	)	)	PUNCT
njb-29	216	35	increased	increase	VERB
njb-29	216	36	expression	expression	NOUN
njb-29	216	37	of	of	ADP
njb-29	216	38	the	the	DET
njb-29	216	39	abc	abc	PROPN
njb-29	216	40	transporter	transporter	PROPN
njb-29	216	41	mrpa	mrpa	PROPN
njb-29	216	42	,	,	PUNCT
njb-29	216	43	which	which	PRON
njb-29	216	44	sequesters	sequester	VERB
njb-29	216	45	sbiii	sbiii	PROPN
njb-29	216	46	-	-	PUNCT
njb-29	216	47	thiol	thiol	ADJ
njb-29	216	48	conjugate	conjugate	NOUN
njb-29	216	49	[	[	X
njb-29	216	50	16,23	16,23	NUM
njb-29	216	51	]	]	PUNCT
njb-29	216	52	.	.	PUNCT
njb-29	217	1	we	we	PRON
njb-29	217	2	had	have	AUX
njb-29	217	3	earlier	early	ADV
njb-29	217	4	reported	report	VERB
njb-29	217	5	decreased	decrease	VERB
njb-29	217	6	uptake	uptake	NOUN
njb-29	217	7	of	of	ADP
njb-29	217	8	antimony	antimony	NOUN
njb-29	217	9	in	in	ADP
njb-29	217	10	all	all	DET
njb-29	217	11	nine	nine	NUM
njb-29	217	12	sag	sag	ADJ
njb-29	217	13	-	-	PUNCT
njb-29	217	14	r	r	NOUN
njb-29	217	15	isolates	isolate	NOUN
njb-29	217	16	used	use	VERB
njb-29	217	17	in	in	ADP
njb-29	217	18	the	the	DET
njb-29	217	19	present	present	ADJ
njb-29	217	20	study	study	NOUN
njb-29	217	21	.	.	PUNCT
njb-29	218	1	down	down	ADP
njb-29	218	2	-	-	PUNCT
njb-29	218	3	regulation	regulation	NOUN
njb-29	218	4	of	of	ADP
njb-29	218	5	sbiii	sbiii	NOUN
njb-29	218	6	influx	influx	NOUN
njb-29	218	7	pump	pump	NOUN
njb-29	218	8	;	;	PUNCT
njb-29	218	9	aquaglyceroporin	aquaglyceroporin	PROPN
njb-29	218	10	(	(	PUNCT
njb-29	218	11	aqp1	aqp1	PROPN
njb-29	218	12	)	)	PUNCT
njb-29	218	13	was	be	AUX
njb-29	218	14	observed	observe	VERB
njb-29	218	15	in	in	ADP
njb-29	218	16	seven	seven	NUM
njb-29	218	17	out	out	ADP
njb-29	218	18	of	of	ADP
njb-29	218	19	the	the	DET
njb-29	218	20	nine	nine	NUM
njb-29	218	21	resistant	resistant	ADJ
njb-29	218	22	isolates	isolate	NOUN
njb-29	218	23	strains	strain	NOUN
njb-29	218	24	,	,	PUNCT
njb-29	218	25	mc8	mc8	NOUN
njb-29	218	26	-	-	PUNCT
njb-29	218	27	r	r	NOUN
njb-29	218	28	and	and	CCONJ
njb-29	218	29	nr3a	nr3a	NOUN
njb-29	218	30	-	-	NOUN
njb-29	218	31	r	r	NOUN
njb-29	218	32	were	be	AUX
njb-29	218	33	an	an	DET
njb-29	218	34	exception	exception	NOUN
njb-29	218	35	since	since	SCONJ
njb-29	218	36	they	they	PRON
njb-29	218	37	showed	show	VERB
njb-29	218	38	up	up	ADP
njb-29	218	39	-	-	PUNCT
njb-29	218	40	regulation	regulation	NOUN
njb-29	218	41	of	of	ADP
njb-29	218	42	aqp1	aqp1	PROPN
njb-29	218	43	gene	gene	NOUN
njb-29	218	44	expression	expression	NOUN
njb-29	218	45	[	[	PUNCT
njb-29	218	46	20	20	NUM
njb-29	218	47	]	]	PUNCT
njb-29	218	48	.	.	PUNCT
njb-29	219	1	the	the	DET
njb-29	219	2	abc	abc	PROPN
njb-29	219	3	transporter	transporter	NOUN
njb-29	219	4	gene	gene	NOUN
njb-29	219	5	mrpa	mrpa	ADV
njb-29	219	6	causes	cause	VERB
njb-29	219	7	drug	drug	NOUN
njb-29	219	8	sequestration	sequestration	NOUN
njb-29	219	9	in	in	ADP
njb-29	219	10	leishmania	leishmania	PROPN
njb-29	219	11	promastigotes	promastigote	NOUN
njb-29	219	12	and	and	CCONJ
njb-29	219	13	amastigotes	amastigote	NOUN
njb-29	219	14	selected	select	VERB
njb-29	219	15	for	for	ADP
njb-29	219	16	sbiii	sbiii	NOUN
njb-29	219	17	resistance	resistance	NOUN
njb-29	220	1	[	[	X
njb-29	220	2	17,30	17,30	NUM
njb-29	220	3	]	]	X
njb-29	220	4	.	.	PUNCT
njb-29	221	1	increased	increase	VERB
njb-29	221	2	copy	copy	NOUN
njb-29	221	3	number	number	NOUN
njb-29	221	4	of	of	ADP
njb-29	221	5	mrpa	mrpa	NOUN
njb-29	221	6	has	have	AUX
njb-29	221	7	been	be	AUX
njb-29	221	8	reported	report	VERB
njb-29	221	9	in	in	ADP
njb-29	221	10	sbiii	sbiii	NOUN
njb-29	221	11	resistant	resistant	ADJ
njb-29	221	12	mutant	mutant	NOUN
njb-29	221	13	[	[	X
njb-29	221	14	2	2	NUM
njb-29	221	15	]	]	PUNCT
njb-29	221	16	.	.	PUNCT
njb-29	222	1	our	our	PRON
njb-29	222	2	earlier	early	ADJ
njb-29	222	3	studies	study	NOUN
njb-29	222	4	using	use	VERB
njb-29	222	5	limited	limit	VERB
njb-29	222	6	number	number	NOUN
njb-29	222	7	of	of	ADP
njb-29	222	8	sag	sag	PROPN
njb-29	222	9	-	-	PUNCT
njb-29	222	10	s	s	NOUN
njb-29	222	11	and	and	CCONJ
njb-29	222	12	sag	sag	ADJ
njb-29	222	13	-	-	PUNCT
njb-29	222	14	r	r	NOUN
njb-29	222	15	clinical	clinical	ADJ
njb-29	222	16	isolates	isolate	NOUN
njb-29	222	17	showed	show	VERB
njb-29	222	18	amplification	amplification	NOUN
njb-29	222	19	of	of	ADP
njb-29	222	20	mrpa	mrpa	NOUN
njb-29	222	21	gene	gene	NOUN
njb-29	222	22	as	as	ADP
njb-29	222	23	part	part	NOUN
njb-29	222	24	of	of	ADP
njb-29	222	25	an	an	DET
njb-29	222	26	extrachromosomal	extrachromosomal	NOUN
njb-29	222	27	circle	circle	NOUN
njb-29	222	28	[	[	PUNCT
njb-29	222	29	23	23	NUM
njb-29	222	30	]	]	PUNCT
njb-29	222	31	.	.	PUNCT
njb-29	223	1	in	in	ADP
njb-29	223	2	the	the	DET
njb-29	223	3	present	present	ADJ
njb-29	223	4	study	study	NOUN
njb-29	223	5	,	,	PUNCT
njb-29	223	6	we	we	PRON
njb-29	223	7	found	find	VERB
njb-29	223	8	distinct	distinct	ADJ
njb-29	223	9	correlation	correlation	NOUN
njb-29	223	10	between	between	ADP
njb-29	223	11	copy	copy	NOUN
njb-29	223	12	number	number	NOUN
njb-29	223	13	of	of	ADP
njb-29	223	14	mrpa	mrpa	NOUN
njb-29	223	15	gene	gene	NOUN
njb-29	223	16	and	and	CCONJ
njb-29	223	17	antimony	antimony	NOUN
njb-29	223	18	sensitivity	sensitivity	NOUN
njb-29	223	19	in	in	ADP
njb-29	223	20	a	a	DET
njb-29	223	21	majority	majority	NOUN
njb-29	223	22	of	of	ADP
njb-29	223	23	the	the	DET
njb-29	223	24	isolates	isolate	NOUN
njb-29	223	25	(	(	PUNCT
njb-29	223	26	figure	figure	NOUN
njb-29	223	27	2a	2a	NUM
njb-29	223	28	)	)	PUNCT
njb-29	223	29	.	.	PUNCT
njb-29	224	1	however	however	ADV
njb-29	224	2	,	,	PUNCT
njb-29	224	3	two	two	NUM
njb-29	224	4	sag	sag	ADJ
njb-29	224	5	-	-	PUNCT
njb-29	224	6	r	r	NOUN
njb-29	224	7	strains	strain	NOUN
njb-29	224	8	,	,	PUNCT
njb-29	224	9	nr3a	nr3a	ADV
njb-29	224	10	-	-	PUNCT
njb-29	224	11	r	r	NOUN
njb-29	224	12	and	and	CCONJ
njb-29	224	13	rmp8	rmp8	PROPN
njb-29	224	14	-	-	PUNCT
njb-29	224	15	r	r	NOUN
njb-29	224	16	were	be	AUX
njb-29	224	17	an	an	DET
njb-29	224	18	exception	exception	NOUN
njb-29	224	19	.	.	PUNCT
njb-29	225	1	we	we	PRON
njb-29	225	2	have	have	AUX
njb-29	225	3	reported	report	VERB
njb-29	225	4	earlier	early	ADV
njb-29	225	5	that	that	SCONJ
njb-29	225	6	abc	abc	PROPN
njb-29	225	7	transporter	transporter	NOUN
njb-29	225	8	gene	gene	NOUN
njb-29	225	9	mrpa	mrpa	ADV
njb-29	225	10	was	be	AUX
njb-29	225	11	amplified	amplify	VERB
njb-29	225	12	in	in	ADP
njb-29	225	13	three	three	NUM
njb-29	225	14	out	out	ADP
njb-29	225	15	of	of	ADP
njb-29	225	16	four	four	NUM
njb-29	225	17	resistant	resistant	ADJ
njb-29	225	18	vl	vl	NOUN
njb-29	225	19	isolates	isolate	NOUN
njb-29	225	20	as	as	ADP
njb-29	225	21	part	part	NOUN
njb-29	225	22	of	of	ADP
njb-29	225	23	the	the	DET
njb-29	225	24	extrachromosmal	extrachromosmal	NOUN
njb-29	225	25	circle	circle	NOUN
njb-29	225	26	and	and	CCONJ
njb-29	225	27	coamplifcation	coamplifcation	NOUN
njb-29	225	28	of	of	ADP
njb-29	225	29	ptr1	ptr1	PROPN
njb-29	225	30	along	along	ADP
njb-29	225	31	with	with	ADP
njb-29	225	32	mrpa	mrpa	NOUN
njb-29	225	33	suggested	suggest	VERB
njb-29	225	34	amplification	amplification	NOUN
njb-29	225	35	of	of	ADP
njb-29	225	36	the	the	DET
njb-29	225	37	h	h	PROPN
njb-29	225	38	locus	locus	PROPN
njb-29	225	39	in	in	ADP
njb-29	225	40	sag	sag	ADJ
njb-29	225	41	-	-	PUNCT
njb-29	225	42	resistant	resistant	ADJ
njb-29	225	43	clinical	clinical	ADJ
njb-29	225	44	isolates	isolate	NOUN
njb-29	225	45	[	[	PUNCT
njb-29	225	46	23	23	NUM
njb-29	225	47	]	]	PUNCT
njb-29	225	48	.	.	PUNCT
njb-29	226	1	in	in	ADP
njb-29	226	2	the	the	DET
njb-29	226	3	present	present	ADJ
njb-29	226	4	study	study	NOUN
njb-29	226	5	,	,	PUNCT
njb-29	226	6	co	co	NOUN
njb-29	226	7	-	-	NOUN
njb-29	226	8	amplification	amplification	NOUN
njb-29	226	9	of	of	ADP
njb-29	226	10	ptr1	ptr1	PROPN
njb-29	226	11	gene	gene	NOUN
njb-29	226	12	with	with	ADP
njb-29	226	13	mrpa	mrpa	PROPN
njb-29	226	14	gene	gene	NOUN
njb-29	226	15	was	be	AUX
njb-29	226	16	not	not	PART
njb-29	226	17	observed	observe	VERB
njb-29	226	18	in	in	ADP
njb-29	226	19	any	any	PRON
njb-29	226	20	of	of	ADP
njb-29	226	21	the	the	DET
njb-29	226	22	clinical	clinical	ADJ
njb-29	226	23	isolates	isolate	NOUN
njb-29	226	24	.	.	PUNCT
njb-29	227	1	chef	chef	NOUN
njb-29	227	2	gel	gel	PROPN
njb-29	227	3	analysis	analysis	NOUN
njb-29	227	4	of	of	ADP
njb-29	227	5	the	the	DET
njb-29	227	6	sag	sag	PROPN
njb-29	227	7	-	-	PUNCT
njb-29	227	8	s	s	NOUN
njb-29	227	9	and	and	CCONJ
njb-29	227	10	sag	sag	ADJ
njb-29	227	11	-	-	PUNCT
njb-29	227	12	r	r	NOUN
njb-29	227	13	isolates	isolate	NOUN
njb-29	227	14	did	do	AUX
njb-29	227	15	not	not	PART
njb-29	227	16	show	show	VERB
njb-29	227	17	any	any	DET
njb-29	227	18	circular	circular	ADJ
njb-29	227	19	amplification	amplification	NOUN
njb-29	227	20	in	in	ADP
njb-29	227	21	any	any	PRON
njb-29	227	22	of	of	ADP
njb-29	227	23	the	the	DET
njb-29	227	24	sag	sag	ADJ
njb-29	227	25	-	-	PUNCT
njb-29	227	26	r	r	NOUN
njb-29	227	27	isolates	isolate	NOUN
njb-29	227	28	.	.	PUNCT
njb-29	228	1	mrpa	mrpa	PROPN
njb-29	228	2	gene	gene	NOUN
njb-29	228	3	expression	expression	NOUN
njb-29	228	4	in	in	ADP
njb-29	228	5	sag	sag	PROPN
njb-29	228	6	-	-	PUNCT
njb-29	228	7	s	s	NOUN
njb-29	228	8	versus	versus	X
njb-29	228	9	sag	sag	ADJ
njb-29	228	10	-	-	PUNCT
njb-29	228	11	r	r	NOUN
njb-29	228	12	field	field	NOUN
njb-29	228	13	isolates	isolate	NOUN
njb-29	228	14	showed	show	VERB
njb-29	228	15	correlation	correlation	NOUN
njb-29	228	16	between	between	ADP
njb-29	228	17	mrpa	mrpa	PROPN
njb-29	228	18	gene	gene	NOUN
njb-29	228	19	expression	expression	NOUN
njb-29	228	20	and	and	CCONJ
njb-29	228	21	sag	sag	ADJ
njb-29	228	22	susceptibility	susceptibility	NOUN
njb-29	228	23	profile	profile	NOUN
njb-29	228	24	of	of	ADP
njb-29	228	25	the	the	DET
njb-29	228	26	clinical	clinical	ADJ
njb-29	228	27	isolates	isolate	NOUN
njb-29	228	28	.	.	PUNCT
njb-29	229	1	the	the	DET
njb-29	229	2	present	present	ADJ
njb-29	229	3	observation	observation	NOUN
njb-29	229	4	validated	validate	VERB
njb-29	229	5	our	our	PRON
njb-29	229	6	earlier	early	ADJ
njb-29	229	7	results	result	NOUN
njb-29	229	8	where	where	SCONJ
njb-29	229	9	we	we	PRON
njb-29	229	10	have	have	AUX
njb-29	229	11	shown	show	VERB
njb-29	229	12	correlation	correlation	NOUN
njb-29	229	13	between	between	ADP
njb-29	229	14	mrpa	mrpa	PROPN
njb-29	229	15	gene	gene	NOUN
njb-29	229	16	expressions	expression	NOUN
njb-29	229	17	with	with	ADP
njb-29	229	18	the	the	DET
njb-29	229	19	antimony	antimony	NOUN
njb-29	229	20	resistant	resistant	ADJ
njb-29	229	21	clinical	clinical	ADJ
njb-29	229	22	profile	profile	NOUN
njb-29	229	23	in	in	ADP
njb-29	229	24	the	the	DET
njb-29	229	25	field	field	NOUN
njb-29	229	26	conditions	condition	NOUN
njb-29	229	27	[	[	PUNCT
njb-29	229	28	23	23	NUM
njb-29	229	29	]	]	PUNCT
njb-29	229	30	.	.	PUNCT
njb-29	230	1	in	in	ADP
njb-29	230	2	our	our	PRON
njb-29	230	3	previous	previous	ADJ
njb-29	230	4	study	study	NOUN
njb-29	230	5	amplification	amplification	NOUN
njb-29	230	6	of	of	ADP
njb-29	230	7	odc	odc	PROPN
njb-29	230	8	gene	gene	NOUN
njb-29	230	9	was	be	AUX
njb-29	230	10	noted	note	VERB
njb-29	230	11	in	in	ADP
njb-29	230	12	the	the	DET
njb-29	230	13	resistant	resistant	ADJ
njb-29	230	14	isolates	isolate	NOUN
njb-29	230	15	but	but	CCONJ
njb-29	230	16	not	not	PART
njb-29	230	17	that	that	PRON
njb-29	230	18	of	of	ADP
njb-29	230	19	the	the	DET
njb-29	230	20	γ	γ	PROPN
njb-29	230	21	-	-	PUNCT
njb-29	230	22	gcs	gcs	PROPN
njb-29	231	1	[	[	PUNCT
njb-29	231	2	23	23	NUM
njb-29	231	3	]	]	PUNCT
njb-29	231	4	.	.	PUNCT
njb-29	232	1	in	in	ADP
njb-29	232	2	another	another	DET
njb-29	232	3	study	study	NOUN
njb-29	232	4	on	on	ADP
njb-29	232	5	l.	l.	PROPN
njb-29	232	6	donovani	donovani	PROPN
njb-29	232	7	isolates	isolate	VERB
njb-29	232	8	from	from	ADP
njb-29	232	9	nepal	nepal	ADJ
njb-29	232	10	,	,	PUNCT
njb-29	232	11	expression	expression	NOUN
njb-29	232	12	of	of	ADP
njb-29	232	13	γ	γ	PROPN
njb-29	232	14	-	-	PUNCT
njb-29	232	15	gcs	gcs	PROPN
njb-29	232	16	and	and	CCONJ
njb-29	232	17	odc	odc	PROPN
njb-29	232	18	was	be	AUX
njb-29	232	19	significantly	significantly	ADV
njb-29	232	20	decreased	decrease	VERB
njb-29	232	21	in	in	ADP
njb-29	232	22	the	the	DET
njb-29	232	23	resistant	resistant	ADJ
njb-29	232	24	isolates	isolate	NOUN
njb-29	232	25	[	[	PUNCT
njb-29	232	26	31	31	NUM
njb-29	232	27	]	]	PUNCT
njb-29	232	28	.	.	PUNCT
njb-29	233	1	in	in	ADP
njb-29	233	2	the	the	DET
njb-29	233	3	present	present	ADJ
njb-29	233	4	study	study	NOUN
njb-29	233	5	we	we	PRON
njb-29	233	6	observed	observe	VERB
njb-29	233	7	increased	increase	VERB
njb-29	233	8	expression	expression	NOUN
njb-29	233	9	of	of	ADP
njb-29	233	10	odc	odc	PROPN
njb-29	233	11	gene	gene	NOUN
njb-29	233	12	and	and	CCONJ
njb-29	233	13	γ	γ	PROPN
njb-29	233	14	-	-	PUNCT
njb-29	233	15	gcs	gcs	PROPN
njb-29	233	16	in	in	ADP
njb-29	233	17	all	all	DET
njb-29	233	18	sag	sag	ADJ
njb-29	233	19	-	-	PUNCT
njb-29	233	20	r	r	NOUN
njb-29	233	21	isolates	isolate	NOUN
njb-29	233	22	.	.	PUNCT
njb-29	234	1	it	it	PRON
njb-29	234	2	has	have	AUX
njb-29	234	3	been	be	AUX
njb-29	234	4	reported	report	VERB
njb-29	234	5	earlier	early	ADV
njb-29	234	6	that	that	SCONJ
njb-29	234	7	abc	abc	PROPN
njb-29	234	8	transporter	transporter	PROPN
njb-29	234	9	mrpa	mrpa	PROPN
njb-29	234	10	,	,	PUNCT
njb-29	234	11	confers	confer	VERB
njb-29	234	12	resistance	resistance	NOUN
njb-29	234	13	to	to	ADP
njb-29	234	14	antimonials	antimonial	NOUN
njb-29	234	15	by	by	ADP
njb-29	234	16	sequestration	sequestration	NOUN
njb-29	234	17	of	of	ADP
njb-29	234	18	metal	metal	NOUN
njb-29	234	19	thiol	thiol	ADJ
njb-29	234	20	conjugates	conjugate	NOUN
njb-29	234	21	in	in	ADP
njb-29	234	22	an	an	DET
njb-29	234	23	intracellular	intracellular	ADJ
njb-29	234	24	organelle	organelle	NOUN
njb-29	234	25	located	locate	VERB
njb-29	234	26	close	close	ADV
njb-29	234	27	to	to	ADP
njb-29	234	28	the	the	DET
njb-29	234	29	flagellar	flagellar	ADJ
njb-29	234	30	pocket	pocket	NOUN
njb-29	234	31	[	[	PUNCT
njb-29	234	32	16	16	NUM
njb-29	234	33	]	]	PUNCT
njb-29	234	34	.	.	PUNCT
njb-29	235	1	this	this	DET
njb-29	235	2	model	model	NOUN
njb-29	235	3	has	have	AUX
njb-29	235	4	been	be	AUX
njb-29	235	5	demonstrated	demonstrate	VERB
njb-29	235	6	in	in	ADP
njb-29	235	7	promastigotes	promastigote	NOUN
njb-29	235	8	of	of	ADP
njb-29	235	9	l.	l.	PROPN
njb-29	235	10	tarentolae	tarentolae	PROPN
njb-29	235	11	,	,	PUNCT
njb-29	235	12	in	in	ADP
njb-29	235	13	amastigotes	amastigote	NOUN
njb-29	235	14	and	and	CCONJ
njb-29	235	15	also	also	ADV
njb-29	235	16	in	in	ADP
njb-29	235	17	clinical	clinical	ADJ
njb-29	235	18	isolates	isolate	NOUN
njb-29	235	19	from	from	ADP
njb-29	235	20	india	india	PROPN
njb-29	236	1	[	[	PUNCT
njb-29	236	2	16,23,30	16,23,30	NUM
njb-29	236	3	]	]	PUNCT
njb-29	236	4	.	.	PUNCT
njb-29	237	1	these	these	DET
njb-29	237	2	observations	observation	NOUN
njb-29	237	3	clearly	clearly	ADV
njb-29	237	4	highlighted	highlight	VERB
njb-29	237	5	the	the	DET
njb-29	237	6	importance	importance	NOUN
njb-29	237	7	of	of	ADP
njb-29	237	8	intracellular	intracellular	ADJ
njb-29	237	9	thiol	thiol	PROPN
njb-29	237	10	in	in	ADP
njb-29	237	11	mrpa	mrpa	PROPN
njb-29	237	12	mediated	mediate	VERB
njb-29	237	13	efflux	efflux	NOUN
njb-29	237	14	of	of	ADP
njb-29	237	15	the	the	DET
njb-29	237	16	antimony	antimony	NOUN
njb-29	237	17	.	.	PUNCT
njb-29	238	1	an	an	DET
njb-29	238	2	increase	increase	NOUN
njb-29	238	3	in	in	ADP
njb-29	238	4	cysteine	cysteine	NOUN
njb-29	238	5	and	and	CCONJ
njb-29	238	6	glutathione	glutathione	NOUN
njb-29	238	7	levels	level	NOUN
njb-29	238	8	were	be	AUX
njb-29	238	9	reported	report	VERB
njb-29	238	10	in	in	ADP
njb-29	238	11	antimony	antimony	PROPN
njb-29	238	12	resistant	resistant	ADJ
njb-29	238	13	l.	l.	PROPN
njb-29	238	14	donovani	donovani	PROPN
njb-29	238	15	clinical	clinical	ADJ
njb-29	238	16	isolates	isolate	NOUN
njb-29	238	17	[	[	PUNCT
njb-29	238	18	23	23	NUM
njb-29	238	19	]	]	PUNCT
njb-29	238	20	.	.	PUNCT
njb-29	239	1	in	in	ADP
njb-29	239	2	the	the	DET
njb-29	239	3	present	present	ADJ
njb-29	239	4	study	study	NOUN
njb-29	239	5	also	also	ADV
njb-29	239	6	,	,	PUNCT
njb-29	239	7	we	we	PRON
njb-29	239	8	observed	observe	VERB
njb-29	239	9	increase	increase	NOUN
njb-29	239	10	in	in	ADP
njb-29	239	11	cysteine	cysteine	NOUN
njb-29	239	12	and	and	CCONJ
njb-29	239	13	glutathione	glutathione	NOUN
njb-29	239	14	levels	level	NOUN
njb-29	239	15	in	in	ADP
njb-29	239	16	all	all	DET
njb-29	239	17	sag	sag	ADJ
njb-29	239	18	-	-	PUNCT
njb-29	239	19	r	r	NOUN
njb-29	239	20	isolates	isolate	NOUN
njb-29	239	21	.	.	PUNCT
njb-29	240	1	however	however	ADV
njb-29	240	2	,	,	PUNCT
njb-29	240	3	no	no	DET
njb-29	240	4	change	change	NOUN
njb-29	240	5	in	in	ADP
njb-29	240	6	trypanothione	trypanothione	NOUN
njb-29	240	7	levels	level	NOUN
njb-29	240	8	were	be	AUX
njb-29	240	9	observed	observe	VERB
njb-29	240	10	in	in	ADP
njb-29	240	11	sag	sag	ADJ
njb-29	240	12	-	-	PUNCT
njb-29	240	13	r	r	NOUN
njb-29	240	14	isolates	isolate	NOUN
njb-29	240	15	in	in	ADP
njb-29	240	16	comparison	comparison	NOUN
njb-29	240	17	to	to	ADP
njb-29	240	18	sag	sag	ADJ
njb-29	240	19	-	-	PUNCT
njb-29	240	20	s	s	NOUN
njb-29	240	21	isolates	isolate	NOUN
njb-29	240	22	.	.	PUNCT
njb-29	241	1	similar	similar	ADJ
njb-29	241	2	observation	observation	NOUN
njb-29	241	3	was	be	AUX
njb-29	241	4	made	make	VERB
njb-29	241	5	in	in	ADP
njb-29	241	6	our	our	PRON
njb-29	241	7	analysis	analysis	NOUN
njb-29	241	8	of	of	ADP
njb-29	241	9	the	the	DET
njb-29	241	10	mode	mode	NOUN
njb-29	241	11	of	of	ADP
njb-29	241	12	action	action	NOUN
njb-29	241	13	of	of	ADP
njb-29	241	14	antimony	antimony	NOUN
njb-29	241	15	in	in	ADP
njb-29	241	16	clinical	clinical	ADJ
njb-29	241	17	isolates	isolate	NOUN
njb-29	241	18	and	and	CCONJ
njb-29	241	19	earlier	early	ADJ
njb-29	241	20	studies	study	NOUN
njb-29	241	21	in	in	ADP
njb-29	241	22	l.	l.	PROPN
njb-29	241	23	infantum	infantum	PROPN
njb-29	241	24	resistant	resistant	ADJ
njb-29	241	25	to	to	ADP
njb-29	241	26	sb(iii	sb(iii	PROPN
njb-29	241	27	)	)	PUNCT
njb-29	242	1	[	[	X
njb-29	242	2	23	23	NUM
njb-29	242	3	]	]	PUNCT
njb-29	242	4	.	.	PUNCT
njb-29	243	1	it	it	PRON
njb-29	243	2	was	be	AUX
njb-29	243	3	pointed	point	VERB
njb-29	243	4	out	out	ADP
njb-29	243	5	that	that	SCONJ
njb-29	243	6	antimony	antimony	NOUN
njb-29	243	7	possibly	possibly	ADV
njb-29	243	8	depleted	deplete	VERB
njb-29	243	9	trypanothione	trypanothione	NOUN
njb-29	243	10	by	by	ADP
njb-29	243	11	efflux	efflux	NOUN
njb-29	243	12	of	of	ADP
njb-29	243	13	sbtrypanothione	sbtrypanothione	PROPN
njb-29	243	14	conjugate	conjugate	NOUN
njb-29	244	1	[	[	X
njb-29	244	2	16	16	NUM
njb-29	244	3	]	]	PUNCT
njb-29	244	4	.	.	PUNCT
njb-29	245	1	it	it	PRON
njb-29	245	2	is	be	AUX
njb-29	245	3	possible	possible	ADJ
njb-29	245	4	that	that	SCONJ
njb-29	245	5	the	the	DET
njb-29	245	6	efflux	efflux	NOUN
njb-29	245	7	system	system	NOUN
njb-29	245	8	is	be	AUX
njb-29	245	9	increased	increase	VERB
njb-29	245	10	in	in	ADP
njb-29	245	11	the	the	DET
njb-29	245	12	resistant	resistant	ADJ
njb-29	245	13	isolates	isolate	NOUN
njb-29	245	14	thereby	thereby	ADV
njb-29	245	15	leading	lead	VERB
njb-29	245	16	to	to	ADP
njb-29	245	17	increased	increase	VERB
njb-29	245	18	trypanothione	trypanothione	PROPN
njb-29	245	19	efflux	efflux	PROPN
njb-29	245	20	.	.	PUNCT
njb-29	246	1	this	this	PRON
njb-29	246	2	would	would	AUX
njb-29	246	3	explain	explain	VERB
njb-29	246	4	the	the	DET
njb-29	246	5	constant	constant	ADJ
njb-29	246	6	levels	level	NOUN
njb-29	246	7	of	of	ADP
njb-29	246	8	trypanothione	trypanothione	NOUN
njb-29	246	9	in	in	ADP
njb-29	246	10	the	the	DET
njb-29	246	11	present	present	ADJ
njb-29	246	12	study	study	NOUN
njb-29	246	13	in	in	ADP
njb-29	246	14	the	the	DET
njb-29	246	15	resistant	resistant	ADJ
njb-29	246	16	isolates	isolate	NOUN
njb-29	246	17	.	.	PUNCT
njb-29	247	1	rk1	rk1	PROPN
njb-29	247	2	-	-	PUNCT
njb-29	247	3	s	s	PROPN
njb-29	247	4	though	though	SCONJ
njb-29	247	5	a	a	DET
njb-29	247	6	sag	sag	PROPN
njb-29	247	7	-	-	PUNCT
njb-29	247	8	s	s	NOUN
njb-29	247	9	isolate	isolate	NOUN
njb-29	247	10	,	,	PUNCT
njb-29	247	11	was	be	AUX
njb-29	247	12	an	an	DET
njb-29	247	13	exception	exception	NOUN
njb-29	247	14	to	to	ADP
njb-29	247	15	the	the	DET
njb-29	247	16	mutlifactorial	mutlifactorial	ADJ
njb-29	247	17	antimony	antimony	NOUN
njb-29	247	18	resistant	resistant	ADJ
njb-29	247	19	mechanisms	mechanism	NOUN
njb-29	247	20	reported	report	VERB
njb-29	247	21	in	in	ADP
njb-29	247	22	clinical	clinical	ADJ
njb-29	247	23	isolates	isolate	NOUN
njb-29	247	24	and	and	CCONJ
njb-29	247	25	also	also	ADV
njb-29	247	26	in	in	ADP
njb-29	247	27	the	the	DET
njb-29	247	28	lab	lab	NOUN
njb-29	247	29	based	base	VERB
njb-29	247	30	resistant	resistant	ADJ
njb-29	247	31	isolates	isolate	NOUN
njb-29	247	32	.	.	PUNCT
njb-29	248	1	clinical	clinical	ADJ
njb-29	248	2	history	history	NOUN
njb-29	248	3	of	of	ADP
njb-29	248	4	the	the	DET
njb-29	248	5	rk1	rk1	PROPN
njb-29	248	6	-	-	PUNCT
njb-29	248	7	s	s	PART
njb-29	248	8	patient	patient	NOUN
njb-29	248	9	showed	show	VERB
njb-29	248	10	that	that	SCONJ
njb-29	248	11	the	the	DET
njb-29	248	12	interval	interval	NOUN
njb-29	248	13	between	between	ADP
njb-29	248	14	the	the	DET
njb-29	248	15	cure	cure	NOUN
njb-29	248	16	of	of	ADP
njb-29	248	17	vl	vl	NOUN
njb-29	248	18	and	and	CCONJ
njb-29	248	19	the	the	DET
njb-29	248	20	onset	onset	NOUN
njb-29	248	21	of	of	ADP
njb-29	248	22	pkdl	pkdl	PROPN
njb-29	248	23	was	be	AUX
njb-29	248	24	2.5	2.5	NUM
njb-29	248	25	years	year	NOUN
njb-29	248	26	where	where	SCONJ
njb-29	248	27	as	as	SCONJ
njb-29	248	28	ms2	ms2	PROPN
njb-29	248	29	-	-	PUNCT
njb-29	248	30	s	s	PROPN
njb-29	248	31	and	and	CCONJ
njb-29	248	32	nr3a	nr3a	ADV
njb-29	248	33	-	-	PUNCT
njb-29	248	34	r	r	NOUN
njb-29	248	35	,	,	PUNCT
njb-29	248	36	pkdl	pkdl	PROPN
njb-29	248	37	isolates	isolate	VERB
njb-29	248	38	the	the	DET
njb-29	248	39	interval	interval	NOUN
njb-29	248	40	between	between	ADP
njb-29	248	41	the	the	DET
njb-29	248	42	cure	cure	NOUN
njb-29	248	43	of	of	ADP
njb-29	248	44	vl	vl	NOUN
njb-29	248	45	and	and	CCONJ
njb-29	248	46	the	the	DET
njb-29	248	47	onset	onset	NOUN
njb-29	248	48	of	of	ADP
njb-29	248	49	pkdl	pkdl	PROPN
njb-29	248	50	was	be	AUX
njb-29	248	51	7	7	NUM
njb-29	248	52	and	and	CCONJ
njb-29	248	53	11	11	NUM
njb-29	248	54	years	year	NOUN
njb-29	248	55	respectively	respectively	ADV
njb-29	248	56	.	.	PUNCT
njb-29	249	1	it	it	PRON
njb-29	249	2	will	will	AUX
njb-29	249	3	be	be	AUX
njb-29	249	4	interesting	interesting	ADJ
njb-29	249	5	to	to	PART
njb-29	249	6	look	look	VERB
njb-29	249	7	at	at	ADP
njb-29	249	8	the	the	DET
njb-29	249	9	nepal	nepal	ADJ
njb-29	249	10	journal	journal	NOUN
njb-29	249	11	of	of	ADP
njb-29	249	12	biotechnology	biotechnology	NOUN
njb-29	249	13	.	.	PUNCT
njb-29	250	1	d	d	X
njb-29	250	2	e	e	PROPN
njb-29	250	3	c	c	PROPN
njb-29	250	4	.	.	PUNCT
njb-29	251	1	2	2	NUM
njb-29	251	2	0	0	NUM
njb-29	251	3	1	1	NUM
njb-29	251	4	6	6	NUM
njb-29	251	5	vol	vol	NOUN
njb-29	251	6	.	.	PROPN
njb-29	252	1	4	4	NUM
njb-29	252	2	,	,	PUNCT
njb-29	252	3	no	no	NOUN
njb-29	252	4	.	.	NOUN
njb-29	252	5	1	1	NUM
njb-29	252	6	:	:	SYM
njb-29	252	7	1	1	NUM
njb-29	252	8	-	-	SYM
njb-29	252	9	13	13	NUM
njb-29	252	10	maharjan	maharjan	NOUN
njb-29	252	11	et	et	NOUN
njb-29	252	12	al	al	PROPN
njb-29	252	13	.	.	PUNCT
njb-29	253	1	©	©	PROPN
njb-29	253	2	njb	njb	PROPN
njb-29	253	3	,	,	PUNCT
njb-29	253	4	biotechnology	biotechnology	NOUN
njb-29	253	5	society	society	NOUN
njb-29	253	6	of	of	ADP
njb-29	253	7	nepal	nepal	ADJ
njb-29	253	8	12	12	NUM
njb-29	253	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-29	253	10	pkdl	pkdl	NOUN
njb-29	253	11	isolates	isolate	VERB
njb-29	253	12	with	with	ADP
njb-29	253	13	known	know	VERB
njb-29	253	14	clinical	clinical	ADJ
njb-29	253	15	history	history	NOUN
njb-29	253	16	in	in	ADP
njb-29	253	17	order	order	NOUN
njb-29	253	18	to	to	PART
njb-29	253	19	determine	determine	VERB
njb-29	253	20	if	if	SCONJ
njb-29	253	21	this	this	DET
njb-29	253	22	interval	interval	NOUN
njb-29	253	23	has	have	VERB
njb-29	253	24	a	a	DET
njb-29	253	25	role	role	NOUN
njb-29	253	26	to	to	PART
njb-29	253	27	play	play	VERB
njb-29	253	28	in	in	ADP
njb-29	253	29	antimony	antimony	ADJ
njb-29	253	30	susceptibility	susceptibility	NOUN
njb-29	253	31	/	/	SYM
njb-29	253	32	resistance	resistance	NOUN
njb-29	253	33	.	.	PUNCT
njb-29	254	1	the	the	DET
njb-29	254	2	data	datum	NOUN
njb-29	254	3	presented	present	VERB
njb-29	254	4	here	here	ADV
njb-29	254	5	in	in	ADP
njb-29	254	6	vl	vl	PROPN
njb-29	254	7	and	and	CCONJ
njb-29	254	8	for	for	ADP
njb-29	254	9	the	the	DET
njb-29	254	10	first	first	ADJ
njb-29	254	11	time	time	NOUN
njb-29	254	12	in	in	ADP
njb-29	254	13	pkdl	pkdl	NOUN
njb-29	254	14	isolates	isolate	NOUN
njb-29	254	15	,	,	PUNCT
njb-29	254	16	establishes	establish	VERB
njb-29	254	17	the	the	DET
njb-29	254	18	relevance	relevance	NOUN
njb-29	254	19	of	of	ADP
njb-29	254	20	overexpression	overexpression	NOUN
njb-29	254	21	of	of	ADP
njb-29	254	22	γ	γ	PROPN
njb-29	254	23	–	–	PUNCT
njb-29	254	24	gcs	gcs	PROPN
njb-29	254	25	and	and	CCONJ
njb-29	254	26	odc	odc	PROPN
njb-29	254	27	and	and	CCONJ
njb-29	254	28	an	an	DET
njb-29	254	29	increased	increase	VERB
njb-29	254	30	expression	expression	NOUN
njb-29	254	31	of	of	ADP
njb-29	254	32	mrpa	mrpa	NOUN
njb-29	254	33	that	that	PRON
njb-29	254	34	may	may	AUX
njb-29	254	35	be	be	AUX
njb-29	254	36	responsible	responsible	ADJ
njb-29	254	37	for	for	ADP
njb-29	254	38	an	an	DET
njb-29	254	39	increased	increase	VERB
njb-29	254	40	efflux	efflux	NOUN
njb-29	254	41	of	of	ADP
njb-29	254	42	thiol	thiol	PROPN
njb-29	254	43	-	-	PUNCT
njb-29	254	44	sb	sb	PROPN
njb-29	254	45	-	-	PUNCT
njb-29	254	46	iii	iii	NOUN
njb-29	254	47	conjugate	conjugate	NOUN
njb-29	254	48	.	.	PUNCT
njb-29	255	1	our	our	PRON
njb-29	255	2	data	datum	NOUN
njb-29	255	3	further	far	ADV
njb-29	255	4	confirms	confirm	VERB
njb-29	255	5	that	that	SCONJ
njb-29	255	6	resistance	resistance	NOUN
njb-29	255	7	mechanisms	mechanism	NOUN
njb-29	255	8	present	present	ADJ
njb-29	255	9	in	in	ADP
njb-29	255	10	the	the	DET
njb-29	255	11	laboratory	laboratory	NOUN
njb-29	255	12	strains	strain	NOUN
njb-29	255	13	can	can	AUX
njb-29	255	14	be	be	AUX
njb-29	255	15	found	find	VERB
njb-29	255	16	in	in	ADP
njb-29	255	17	the	the	DET
njb-29	255	18	clinical	clinical	ADJ
njb-29	255	19	isolates	isolate	NOUN
njb-29	255	20	.	.	PUNCT
njb-29	256	1	further	further	ADJ
njb-29	256	2	work	work	NOUN
njb-29	256	3	is	be	AUX
njb-29	256	4	presently	presently	ADV
njb-29	256	5	going	go	VERB
njb-29	256	6	on	on	ADP
njb-29	256	7	the	the	DET
njb-29	256	8	laboratory	laboratory	NOUN
njb-29	256	9	to	to	PART
njb-29	256	10	get	get	VERB
njb-29	256	11	a	a	DET
njb-29	256	12	global	global	ADJ
njb-29	256	13	overview	overview	NOUN
njb-29	256	14	of	of	ADP
njb-29	256	15	the	the	DET
njb-29	256	16	resistant	resistant	ADJ
njb-29	256	17	mechanism	mechanism	NOUN
njb-29	256	18	by	by	ADP
njb-29	256	19	proteomics	proteomic	NOUN
njb-29	256	20	approach	approach	NOUN
njb-29	256	21	in	in	ADP
njb-29	256	22	order	order	NOUN
njb-29	256	23	to	to	PART
njb-29	256	24	find	find	VERB
njb-29	256	25	other	other	ADJ
njb-29	256	26	possible	possible	ADJ
njb-29	256	27	resistant	resistant	ADJ
njb-29	256	28	determinants	determinant	NOUN
njb-29	256	29	.	.	PUNCT
njb-29	257	1	it	it	PRON
njb-29	257	2	will	will	AUX
njb-29	257	3	further	far	ADV
njb-29	257	4	help	help	VERB
njb-29	257	5	in	in	ADP
njb-29	257	6	proper	proper	ADJ
njb-29	257	7	selection	selection	NOUN
njb-29	257	8	of	of	ADP
njb-29	257	9	therapeutic	therapeutic	ADJ
njb-29	257	10	regimen	regiman	NOUN
njb-29	257	11	and	and	CCONJ
njb-29	257	12	improve	improve	VERB
njb-29	257	13	treatment	treatment	NOUN
njb-29	257	14	strategy	strategy	NOUN
njb-29	257	15	against	against	ADP
njb-29	257	16	leishmaniasis	leishmaniasis	NOUN
njb-29	257	17	.	.	PUNCT
njb-29	258	1	acknowledgements	acknowledgement	VERB
njb-29	258	2	the	the	DET
njb-29	258	3	clinical	clinical	ADJ
njb-29	258	4	isolates	isolate	NOUN
njb-29	258	5	used	use	VERB
njb-29	258	6	in	in	ADP
njb-29	258	7	this	this	DET
njb-29	258	8	study	study	NOUN
njb-29	258	9	were	be	AUX
njb-29	258	10	kindly	kindly	ADV
njb-29	258	11	provided	provide	VERB
njb-29	258	12	by	by	ADP
njb-29	258	13	dr	dr	PROPN
njb-29	258	14	.	.	PROPN
njb-29	258	15	mitali	mitali	PROPN
njb-29	258	16	chatterjee	chatterjee	PROPN
njb-29	258	17	(	(	PUNCT
njb-29	258	18	institute	institute	NOUN
njb-29	258	19	of	of	ADP
njb-29	258	20	post	post	PROPN
njb-29	258	21	graduate	graduate	NOUN
njb-29	258	22	medical	medical	ADJ
njb-29	258	23	education	education	NOUN
njb-29	258	24	and	and	CCONJ
njb-29	258	25	research	research	NOUN
njb-29	258	26	,	,	PUNCT
njb-29	258	27	kolkata	kolkata	PROPN
njb-29	258	28	,	,	PUNCT
njb-29	258	29	india	india	PROPN
njb-29	258	30	)	)	PUNCT
njb-29	258	31	and	and	CCONJ
njb-29	258	32	dr	dr	PROPN
njb-29	258	33	.	.	PROPN
njb-29	258	34	sarman	sarman	PROPN
njb-29	258	35	singh	singh	PROPN
njb-29	258	36	,	,	PUNCT
njb-29	258	37	(	(	PUNCT
njb-29	258	38	division	division	NOUN
njb-29	258	39	of	of	ADP
njb-29	258	40	clinical	clinical	ADJ
njb-29	258	41	microbiology	microbiology	NOUN
njb-29	258	42	,	,	PUNCT
njb-29	258	43	all	all	DET
njb-29	258	44	india	india	PROPN
njb-29	258	45	institute	institute	PROPN
njb-29	258	46	of	of	ADP
njb-29	258	47	medical	medical	PROPN
njb-29	258	48	sciences	sciences	PROPN
njb-29	258	49	,	,	PUNCT
njb-29	258	50	new	new	PROPN
njb-29	258	51	delhi	delhi	PROPN
njb-29	258	52	,	,	PUNCT
njb-29	258	53	india	india	PROPN
njb-29	258	54	)	)	PUNCT
njb-29	258	55	.	.	PUNCT
njb-29	259	1	funding	fund	VERB
njb-29	259	2	this	this	DET
njb-29	259	3	work	work	NOUN
njb-29	259	4	is	be	AUX
njb-29	259	5	supported	support	VERB
njb-29	259	6	by	by	ADP
njb-29	259	7	a	a	DET
njb-29	259	8	grant	grant	NOUN
njb-29	259	9	from	from	ADP
njb-29	259	10	the	the	DET
njb-29	259	11	department	department	NOUN
njb-29	259	12	of	of	ADP
njb-29	259	13	biotechnology	biotechnology	NOUN
njb-29	259	14	to	to	ADP
njb-29	259	15	dr	dr	PROPN
njb-29	259	16	.	.	PROPN
njb-29	259	17	rentala	rentala	PROPN
njb-29	259	18	madhubala	madhubala	PROPN
njb-29	259	19	.	.	PUNCT
njb-29	260	1	mahendra	mahendra	PROPN
njb-29	260	2	maharjan	maharjan	PROPN
njb-29	260	3	and	and	CCONJ
njb-29	260	4	swati	swati	PROPN
njb-29	260	5	mandal	mandal	PROPN
njb-29	260	6	are	be	AUX
njb-29	260	7	supported	support	VERB
njb-29	260	8	by	by	ADP
njb-29	260	9	a	a	DET
njb-29	260	10	fellowship	fellowship	NOUN
njb-29	260	11	from	from	ADP
njb-29	260	12	the	the	DET
njb-29	260	13	university	university	PROPN
njb-29	260	14	grants	grants	PROPN
njb-29	260	15	commission	commission	PROPN
njb-29	260	16	,	,	PUNCT
njb-29	260	17	government	government	NOUN
njb-29	260	18	of	of	ADP
njb-29	260	19	india	india	PROPN
njb-29	260	20	transparency	transparency	PROPN
njb-29	260	21	declarations	declaration	NOUN
njb-29	260	22	:	:	PUNCT
njb-29	260	23	none	none	NOUN
njb-29	260	24	to	to	PART
njb-29	260	25	declare	declare	VERB
njb-29	260	26	.	.	PUNCT
njb-29	261	1	references	reference	NOUN
njb-29	261	2	1	1	NUM
njb-29	261	3	.	.	PUNCT
njb-29	262	1	guerin	guerin	PROPN
njb-29	262	2	pj	pj	PROPN
njb-29	262	3	,	,	PUNCT
njb-29	262	4	olliaro	olliaro	NOUN
njb-29	262	5	p	p	PROPN
njb-29	262	6	,	,	PUNCT
njb-29	262	7	sundar	sundar	PROPN
njb-29	262	8	s	s	PROPN
njb-29	262	9	,	,	PUNCT
njb-29	262	10	boelaert	boelaert	PROPN
njb-29	262	11	m	m	PROPN
njb-29	262	12	,	,	PUNCT
njb-29	262	13	croft	croft	PROPN
njb-29	262	14	sl	sl	PROPN
njb-29	262	15	,	,	PUNCT
njb-29	262	16	desjeux	desjeux	PROPN
njb-29	262	17	p	p	PROPN
njb-29	262	18	,	,	PUNCT
njb-29	262	19	wasunna	wasunna	PROPN
njb-29	262	20	mk	mk	PROPN
njb-29	262	21	,	,	PUNCT
njb-29	262	22	bryceson	bryceson	PROPN
njb-29	262	23	ad	ad	PROPN
njb-29	262	24	:	:	PUNCT
njb-29	262	25	visceral	visceral	ADJ
njb-29	262	26	leishmaniasis	leishmaniasis	NOUN
njb-29	262	27	:	:	PUNCT
njb-29	262	28	current	current	ADJ
njb-29	262	29	status	status	NOUN
njb-29	262	30	of	of	ADP
njb-29	262	31	control	control	NOUN
njb-29	262	32	,	,	PUNCT
njb-29	262	33	diagnosis	diagnosis	NOUN
njb-29	262	34	,	,	PUNCT
njb-29	262	35	and	and	CCONJ
njb-29	262	36	treatment	treatment	NOUN
njb-29	262	37	,	,	PUNCT
njb-29	262	38	and	and	CCONJ
njb-29	262	39	a	a	DET
njb-29	262	40	proposed	propose	VERB
njb-29	262	41	research	research	NOUN
njb-29	262	42	and	and	CCONJ
njb-29	262	43	development	development	NOUN
njb-29	262	44	agenda	agenda	NOUN
njb-29	262	45	.	.	PUNCT
njb-29	263	1	lancet	lancet	PROPN
njb-29	263	2	infect	infect	PROPN
njb-29	263	3	dis	dis	PROPN
njb-29	263	4	.	.	PROPN
njb-29	263	5	2002	2002	NUM
njb-29	263	6	,	,	PUNCT
njb-29	263	7	2(8):494501	2(8):494501	NUM
njb-29	263	8	.	.	PROPN
njb-29	263	9	2	2	X
njb-29	263	10	.	.	X
njb-29	263	11	haimeur	haimeur	VERB
njb-29	263	12	a	a	PRON
njb-29	263	13	,	,	PUNCT
njb-29	263	14	brochu	brochu	PROPN
njb-29	263	15	c	c	PROPN
njb-29	263	16	,	,	PUNCT
njb-29	263	17	genest	genest	PROPN
njb-29	263	18	p	p	PROPN
njb-29	263	19	,	,	PUNCT
njb-29	263	20	papadopoulou	papadopoulou	PROPN
njb-29	263	21	b	b	PROPN
njb-29	263	22	,	,	PUNCT
njb-29	263	23	ouellette	ouellette	NOUN
njb-29	263	24	m	m	NOUN
njb-29	263	25	:	:	PUNCT
njb-29	263	26	amplification	amplification	NOUN
njb-29	263	27	of	of	ADP
njb-29	263	28	the	the	DET
njb-29	263	29	abc	abc	PROPN
njb-29	263	30	transporter	transporter	PROPN
njb-29	263	31	gene	gene	NOUN
njb-29	263	32	pgpa	pgpa	NOUN
njb-29	263	33	and	and	CCONJ
njb-29	263	34	increased	increase	VERB
njb-29	263	35	trypanothione	trypanothione	NOUN
njb-29	263	36	levels	level	NOUN
njb-29	263	37	in	in	ADP
njb-29	263	38	potassium	potassium	NOUN
njb-29	263	39	antimonyl	antimonyl	PROPN
njb-29	264	1	tartrate	tartrate	VERB
njb-29	264	2	(	(	PUNCT
njb-29	264	3	sbiii	sbiii	NOUN
njb-29	264	4	)	)	PUNCT
njb-29	264	5	resistant	resistant	ADJ
njb-29	264	6	leishmania	leishmania	PROPN
njb-29	264	7	tarentolae	tarentolae	PROPN
njb-29	264	8	.	.	PUNCT
njb-29	265	1	mol	mol	PROPN
njb-29	265	2	biochem	biochem	NOUN
njb-29	265	3	parasitol	parasitol	PROPN
njb-29	265	4	.	.	PUNCT
njb-29	266	1	2000	2000	NUM
njb-29	266	2	,	,	PUNCT
njb-29	266	3	108(1):131	108(1):131	NUM
njb-29	266	4	-	-	SYM
njb-29	266	5	135	135	NUM
njb-29	266	6	.	.	NUM
njb-29	266	7	3	3	X
njb-29	266	8	.	.	X
njb-29	266	9	sundar	sundar	PROPN
njb-29	266	10	s	s	PROPN
njb-29	266	11	,	,	PUNCT
njb-29	266	12	more	more	ADV
njb-29	266	13	dk	dk	PROPN
njb-29	266	14	,	,	PUNCT
njb-29	266	15	singh	singh	PROPN
njb-29	266	16	mk	mk	PROPN
njb-29	266	17	,	,	PUNCT
njb-29	266	18	singh	singh	PROPN
njb-29	266	19	vp	vp	PROPN
njb-29	266	20	,	,	PUNCT
njb-29	266	21	sharma	sharma	PROPN
njb-29	266	22	s	s	PROPN
njb-29	266	23	,	,	PUNCT
njb-29	266	24	makharia	makharia	PROPN
njb-29	266	25	a	a	PROPN
njb-29	266	26	,	,	PUNCT
njb-29	266	27	kumar	kumar	PROPN
njb-29	266	28	pc	pc	PROPN
njb-29	266	29	,	,	PUNCT
njb-29	266	30	murray	murray	PROPN
njb-29	266	31	hw	hw	PROPN
njb-29	266	32	:	:	PUNCT
njb-29	266	33	failure	failure	NOUN
njb-29	266	34	of	of	ADP
njb-29	266	35	pentavalent	pentavalent	NOUN
njb-29	266	36	antimony	antimony	NOUN
njb-29	266	37	in	in	ADP
njb-29	266	38	visceral	visceral	NOUN
njb-29	266	39	leishmaniasis	leishmaniasis	NOUN
njb-29	266	40	in	in	ADP
njb-29	266	41	india	india	PROPN
njb-29	266	42	:	:	PUNCT
njb-29	266	43	report	report	NOUN
njb-29	266	44	from	from	ADP
njb-29	266	45	the	the	DET
njb-29	266	46	center	center	NOUN
njb-29	266	47	of	of	ADP
njb-29	266	48	the	the	DET
njb-29	266	49	indian	indian	ADJ
njb-29	266	50	epidemic	epidemic	NOUN
njb-29	266	51	.	.	PUNCT
njb-29	267	1	clin	clin	PROPN
njb-29	267	2	.	.	PUNCT
njb-29	267	3	infect	infect	PROPN
njb-29	267	4	.	.	PUNCT
njb-29	268	1	dis	dis	PROPN
njb-29	268	2	.	.	PROPN
njb-29	268	3	200	200	NUM
njb-29	268	4	,	,	PUNCT
njb-29	268	5	31(4	31(4	NUM
njb-29	268	6	):	):	PUNCT
njb-29	268	7	1104	1104	NUM
njb-29	268	8	-	-	SYM
njb-29	268	9	1107	1107	NUM
njb-29	268	10	.	.	PUNCT
njb-29	269	1	4	4	X
njb-29	269	2	.	.	PROPN
njb-29	269	3	thakur	thakur	PROPN
njb-29	269	4	cp	cp	PROPN
njb-29	269	5	,	,	PUNCT
njb-29	269	6	kumar	kumar	PROPN
njb-29	269	7	k	k	PROPN
njb-29	269	8	:	:	PUNCT
njb-29	269	9	post	post	PROPN
njb-29	269	10	kala	kala	PROPN
njb-29	269	11	-	-	PUNCT
njb-29	269	12	azar	azar	PROPN
njb-29	269	13	dermal	dermal	ADJ
njb-29	269	14	leishmaniasis	leishmaniasis	NOUN
njb-29	269	15	:	:	PUNCT
njb-29	269	16	a	a	DET
njb-29	269	17	neglected	neglect	VERB
njb-29	269	18	aspect	aspect	NOUN
njb-29	269	19	of	of	ADP
njb-29	269	20	kala	kala	PROPN
njb-29	269	21	-	-	PUNCT
njb-29	269	22	azar	azar	PROPN
njb-29	269	23	control	control	NOUN
njb-29	269	24	programmes	programme	NOUN
njb-29	269	25	.	.	PUNCT
njb-29	270	1	ann	ann	PROPN
njb-29	270	2	trop	trop	PROPN
njb-29	270	3	med	med	PROPN
njb-29	270	4	parasitol	parasitol	PROPN
njb-29	270	5	.	.	PUNCT
njb-29	271	1	1992	1992	NUM
njb-29	271	2	,	,	PUNCT
njb-29	271	3	86(4	86(4	NUM
njb-29	271	4	):	):	PUNCT
njb-29	271	5	355	355	NUM
njb-29	271	6	-	-	SYM
njb-29	271	7	359	359	NUM
njb-29	271	8	.	.	NOUN
njb-29	271	9	5	5	X
njb-29	271	10	.	.	PUNCT
njb-29	272	1	zijlstra	zijlstra	PROPN
njb-29	272	2	ee	ee	PROPN
njb-29	272	3	,	,	PUNCT
njb-29	272	4	musa	musa	PROPN
njb-29	272	5	am	am	PROPN
njb-29	272	6	,	,	PUNCT
njb-29	272	7	khalil	khalil	PROPN
njb-29	272	8	ea	ea	PROPN
njb-29	272	9	,	,	PUNCT
njb-29	272	10	el	el	PROPN
njb-29	272	11	-	-	PUNCT
njb-29	272	12	hassan	hassan	PROPN
njb-29	272	13	i	i	PRON
njb-29	272	14	m	m	VERB
njb-29	272	15	,	,	PUNCT
njb-29	272	16	elhassan	elhassan	PROPN
njb-29	272	17	am	be	AUX
njb-29	272	18	:	:	PUNCT
njb-29	272	19	post	post	ADJ
njb-29	272	20	-	-	ADJ
njb-29	272	21	kala	kala	ADJ
njb-29	272	22	-	-	PUNCT
njb-29	272	23	azar	azar	PROPN
njb-29	272	24	dermal	dermal	ADJ
njb-29	272	25	leishmaniasis	leishmaniasis	NOUN
njb-29	272	26	.	.	PUNCT
njb-29	273	1	lancet	lancet	PROPN
njb-29	273	2	infect	infect	PROPN
njb-29	273	3	.	.	PUNCT
njb-29	274	1	dis	dis	PROPN
njb-29	274	2	.	.	PROPN
njb-29	274	3	2003	2003	NUM
njb-29	274	4	,	,	PUNCT
njb-29	274	5	3(2	3(2	NOUN
njb-29	274	6	):	):	PUNCT
njb-29	274	7	87	87	NUM
njb-29	274	8	-	-	SYM
njb-29	274	9	98	98	NUM
njb-29	274	10	.	.	NUM
njb-29	274	11	6	6	NUM
njb-29	274	12	.	.	PUNCT
njb-29	274	13	roberts	roberts	PROPN
njb-29	274	14	wl	wl	PROPN
njb-29	274	15	,	,	PUNCT
njb-29	274	16	berman	berman	PROPN
njb-29	274	17	jd	jd	PROPN
njb-29	274	18	,	,	PUNCT
njb-29	274	19	rainey	rainey	PROPN
njb-29	274	20	pm	pm	PROPN
njb-29	274	21	:	:	PUNCT
njb-29	274	22	in	in	ADP
njb-29	274	23	vitro	vitro	X
njb-29	274	24	antileishmanial	antileishmanial	ADJ
njb-29	274	25	properties	property	NOUN
njb-29	274	26	of	of	ADP
njb-29	274	27	triand	triand	NOUN
njb-29	274	28	pentavalent	pentavalent	ADJ
njb-29	274	29	antimonial	antimonial	ADJ
njb-29	274	30	preparations	preparation	NOUN
njb-29	274	31	.	.	PUNCT
njb-29	275	1	antimicrob	antimicrob	PROPN
njb-29	275	2	agents	agents	PROPN
njb-29	275	3	chemother	chemother	PROPN
njb-29	275	4	.	.	PUNCT
njb-29	275	5	1995	1995	NUM
njb-29	275	6	,	,	PUNCT
njb-29	275	7	39(6	39(6	NUM
njb-29	275	8	):	):	PUNCT
njb-29	275	9	1234	1234	NUM
njb-29	275	10	-	-	SYM
njb-29	275	11	1239	1239	NUM
njb-29	275	12	.	.	PUNCT
njb-29	276	1	7	7	X
njb-29	276	2	.	.	X
njb-29	276	3	denton	denton	PROPN
njb-29	276	4	h	h	PROPN
njb-29	276	5	,	,	PUNCT
njb-29	276	6	mcgregor	mcgregor	PROPN
njb-29	276	7	jc	jc	PROPN
njb-29	276	8	,	,	PUNCT
njb-29	276	9	coombs	coombs	PROPN
njb-29	276	10	gh	gh	PROPN
njb-29	276	11	:	:	PUNCT
njb-29	276	12	reduction	reduction	NOUN
njb-29	276	13	of	of	ADP
njb-29	276	14	anti	anti	ADJ
njb-29	276	15	-	-	ADJ
njb-29	276	16	leishmanial	leishmanial	ADJ
njb-29	276	17	pentavalent	pentavalent	NOUN
njb-29	276	18	antimonial	antimonial	ADJ
njb-29	276	19	drugs	drug	NOUN
njb-29	276	20	by	by	ADP
njb-29	276	21	a	a	DET
njb-29	276	22	parasite	parasite	NOUN
njb-29	276	23	-	-	PUNCT
njb-29	276	24	specific	specific	ADJ
njb-29	276	25	thiol	thiol	ADJ
njb-29	276	26	-	-	PUNCT
njb-29	276	27	dependent	dependent	ADJ
njb-29	276	28	reductase	reductase	NOUN
njb-29	276	29	,	,	PUNCT
njb-29	276	30	tdr1	tdr1	PROPN
njb-29	276	31	.	.	PROPN
njb-29	276	32	biochem	biochem	PROPN
njb-29	276	33	j.	j.	PROPN
njb-29	276	34	2004	2004	PROPN
njb-29	276	35	,	,	PUNCT
njb-29	276	36	381(2	381(2	NUM
njb-29	276	37	):	):	PUNCT
njb-29	276	38	405	405	NUM
njb-29	276	39	-	-	SYM
njb-29	276	40	412	412	NUM
njb-29	276	41	.	.	PROPN
njb-29	276	42	8	8	NUM
njb-29	276	43	.	.	PUNCT
njb-29	276	44	ferreira	ferreira	PROPN
njb-29	276	45	cs	cs	PROPN
njb-29	276	46	,	,	PUNCT
njb-29	276	47	martins	martin	NOUN
njb-29	276	48	ps	ps	PROPN
njb-29	276	49	,	,	PUNCT
njb-29	276	50	demicheli	demicheli	PROPN
njb-29	276	51	c	c	PROPN
njb-29	276	52	,	,	PUNCT
njb-29	276	53	brochu	brochu	PROPN
njb-29	276	54	c	c	PROPN
njb-29	276	55	,	,	PUNCT
njb-29	276	56	ouellette	ouellette	NOUN
njb-29	276	57	m	m	PROPN
njb-29	276	58	,	,	PUNCT
njb-29	276	59	frezard	frezard	PROPN
njb-29	276	60	f	f	PROPN
njb-29	276	61	:	:	PUNCT
njb-29	276	62	thiol	thiol	PROPN
njb-29	276	63	-	-	PUNCT
njb-29	276	64	induced	induce	VERB
njb-29	276	65	reduction	reduction	NOUN
njb-29	276	66	of	of	ADP
njb-29	276	67	antimony(v	antimony(v	NOUN
njb-29	276	68	)	)	PUNCT
njb-29	276	69	into	into	ADP
njb-29	276	70	antimony(iii	antimony(iii	PROPN
njb-29	276	71	):	):	PUNCT
njb-29	276	72	a	a	DET
njb-29	276	73	comparative	comparative	ADJ
njb-29	276	74	study	study	NOUN
njb-29	276	75	with	with	ADP
njb-29	276	76	trypanothione	trypanothione	PROPN
njb-29	276	77	,	,	PUNCT
njb-29	276	78	cysteinyl	cysteinyl	NOUN
njb-29	276	79	-	-	PUNCT
njb-29	276	80	glycine	glycine	NOUN
njb-29	276	81	,	,	PUNCT
njb-29	276	82	cysteine	cysteine	NOUN
njb-29	276	83	and	and	CCONJ
njb-29	276	84	glutathione	glutathione	PROPN
njb-29	276	85	.	.	PUNCT
njb-29	277	1	biometals	biometal	NOUN
njb-29	277	2	2003	2003	NUM
njb-29	277	3	,	,	PUNCT
njb-29	277	4	16(3	16(3	NUM
njb-29	277	5	):	):	PUNCT
njb-29	277	6	441446	441446	NUM
njb-29	277	7	.	.	PUNCT
njb-29	278	1	9	9	NUM
njb-29	278	2	.	.	PUNCT
njb-29	278	3	zhou	zhou	PROPN
njb-29	278	4	y	y	PROPN
njb-29	278	5	,	,	PUNCT
njb-29	278	6	messier	messy	ADJ
njb-29	278	7	n	n	NOUN
njb-29	278	8	,	,	PUNCT
njb-29	278	9	ouellette	ouellette	NOUN
njb-29	278	10	m	m	PROPN
njb-29	278	11	,	,	PUNCT
njb-29	278	12	rosen	rosen	PROPN
njb-29	278	13	bp	bp	PROPN
njb-29	278	14	,	,	PUNCT
njb-29	278	15	mukhopadhyay	mukhopadhyay	PROPN
njb-29	278	16	r	r	NOUN
njb-29	278	17	:	:	PUNCT
njb-29	278	18	leishmania	leishmania	PROPN
njb-29	278	19	major	major	ADJ
njb-29	278	20	lmacr2	lmacr2	PROPN
njb-29	278	21	is	be	AUX
njb-29	278	22	a	a	DET
njb-29	278	23	pentavalent	pentavalent	NOUN
njb-29	278	24	antimony	antimony	NOUN
njb-29	278	25	reductase	reductase	NOUN
njb-29	278	26	that	that	PRON
njb-29	278	27	confers	confer	VERB
njb-29	278	28	sensitivity	sensitivity	NOUN
njb-29	278	29	to	to	ADP
njb-29	278	30	the	the	DET
njb-29	278	31	drug	drug	NOUN
njb-29	278	32	pentostam	pentostam	NOUN
njb-29	278	33	.	.	PUNCT
njb-29	279	1	j	j	PROPN
njb-29	279	2	biol	biol	PROPN
njb-29	279	3	chem	chem	PROPN
njb-29	279	4	.	.	PUNCT
njb-29	280	1	2004	2004	NUM
njb-29	280	2	,	,	PUNCT
njb-29	280	3	279	279	NUM
njb-29	280	4	:	:	PUNCT
njb-29	280	5	37445	37445	NUM
njb-29	280	6	-	-	SYM
njb-29	280	7	37451	37451	NUM
njb-29	280	8	.	.	PUNCT
njb-29	281	1	10	10	X
njb-29	281	2	.	.	X
njb-29	282	1	shaked	shaked	PROPN
njb-29	282	2	-	-	PUNCT
njb-29	282	3	mishan	mishan	PROPN
njb-29	282	4	p	p	PROPN
njb-29	282	5	,	,	PUNCT
njb-29	282	6	ulrich	ulrich	PROPN
njb-29	282	7	n	n	PROPN
njb-29	282	8	,	,	PUNCT
njb-29	282	9	ephros	ephros	PROPN
njb-29	282	10	m	m	PROPN
njb-29	282	11	,	,	PUNCT
njb-29	282	12	zilberstein	zilberstein	PROPN
njb-29	282	13	d	d	PROPN
njb-29	282	14	:	:	PUNCT
njb-29	282	15	novel	novel	PROPN
njb-29	282	16	intracellular	intracellular	NOUN
njb-29	282	17	sbv	sbv	ADP
njb-29	282	18	reducing	reduce	VERB
njb-29	282	19	activity	activity	NOUN
njb-29	282	20	correlates	correlate	VERB
njb-29	282	21	with	with	ADP
njb-29	282	22	antimony	antimony	ADJ
njb-29	282	23	susceptibility	susceptibility	NOUN
njb-29	282	24	in	in	ADP
njb-29	282	25	leishmania	leishmania	PROPN
njb-29	282	26	donovani	donovani	PROPN
njb-29	282	27	.	.	PUNCT
njb-29	283	1	j	j	PROPN
njb-29	283	2	biol	biol	PROPN
njb-29	283	3	chem	chem	PROPN
njb-29	283	4	.	.	PUNCT
njb-29	283	5	2001	2001	NUM
njb-29	283	6	,	,	PUNCT
njb-29	283	7	276(6	276(6	NUM
njb-29	283	8	):	):	PUNCT
njb-29	283	9	3971	3971	NUM
njb-29	283	10	-	-	SYM
njb-29	283	11	3976	3976	NUM
njb-29	283	12	.	.	PUNCT
njb-29	284	1	11	11	NUM
njb-29	284	2	.	.	PUNCT
njb-29	284	3	gourbal	gourbal	PROPN
njb-29	284	4	b	b	PROPN
njb-29	284	5	,	,	PUNCT
njb-29	284	6	sonuc	sonuc	NOUN
njb-29	284	7	n	n	PRON
njb-29	284	8	,	,	PUNCT
njb-29	284	9	bhattacharjee	bhattacharjee	PROPN
njb-29	284	10	h	h	PROPN
njb-29	284	11	,	,	PUNCT
njb-29	284	12	legare	legare	PROPN
njb-29	284	13	d	d	PROPN
njb-29	284	14	,	,	PUNCT
njb-29	284	15	sundar	sundar	PROPN
njb-29	284	16	s	s	PROPN
njb-29	284	17	,	,	PUNCT
njb-29	284	18	ouellette	ouellette	NOUN
njb-29	284	19	m	m	PROPN
njb-29	284	20	,	,	PUNCT
njb-29	284	21	rosen	rosen	PROPN
njb-29	284	22	bp	bp	PROPN
njb-29	284	23	,	,	PUNCT
njb-29	284	24	mukhopadhyay	mukhopadhyay	PROPN
njb-29	284	25	r	r	NOUN
njb-29	284	26	:	:	PUNCT
njb-29	284	27	drug	drug	NOUN
njb-29	284	28	uptake	uptake	NOUN
njb-29	284	29	and	and	CCONJ
njb-29	284	30	modulation	modulation	NOUN
njb-29	284	31	of	of	ADP
njb-29	284	32	drug	drug	NOUN
njb-29	284	33	resistance	resistance	NOUN
njb-29	284	34	in	in	ADP
njb-29	284	35	leishmania	leishmania	PROPN
njb-29	284	36	by	by	ADP
njb-29	284	37	an	an	DET
njb-29	284	38	aquaglyceroporin	aquaglyceroporin	NOUN
njb-29	284	39	.	.	PUNCT
njb-29	285	1	j	j	PROPN
njb-29	285	2	biol	biol	PROPN
njb-29	285	3	chem	chem	PROPN
njb-29	285	4	.	.	PUNCT
njb-29	286	1	2004	2004	NUM
njb-29	286	2	,	,	PUNCT
njb-29	286	3	279(30	279(30	NUM
njb-29	286	4	):	):	PUNCT
njb-29	286	5	31010	31010	NUM
njb-29	286	6	-	-	SYM
njb-29	286	7	31017	31017	NUM
njb-29	286	8	.	.	PUNCT
njb-29	287	1	12	12	NUM
njb-29	287	2	.	.	PUNCT
njb-29	287	3	marquis	marquis	PROPN
njb-29	287	4	n	n	PROPN
njb-29	287	5	,	,	PUNCT
njb-29	287	6	gourbal	gourbal	PROPN
njb-29	287	7	b	b	PROPN
njb-29	287	8	,	,	PUNCT
njb-29	287	9	rosen	rosen	PROPN
njb-29	287	10	bp	bp	PROPN
njb-29	287	11	,	,	PUNCT
njb-29	287	12	mukhopadhyay	mukhopadhyay	PROPN
njb-29	287	13	r	r	PROPN
njb-29	287	14	,	,	PUNCT
njb-29	287	15	ouellette	ouellette	NOUN
njb-29	287	16	m	m	NOUN
njb-29	287	17	:	:	PUNCT
njb-29	287	18	modulation	modulation	NOUN
njb-29	287	19	in	in	ADP
njb-29	287	20	aquaglyceroporin	aquaglyceroporin	PROPN
njb-29	287	21	aqp1	aqp1	PROPN
njb-29	287	22	gene	gene	NOUN
njb-29	287	23	transcript	transcript	NOUN
njb-29	287	24	levels	level	NOUN
njb-29	287	25	in	in	ADP
njb-29	287	26	drug	drug	NOUN
njb-29	287	27	-	-	PUNCT
njb-29	287	28	resistant	resistant	ADJ
njb-29	287	29	leishmania	leishmania	PROPN
njb-29	287	30	.	.	PUNCT
njb-29	288	1	mol	mol	PROPN
njb-29	288	2	microbiol	microbiol	PROPN
njb-29	288	3	.	.	PUNCT
njb-29	289	1	2005	2005	NUM
njb-29	289	2	,	,	PUNCT
njb-29	289	3	57(6	57(6	NUM
njb-29	289	4	):	):	PUNCT
njb-29	289	5	1690	1690	NUM
njb-29	289	6	-	-	SYM
njb-29	289	7	1699	1699	NUM
njb-29	289	8	.	.	PUNCT
njb-29	289	9	13	13	NUM
njb-29	289	10	.	.	PUNCT
njb-29	290	1	wyllie	wyllie	PROPN
njb-29	290	2	s	s	PROPN
njb-29	290	3	,	,	PUNCT
njb-29	290	4	cunningham	cunningham	PROPN
njb-29	290	5	ml	ml	PROPN
njb-29	290	6	,	,	PUNCT
njb-29	290	7	fairlamb	fairlamb	X
njb-29	290	8	ah	ah	INTJ
njb-29	290	9	:	:	PUNCT
njb-29	290	10	dual	dual	ADJ
njb-29	290	11	action	action	NOUN
njb-29	290	12	of	of	ADP
njb-29	290	13	antimonial	antimonial	ADJ
njb-29	290	14	drugs	drug	NOUN
njb-29	290	15	on	on	ADP
njb-29	290	16	thiol	thiol	PROPN
njb-29	290	17	redox	redox	PROPN
njb-29	290	18	metabolism	metabolism	NOUN
njb-29	290	19	in	in	ADP
njb-29	290	20	the	the	DET
njb-29	290	21	human	human	PROPN
njb-29	290	22	pathogen	pathogen	PROPN
njb-29	290	23	leishmania	leishmania	PROPN
njb-29	290	24	donovani	donovani	PROPN
njb-29	290	25	.	.	PUNCT
njb-29	291	1	j	j	PROPN
njb-29	291	2	biol	biol	PROPN
njb-29	291	3	chem	chem	PROPN
njb-29	291	4	.	.	PUNCT
njb-29	291	5	2004	2004	NUM
njb-29	291	6	,	,	PUNCT
njb-29	291	7	279(38	279(38	NUM
njb-29	291	8	):	):	PUNCT
njb-29	291	9	39925	39925	NUM
njb-29	291	10	-	-	SYM
njb-29	291	11	39932	39932	NUM
njb-29	291	12	.	.	PUNCT
njb-29	292	1	14	14	NUM
njb-29	292	2	.	.	PUNCT
njb-29	292	3	dey	dey	PROPN
njb-29	292	4	s	s	PROPN
njb-29	292	5	,	,	PUNCT
njb-29	292	6	ouellette	ouellette	NOUN
njb-29	292	7	m	m	PROPN
njb-29	292	8	,	,	PUNCT
njb-29	292	9	lightbody	lightbody	PROPN
njb-29	292	10	j	j	PROPN
njb-29	292	11	,	,	PUNCT
njb-29	292	12	papadopoulou	papadopoulou	PROPN
njb-29	292	13	b	b	PROPN
njb-29	292	14	,	,	PUNCT
njb-29	292	15	rosen	rosen	PROPN
njb-29	292	16	bp	bp	PROPN
njb-29	292	17	:	:	PUNCT
njb-29	292	18	an	an	DET
njb-29	292	19	atp	atp	NOUN
njb-29	292	20	-	-	PUNCT
njb-29	292	21	dependent	dependent	ADJ
njb-29	292	22	as	as	ADP
njb-29	292	23	(	(	PUNCT
njb-29	292	24	iii)-glutathione	iii)-glutathione	PROPN
njb-29	292	25	transport	transport	NOUN
njb-29	292	26	system	system	NOUN
njb-29	292	27	in	in	ADP
njb-29	292	28	membrane	membrane	NOUN
njb-29	292	29	vesicles	vesicle	NOUN
njb-29	292	30	of	of	ADP
njb-29	292	31	leishmania	leishmania	PROPN
njb-29	292	32	tarentolae	tarentolae	PROPN
njb-29	292	33	.	.	PUNCT
njb-29	293	1	proc	proc	PROPN
njb-29	293	2	natl	natl	PROPN
njb-29	293	3	acad	acad	PROPN
njb-29	293	4	sci	sci	PROPN
njb-29	293	5	u	u	PROPN
njb-29	293	6	s	s	PROPN
njb-29	293	7	a.	a.	PROPN
njb-29	293	8	1996	1996	NUM
njb-29	293	9	,	,	PUNCT
njb-29	293	10	93(5	93(5	NUM
njb-29	293	11	)	)	PUNCT
njb-29	293	12	,	,	PUNCT
njb-29	293	13	2192	2192	NUM
njb-29	293	14	-	-	SYM
njb-29	293	15	2197	2197	NUM
njb-29	293	16	.	.	SYM
njb-29	294	1	15	15	NUM
njb-29	294	2	.	.	X
njb-29	294	3	fairlamb	fairlamb	PROPN
njb-29	294	4	ah	ah	INTJ
njb-29	294	5	,	,	PUNCT
njb-29	294	6	cerami	cerami	PROPN
njb-29	294	7	a	a	PRON
njb-29	294	8	:	:	PUNCT
njb-29	294	9	metabolism	metabolism	NOUN
njb-29	294	10	and	and	CCONJ
njb-29	294	11	functions	function	NOUN
njb-29	294	12	of	of	ADP
njb-29	294	13	trypanothione	trypanothione	NOUN
njb-29	294	14	in	in	ADP
njb-29	294	15	the	the	DET
njb-29	294	16	kinetoplastida	kinetoplastida	PROPN
njb-29	294	17	.	.	PUNCT
njb-29	295	1	annu	annu	PROPN
njb-29	295	2	rev	rev	PROPN
njb-29	295	3	microbiol	microbiol	PROPN
njb-29	295	4	.	.	PUNCT
njb-29	296	1	1992	1992	NUM
njb-29	296	2	,	,	PUNCT
njb-29	296	3	46	46	NUM
njb-29	296	4	:	:	SYM
njb-29	296	5	695	695	NUM
njb-29	296	6	-	-	SYM
njb-29	296	7	729	729	NUM
njb-29	296	8	.	.	NUM
njb-29	296	9	16	16	NUM
njb-29	296	10	.	.	PUNCT
njb-29	297	1	legare	legare	PROPN
njb-29	297	2	d	d	PROPN
njb-29	297	3	,	,	PUNCT
njb-29	297	4	richard	richard	PROPN
njb-29	297	5	d	d	PROPN
njb-29	297	6	,	,	PUNCT
njb-29	297	7	mukhopadhyay	mukhopadhyay	PROPN
njb-29	297	8	r	r	PROPN
njb-29	297	9	,	,	PUNCT
njb-29	297	10	stierhof	stierhof	PROPN
njb-29	297	11	yd	yd	PROPN
njb-29	297	12	,	,	PUNCT
njb-29	297	13	rosen	rosen	PROPN
njb-29	297	14	bp	bp	PROPN
njb-29	297	15	,	,	PUNCT
njb-29	297	16	haimeur	haimeur	VERB
njb-29	297	17	a	a	PRON
njb-29	297	18	,	,	PUNCT
njb-29	297	19	papadopoulou	papadopoulou	PROPN
njb-29	297	20	b	b	PROPN
njb-29	297	21	,	,	PUNCT
njb-29	297	22	ouellette	ouellette	NOUN
njb-29	297	23	m	m	PROPN
njb-29	297	24	:	:	PUNCT
njb-29	297	25	nepal	nepal	ADJ
njb-29	297	26	journal	journal	NOUN
njb-29	297	27	of	of	ADP
njb-29	297	28	biotechnology	biotechnology	NOUN
njb-29	297	29	.	.	PUNCT
njb-29	298	1	d	d	X
njb-29	298	2	e	e	PROPN
njb-29	298	3	c	c	PROPN
njb-29	298	4	.	.	PUNCT
njb-29	299	1	2	2	NUM
njb-29	299	2	0	0	NUM
njb-29	299	3	1	1	NUM
njb-29	299	4	6	6	NUM
njb-29	299	5	vol	vol	NOUN
njb-29	299	6	.	.	PROPN
njb-29	300	1	4	4	NUM
njb-29	300	2	,	,	PUNCT
njb-29	300	3	no	no	NOUN
njb-29	300	4	.	.	NOUN
njb-29	300	5	1	1	NUM
njb-29	300	6	:	:	SYM
njb-29	300	7	1	1	NUM
njb-29	300	8	-	-	SYM
njb-29	300	9	13	13	NUM
njb-29	300	10	maharjan	maharjan	NOUN
njb-29	300	11	et	et	NOUN
njb-29	300	12	al	al	PROPN
njb-29	300	13	.	.	PUNCT
njb-29	301	1	©	©	PROPN
njb-29	301	2	njb	njb	PROPN
njb-29	301	3	,	,	PUNCT
njb-29	301	4	biotechnology	biotechnology	NOUN
njb-29	301	5	society	society	NOUN
njb-29	301	6	of	of	ADP
njb-29	301	7	nepal	nepal	ADJ
njb-29	301	8	13	13	NUM
njb-29	301	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	NOUN
njb-29	301	10	the	the	DET
njb-29	301	11	leishmania	leishmania	PROPN
njb-29	301	12	atp	atp	PROPN
njb-29	301	13	-	-	PUNCT
njb-29	301	14	binding	bind	VERB
njb-29	301	15	cassette	cassette	NOUN
njb-29	301	16	protein	protein	NOUN
njb-29	301	17	pgpa	pgpa	NOUN
njb-29	301	18	is	be	AUX
njb-29	301	19	an	an	DET
njb-29	301	20	intracellular	intracellular	ADJ
njb-29	301	21	metal	metal	NOUN
njb-29	301	22	-	-	PUNCT
njb-29	301	23	thiol	thiol	NOUN
njb-29	301	24	transporter	transporter	NOUN
njb-29	301	25	atpase	atpase	PROPN
njb-29	301	26	.	.	PUNCT
njb-29	302	1	j	j	PROPN
njb-29	302	2	biol	biol	PROPN
njb-29	302	3	chem	chem	PROPN
njb-29	302	4	.	.	PUNCT
njb-29	302	5	2001	2001	NUM
njb-29	302	6	,	,	PUNCT
njb-29	302	7	276(28	276(28	NUM
njb-29	302	8	):	):	PUNCT
njb-29	302	9	26301	26301	NUM
njb-29	302	10	-	-	SYM
njb-29	302	11	26307	26307	NUM
njb-29	302	12	.	.	PUNCT
njb-29	303	1	17	17	NUM
njb-29	303	2	.	.	PUNCT
njb-29	304	1	legare	legare	PROPN
njb-29	304	2	d	d	PROPN
njb-29	304	3	,	,	PUNCT
njb-29	304	4	papadopoulou	papadopoulou	PROPN
njb-29	304	5	b	b	PROPN
njb-29	304	6	,	,	PUNCT
njb-29	304	7	roy	roy	PROPN
njb-29	304	8	g	g	PROPN
njb-29	304	9	,	,	PUNCT
njb-29	304	10	mukhopadhyay	mukhopadhyay	PROPN
njb-29	304	11	r	r	PROPN
njb-29	304	12	,	,	PUNCT
njb-29	304	13	haimeur	haimeur	PROPN
njb-29	304	14	a	a	PRON
njb-29	304	15	,	,	PUNCT
njb-29	304	16	dey	dey	PROPN
njb-29	304	17	s	s	PROPN
njb-29	304	18	,	,	PUNCT
njb-29	304	19	grondin	grondin	PROPN
njb-29	304	20	k	k	PROPN
njb-29	304	21	,	,	PUNCT
njb-29	304	22	brochu	brochu	PROPN
njb-29	304	23	c	c	PROPN
njb-29	304	24	,	,	PUNCT
njb-29	304	25	rosen	rosen	PROPN
njb-29	304	26	bp	bp	PROPN
njb-29	304	27	,	,	PUNCT
njb-29	304	28	ouellette	ouellette	NOUN
njb-29	304	29	m	m	NOUN
njb-29	304	30	:	:	PUNCT
njb-29	304	31	efflux	efflux	NOUN
njb-29	304	32	systems	system	NOUN
njb-29	304	33	and	and	CCONJ
njb-29	304	34	increased	increase	VERB
njb-29	304	35	trypanothione	trypanothione	NOUN
njb-29	304	36	levels	level	NOUN
njb-29	304	37	in	in	ADP
njb-29	304	38	arsenite	arsenite	NOUN
njb-29	304	39	-	-	PUNCT
njb-29	304	40	resistant	resistant	ADJ
njb-29	304	41	leishmania	leishmania	PROPN
njb-29	304	42	.	.	PUNCT
njb-29	305	1	exp	exp	PROPN
njb-29	305	2	parasitol	parasitol	PROPN
njb-29	305	3	.	.	PUNCT
njb-29	306	1	1997	1997	NUM
njb-29	306	2	,	,	PUNCT
njb-29	306	3	87(3	87(3	NUM
njb-29	306	4	):	):	PUNCT
njb-29	306	5	275	275	NUM
njb-29	306	6	-	-	SYM
njb-29	306	7	282	282	NUM
njb-29	306	8	.	.	PUNCT
njb-29	306	9	18	18	NUM
njb-29	306	10	.	.	PUNCT
njb-29	306	11	mukhopadhyay	mukhopadhyay	PROPN
njb-29	306	12	r	r	PROPN
njb-29	306	13	,	,	PUNCT
njb-29	306	14	dey	dey	PROPN
njb-29	306	15	s	s	PROPN
njb-29	306	16	,	,	PUNCT
njb-29	306	17	xu	xu	PROPN
njb-29	306	18	n	n	NOUN
njb-29	306	19	,	,	PUNCT
njb-29	306	20	gage	gage	PROPN
njb-29	306	21	d	d	PROPN
njb-29	306	22	,	,	PUNCT
njb-29	306	23	lightbody	lightbody	PROPN
njb-29	306	24	j	j	PROPN
njb-29	306	25	,	,	PUNCT
njb-29	306	26	ouellette	ouellette	NOUN
njb-29	306	27	m	m	PROPN
njb-29	306	28	,	,	PUNCT
njb-29	306	29	rosen	rosen	PROPN
njb-29	306	30	bp	bp	PROPN
njb-29	306	31	:	:	PUNCT
njb-29	306	32	trypanothione	trypanothione	PROPN
njb-29	306	33	overproduction	overproduction	NOUN
njb-29	306	34	and	and	CCONJ
njb-29	306	35	resistance	resistance	NOUN
njb-29	306	36	to	to	ADP
njb-29	306	37	antimonials	antimonial	NOUN
njb-29	306	38	and	and	CCONJ
njb-29	306	39	arsenicals	arsenical	NOUN
njb-29	306	40	in	in	ADP
njb-29	306	41	leishmania	leishmania	PROPN
njb-29	306	42	.	.	PUNCT
njb-29	307	1	proc	proc	PROPN
njb-29	307	2	.	.	PUNCT
njb-29	308	1	natl	natl	PROPN
njb-29	308	2	.	.	PUNCT
njb-29	309	1	acad	acad	PROPN
njb-29	309	2	.	.	PUNCT
njb-29	310	1	sci	sci	PROPN
njb-29	310	2	.	.	PROPN
njb-29	310	3	u.	u.	PROPN
njb-29	310	4	s.	s.	PROPN
njb-29	310	5	a	a	DET
njb-29	310	6	1996	1996	NUM
njb-29	310	7	,	,	PUNCT
njb-29	310	8	93(19	93(19	NUM
njb-29	310	9	):	):	PUNCT
njb-29	310	10	10383	10383	NUM
njb-29	310	11	-	-	SYM
njb-29	310	12	10387	10387	NUM
njb-29	310	13	.	.	PUNCT
njb-29	311	1	19	19	NUM
njb-29	311	2	.	.	PUNCT
njb-29	312	1	dey	dey	PROPN
njb-29	312	2	a	a	PROPN
njb-29	312	3	,	,	PUNCT
njb-29	312	4	singh	singh	PROPN
njb-29	312	5	s	s	PROPN
njb-29	312	6	:	:	PUNCT
njb-29	312	7	genetic	genetic	ADJ
njb-29	312	8	heterogeneity	heterogeneity	NOUN
njb-29	312	9	among	among	ADP
njb-29	312	10	visceral	visceral	NOUN
njb-29	312	11	and	and	CCONJ
njb-29	312	12	post	post	ADJ
njb-29	312	13	-	-	ADJ
njb-29	312	14	kala	kala	ADJ
njb-29	312	15	-	-	PUNCT
njb-29	312	16	azar	azar	PROPN
njb-29	312	17	dermal	dermal	NOUN
njb-29	312	18	leishmaniasis	leishmaniasis	NOUN
njb-29	312	19	strains	strain	VERB
njb-29	312	20	from	from	ADP
njb-29	312	21	eastern	eastern	PROPN
njb-29	312	22	india	india	PROPN
njb-29	312	23	.	.	PUNCT
njb-29	313	1	infect	infect	PROPN
njb-29	313	2	genet	genet	PROPN
njb-29	313	3	evol	evol	NOUN
njb-29	313	4	.	.	PUNCT
njb-29	314	1	2007	2007	NUM
njb-29	314	2	,	,	PUNCT
njb-29	314	3	7(2	7(2	NUM
njb-29	314	4	):	):	PUNCT
njb-29	314	5	219	219	NUM
njb-29	314	6	-	-	SYM
njb-29	314	7	222	222	NUM
njb-29	314	8	.	.	NUM
njb-29	314	9	20	20	NUM
njb-29	314	10	.	.	PUNCT
njb-29	315	1	mandal	mandal	PROPN
njb-29	315	2	s	s	PROPN
njb-29	315	3	,	,	PUNCT
njb-29	315	4	maharjan	maharjan	PROPN
njb-29	315	5	m	m	PROPN
njb-29	315	6	,	,	PUNCT
njb-29	315	7	singh	singh	PROPN
njb-29	315	8	s	s	PROPN
njb-29	315	9	,	,	PUNCT
njb-29	315	10	chatterjee	chatterjee	PROPN
njb-29	315	11	m	m	PROPN
njb-29	315	12	,	,	PUNCT
njb-29	315	13	madhubala	madhubala	PROPN
njb-29	315	14	r	r	PROPN
njb-29	315	15	:	:	PUNCT
njb-29	315	16	(	(	PUNCT
njb-29	315	17	2010	2010	NUM
njb-29	315	18	)	)	PUNCT
njb-29	315	19	assessing	assess	VERB
njb-29	315	20	aquaglyceroporin	aquaglyceroporin	PROPN
njb-29	315	21	gene	gene	NOUN
njb-29	315	22	status	status	NOUN
njb-29	315	23	and	and	CCONJ
njb-29	315	24	expression	expression	NOUN
njb-29	315	25	profile	profile	VERB
njb-29	315	26	in	in	ADP
njb-29	315	27	antimonysusceptible	antimonysusceptible	ADJ
njb-29	315	28	and	and	CCONJ
njb-29	315	29	-resistant	-resistant	ADJ
njb-29	315	30	clinical	clinical	ADJ
njb-29	315	31	isolates	isolate	NOUN
njb-29	315	32	of	of	ADP
njb-29	315	33	leishmania	leishmania	PROPN
njb-29	315	34	donovani	donovani	PROPN
njb-29	315	35	from	from	ADP
njb-29	315	36	india	india	PROPN
njb-29	315	37	.	.	PUNCT
njb-29	316	1	j	j	PROPN
njb-29	316	2	antimicrob	antimicrob	PROPN
njb-29	316	3	chemother	chemother	PROPN
njb-29	316	4	.	.	PUNCT
njb-29	316	5	2010	2010	NUM
njb-29	316	6	,	,	PUNCT
njb-29	316	7	65(3	65(3	NUM
njb-29	316	8	):	):	PUNCT
njb-29	316	9	496	496	NUM
njb-29	316	10	-	-	SYM
njb-29	316	11	507	507	NUM
njb-29	316	12	.	.	NUM
njb-29	317	1	21	21	NUM
njb-29	317	2	.	.	PUNCT
njb-29	318	1	sambrook	sambrook	PROPN
njb-29	318	2	j	j	PROPN
njb-29	318	3	,	,	PUNCT
njb-29	318	4	fritsch	fritsch	PROPN
njb-29	318	5	ef	ef	PROPN
njb-29	318	6	,	,	PUNCT
njb-29	318	7	maniatis	maniatis	PROPN
njb-29	318	8	t	t	PROPN
njb-29	318	9	:	:	PUNCT
njb-29	318	10	molecular	molecular	ADJ
njb-29	318	11	cloning	cloning	NOUN
njb-29	318	12	:	:	PUNCT
njb-29	318	13	a	a	DET
njb-29	318	14	laboratory	laboratory	NOUN
njb-29	318	15	manual	manual	NOUN
njb-29	318	16	.	.	PUNCT
njb-29	319	1	cold	cold	ADJ
njb-29	319	2	spring	spring	NOUN
njb-29	319	3	harbour	harbour	NOUN
njb-29	319	4	press	press	PROPN
njb-29	319	5	.	.	PUNCT
njb-29	320	1	int	int	NOUN
njb-29	320	2	j	j	NOUN
njb-29	320	3	hyperthermia	hyperthermia	NOUN
njb-29	320	4	.	.	PUNCT
njb-29	320	5	1989	1989	NUM
njb-29	320	6	,	,	PUNCT
njb-29	320	7	8	8	NUM
njb-29	320	8	:	:	PUNCT
njb-29	320	9	329	329	NUM
njb-29	320	10	-	-	SYM
njb-29	320	11	340	340	NUM
njb-29	320	12	22	22	NUM
njb-29	320	13	.	.	PUNCT
njb-29	321	1	roy	roy	PROPN
njb-29	321	2	g	g	PROPN
njb-29	321	3	,	,	PUNCT
njb-29	321	4	dumas	dumas	PROPN
njb-29	321	5	c	c	PROPN
njb-29	321	6	,	,	PUNCT
njb-29	321	7	sereno	sereno	PROPN
njb-29	321	8	d	d	PROPN
njb-29	321	9	,	,	PUNCT
njb-29	321	10	wu	wu	PROPN
njb-29	321	11	y	y	PROPN
njb-29	321	12	,	,	PUNCT
njb-29	321	13	singh	singh	PROPN
njb-29	321	14	ak	ak	PROPN
njb-29	321	15	,	,	PUNCT
njb-29	321	16	tremblay	tremblay	PROPN
njb-29	321	17	mj	mj	PROPN
njb-29	321	18	,	,	PUNCT
njb-29	321	19	ouellette	ouellette	NOUN
njb-29	321	20	m	m	PROPN
njb-29	321	21	,	,	PUNCT
njb-29	321	22	olivier	olivier	X
njb-29	321	23	m	m	PROPN
njb-29	321	24	,	,	PUNCT
njb-29	321	25	papadopoulou	papadopoulou	PROPN
njb-29	321	26	b	b	PROPN
njb-29	321	27	:	:	PUNCT
njb-29	321	28	episomal	episomal	ADJ
njb-29	321	29	and	and	CCONJ
njb-29	321	30	stable	stable	ADJ
njb-29	321	31	expression	expression	NOUN
njb-29	321	32	of	of	ADP
njb-29	321	33	the	the	DET
njb-29	321	34	luciferase	luciferase	PROPN
njb-29	321	35	reporter	reporter	NOUN
njb-29	321	36	gene	gene	NOUN
njb-29	321	37	for	for	ADP
njb-29	321	38	quantifying	quantify	VERB
njb-29	321	39	leishmania	leishmania	PROPN
njb-29	321	40	spp	spp	PROPN
njb-29	321	41	.	.	PUNCT
njb-29	322	1	infections	infection	NOUN
njb-29	322	2	in	in	ADP
njb-29	322	3	macrophages	macrophage	NOUN
njb-29	322	4	and	and	CCONJ
njb-29	322	5	in	in	ADP
njb-29	322	6	animal	animal	NOUN
njb-29	322	7	models	model	NOUN
njb-29	322	8	.	.	PUNCT
njb-29	323	1	mol	mol	PROPN
njb-29	323	2	biochem	biochem	NOUN
njb-29	323	3	parasitol	parasitol	PROPN
njb-29	323	4	.	.	PUNCT
njb-29	324	1	2000	2000	NUM
njb-29	324	2	,	,	PUNCT
njb-29	324	3	110(2	110(2	NUM
njb-29	324	4	):	):	PUNCT
njb-29	324	5	195	195	NUM
njb-29	324	6	-	-	SYM
njb-29	324	7	206	206	NUM
njb-29	324	8	.	.	PUNCT
njb-29	325	1	23	23	NUM
njb-29	325	2	.	.	PUNCT
njb-29	326	1	mukherjee	mukherjee	VERB
njb-29	326	2	a	a	PROPN
njb-29	326	3	,	,	PUNCT
njb-29	326	4	padmanabhan	padmanabhan	PROPN
njb-29	326	5	pk	pk	PROPN
njb-29	326	6	,	,	PUNCT
njb-29	326	7	singh	singh	PROPN
njb-29	326	8	s	s	PROPN
njb-29	326	9	,	,	PUNCT
njb-29	326	10	roy	roy	PROPN
njb-29	326	11	g	g	PROPN
njb-29	326	12	,	,	PUNCT
njb-29	326	13	girard	girard	PROPN
njb-29	326	14	i	i	PROPN
njb-29	326	15	,	,	PUNCT
njb-29	326	16	chatterjee	chatterjee	PROPN
njb-29	326	17	m	m	PROPN
njb-29	326	18	,	,	PUNCT
njb-29	326	19	ouellette	ouellette	NOUN
njb-29	326	20	,	,	PUNCT
njb-29	326	21	m	m	PROPN
njb-29	326	22	,	,	PUNCT
njb-29	326	23	madhubala	madhubala	PROPN
njb-29	326	24	r	r	PROPN
njb-29	326	25	:	:	PUNCT
njb-29	326	26	role	role	NOUN
njb-29	326	27	of	of	ADP
njb-29	326	28	abc	abc	PROPN
njb-29	326	29	transporter	transporter	PROPN
njb-29	326	30	mrpa	mrpa	PROPN
njb-29	326	31	,	,	PUNCT
njb-29	326	32	gammaglutamylcysteine	gammaglutamylcysteine	NOUN
njb-29	326	33	synthetase	synthetase	NOUN
njb-29	326	34	and	and	CCONJ
njb-29	326	35	ornithine	ornithine	ADJ
njb-29	326	36	decarboxylase	decarboxylase	NOUN
njb-29	326	37	in	in	ADP
njb-29	326	38	natural	natural	ADJ
njb-29	326	39	antimony	antimony	NOUN
njb-29	326	40	-	-	PUNCT
njb-29	326	41	resistant	resistant	ADJ
njb-29	326	42	isolates	isolate	NOUN
njb-29	326	43	of	of	ADP
njb-29	326	44	leishmania	leishmania	PROPN
njb-29	326	45	donovani	donovani	PROPN
njb-29	326	46	.	.	PUNCT
njb-29	327	1	j	j	PROPN
njb-29	327	2	antimicrob	antimicrob	PROPN
njb-29	327	3	chemother	chemother	PROPN
njb-29	327	4	.	.	PUNCT
njb-29	328	1	2007	2007	NUM
njb-29	328	2	,	,	PUNCT
njb-29	328	3	59(2	59(2	NUM
njb-29	328	4	):	):	PUNCT
njb-29	328	5	204	204	NUM
njb-29	328	6	-	-	SYM
njb-29	328	7	211	211	NUM
njb-29	328	8	.	.	PUNCT
njb-29	329	1	24	24	NUM
njb-29	329	2	.	.	PUNCT
njb-29	330	1	grondin	grondin	PROPN
njb-29	330	2	k	k	PROPN
njb-29	330	3	,	,	PUNCT
njb-29	330	4	haimeur	haimeur	PROPN
njb-29	330	5	a	a	PRON
njb-29	330	6	,	,	PUNCT
njb-29	330	7	mukhopadhyay	mukhopadhyay	PROPN
njb-29	330	8	r	r	NOUN
njb-29	330	9	,	,	PUNCT
njb-29	330	10	rosen	rosen	PROPN
njb-29	330	11	bp	bp	PROPN
njb-29	330	12	,	,	PUNCT
njb-29	330	13	ouellette	ouellette	NOUN
njb-29	330	14	m	m	VERB
njb-29	330	15	:	:	PUNCT
njb-29	330	16	co	co	NOUN
njb-29	330	17	-	-	NOUN
njb-29	330	18	amplification	amplification	NOUN
njb-29	330	19	of	of	ADP
njb-29	330	20	the	the	DET
njb-29	330	21	gammaglutamylcysteine	gammaglutamylcysteine	NOUN
njb-29	330	22	synthetase	synthetase	PROPN
njb-29	330	23	gene	gene	NOUN
njb-29	330	24	gsh1	gsh1	PROPN
njb-29	330	25	and	and	CCONJ
njb-29	330	26	of	of	ADP
njb-29	330	27	the	the	DET
njb-29	330	28	abc	abc	PROPN
njb-29	330	29	transporter	transporter	NOUN
njb-29	330	30	gene	gene	NOUN
njb-29	330	31	pgpa	pgpa	NOUN
njb-29	330	32	in	in	ADP
njb-29	330	33	arsenite	arsenite	NOUN
njb-29	330	34	-	-	PUNCT
njb-29	330	35	resistant	resistant	ADJ
njb-29	330	36	leishmania	leishmania	PROPN
njb-29	330	37	tarentolae	tarentolae	PROPN
njb-29	330	38	.	.	PUNCT
njb-29	331	1	embo	embo	PROPN
njb-29	331	2	j.	j.	PROPN
njb-29	331	3	1997	1997	PROPN
njb-29	331	4	,	,	PUNCT
njb-29	331	5	16(11	16(11	NUM
njb-29	331	6	):	):	PUNCT
njb-29	331	7	30573065	30573065	NUM
njb-29	331	8	.	.	PUNCT
njb-29	332	1	25	25	X
njb-29	332	2	.	.	X
njb-29	332	3	haimeur	haimeur	VERB
njb-29	332	4	a	a	PRON
njb-29	332	5	,	,	PUNCT
njb-29	332	6	guimond	guimond	PROPN
njb-29	332	7	c	c	PROPN
njb-29	332	8	,	,	PUNCT
njb-29	332	9	pilote	pilote	PROPN
njb-29	332	10	s	s	PROPN
njb-29	332	11	,	,	PUNCT
njb-29	332	12	mukhopadhyay	mukhopadhyay	PROPN
njb-29	332	13	r	r	PROPN
njb-29	332	14	,	,	PUNCT
njb-29	332	15	rosen	rosen	PROPN
njb-29	332	16	bp	bp	PROPN
njb-29	332	17	,	,	PUNCT
njb-29	332	18	poulin	poulin	NOUN
njb-29	332	19	r	r	NOUN
njb-29	332	20	,	,	PUNCT
njb-29	332	21	ouellette	ouellette	NOUN
njb-29	332	22	m	m	PRON
njb-29	332	23	:	:	PUNCT
njb-29	332	24	elevated	elevated	ADJ
njb-29	332	25	levels	level	NOUN
njb-29	332	26	of	of	ADP
njb-29	332	27	polyamines	polyamine	NOUN
njb-29	332	28	and	and	CCONJ
njb-29	332	29	trypanothione	trypanothione	NOUN
njb-29	332	30	resulting	result	VERB
njb-29	332	31	from	from	ADP
njb-29	332	32	overexpression	overexpression	NOUN
njb-29	332	33	of	of	ADP
njb-29	332	34	the	the	DET
njb-29	332	35	ornithine	ornithine	ADJ
njb-29	332	36	decarboxylase	decarboxylase	NOUN
njb-29	332	37	gene	gene	NOUN
njb-29	332	38	in	in	ADP
njb-29	332	39	arsenite	arsenite	NOUN
njb-29	332	40	-	-	PUNCT
njb-29	332	41	resistant	resistant	ADJ
njb-29	332	42	leishmania	leishmania	PROPN
njb-29	332	43	.	.	PUNCT
njb-29	333	1	mol	mol	PROPN
njb-29	333	2	microbiol	microbiol	PROPN
njb-29	333	3	.	.	PUNCT
njb-29	334	1	1999	1999	NUM
njb-29	334	2	,	,	PUNCT
njb-29	334	3	34(4	34(4	NUM
njb-29	334	4	):	):	PUNCT
njb-29	334	5	726	726	NUM
njb-29	334	6	-	-	SYM
njb-29	334	7	735	735	NUM
njb-29	334	8	.	.	PROPN
njb-29	334	9	26	26	NUM
njb-29	334	10	.	.	PUNCT
njb-29	335	1	singh	singh	PROPN
njb-29	335	2	s	s	PROPN
njb-29	335	3	,	,	PUNCT
njb-29	335	4	mukherjee	mukherjee	NOUN
njb-29	335	5	a	a	PROPN
njb-29	335	6	,	,	PUNCT
njb-29	335	7	khomutov	khomutov	PROPN
njb-29	335	8	ar	ar	PROPN
njb-29	335	9	,	,	PUNCT
njb-29	335	10	persson	persson	PROPN
njb-29	335	11	l	l	PROPN
njb-29	335	12	,	,	PUNCT
njb-29	335	13	heby	heby	PROPN
njb-29	335	14	o	o	PROPN
njb-29	335	15	,	,	PUNCT
njb-29	335	16	chatterjee	chatterjee	PROPN
njb-29	335	17	m	m	PROPN
njb-29	335	18	,	,	PUNCT
njb-29	335	19	madhubala	madhubala	PROPN
njb-29	335	20	r	r	PROPN
njb-29	335	21	:	:	PUNCT
njb-29	335	22	antileishmanial	antileishmanial	ADJ
njb-29	335	23	effect	effect	NOUN
njb-29	335	24	of	of	ADP
njb-29	335	25	3	3	NUM
njb-29	335	26	-	-	NUM
njb-29	335	27	aminooxy-1aminopropane	aminooxy-1aminopropane	NOUN
njb-29	335	28	is	be	AUX
njb-29	335	29	due	due	ADJ
njb-29	335	30	to	to	ADP
njb-29	335	31	polyamine	polyamine	NOUN
njb-29	335	32	depletion	depletion	NOUN
njb-29	335	33	.	.	PUNCT
njb-29	336	1	antimicrob	antimicrob	PROPN
njb-29	336	2	agents	agents	PROPN
njb-29	336	3	chemother	chemother	PROPN
njb-29	336	4	.	.	PUNCT
njb-29	337	1	2007	2007	NUM
njb-29	337	2	,	,	PUNCT
njb-29	337	3	51(2	51(2	NUM
njb-29	337	4	):	):	PUNCT
njb-29	337	5	528	528	NUM
njb-29	337	6	-	-	SYM
njb-29	337	7	534	534	NUM
njb-29	337	8	.	.	NUM
njb-29	337	9	27	27	NUM
njb-29	337	10	.	.	PUNCT
njb-29	338	1	den	den	PROPN
njb-29	338	2	boer	boer	PROPN
njb-29	338	3	ml	ml	PROPN
njb-29	338	4	,	,	PUNCT
njb-29	338	5	alvar	alvar	PROPN
njb-29	338	6	j	j	PROPN
njb-29	338	7	,	,	PUNCT
njb-29	338	8	davidson	davidson	PROPN
njb-29	338	9	rn	rn	PROPN
njb-29	338	10	,	,	PUNCT
njb-29	338	11	ritmeijer	ritmeijer	PROPN
njb-29	338	12	k	k	PROPN
njb-29	338	13	,	,	PUNCT
njb-29	338	14	balasegaram	balasegaram	PROPN
njb-29	338	15	m	m	PROPN
njb-29	338	16	:	:	PUNCT
njb-29	338	17	developments	development	NOUN
njb-29	338	18	in	in	ADP
njb-29	338	19	the	the	DET
njb-29	338	20	treatment	treatment	NOUN
njb-29	338	21	of	of	ADP
njb-29	338	22	visceral	visceral	NOUN
njb-29	338	23	leishmaniasis	leishmaniasis	NOUN
njb-29	338	24	.	.	PUNCT
njb-29	339	1	expert	expert	NOUN
njb-29	339	2	opin	opin	PROPN
njb-29	339	3	emer	emer	VERB
njb-29	339	4	.	.	PUNCT
njb-29	340	1	drugs	drug	NOUN
njb-29	340	2	.	.	PUNCT
njb-29	341	1	2009	2009	NUM
njb-29	341	2	,	,	PUNCT
njb-29	341	3	14(3	14(3	NUM
njb-29	341	4	):	):	PUNCT
njb-29	341	5	395	395	NUM
njb-29	341	6	-	-	SYM
njb-29	341	7	410	410	NUM
njb-29	341	8	.	.	NUM
njb-29	341	9	28	28	NUM
njb-29	341	10	.	.	PUNCT
njb-29	341	11	sereno	sereno	PROPN
njb-29	341	12	d	d	PROPN
njb-29	341	13	,	,	PUNCT
njb-29	341	14	cavaleyra	cavaleyra	PROPN
njb-29	341	15	m	m	PROPN
njb-29	341	16	,	,	PUNCT
njb-29	341	17	zemzoumi	zemzoumi	PROPN
njb-29	341	18	k	k	PROPN
njb-29	341	19	,	,	PUNCT
njb-29	341	20	maquaire	maquaire	PROPN
njb-29	341	21	s	s	PROPN
njb-29	341	22	,	,	PUNCT
njb-29	341	23	ouaissi	ouaissi	PROPN
njb-29	341	24	a	a	PRON
njb-29	341	25	,	,	PUNCT
njb-29	341	26	lemesre	lemesre	PROPN
njb-29	341	27	jl	jl	PROPN
njb-29	341	28	:	:	PUNCT
njb-29	341	29	axenically	axenically	PROPN
njb-29	341	30	grown	grow	VERB
njb-29	341	31	amastigotes	amastigote	NOUN
njb-29	341	32	of	of	ADP
njb-29	341	33	leishmania	leishmania	PROPN
njb-29	341	34	infantum	infantum	PROPN
njb-29	341	35	used	use	VERB
njb-29	341	36	as	as	ADP
njb-29	341	37	an	an	DET
njb-29	341	38	in	in	X
njb-29	341	39	vitro	vitro	X
njb-29	341	40	model	model	NOUN
njb-29	341	41	to	to	PART
njb-29	341	42	investigate	investigate	VERB
njb-29	341	43	the	the	DET
njb-29	341	44	pentavalent	pentavalent	NOUN
njb-29	341	45	antimony	antimony	NOUN
njb-29	341	46	mode	mode	NOUN
njb-29	341	47	of	of	ADP
njb-29	341	48	action	action	NOUN
njb-29	341	49	.	.	PUNCT
njb-29	342	1	antimicrob	antimicrob	PROPN
njb-29	342	2	agents	agents	PROPN
njb-29	342	3	chemother	chemother	PROPN
njb-29	342	4	.	.	PUNCT
njb-29	343	1	1998	1998	NUM
njb-29	343	2	,	,	PUNCT
njb-29	343	3	42(12	42(12	NUM
njb-29	343	4	):	):	PUNCT
njb-29	343	5	3097	3097	NUM
njb-29	343	6	-	-	SYM
njb-29	343	7	3102	3102	NUM
njb-29	343	8	.	.	NUM
njb-29	343	9	29	29	NUM
njb-29	343	10	.	.	PUNCT
njb-29	344	1	maharjan	maharjan	PROPN
njb-29	344	2	m	m	PROPN
njb-29	344	3	,	,	PUNCT
njb-29	344	4	singh	singh	PROPN
njb-29	344	5	s	s	PROPN
njb-29	344	6	,	,	PUNCT
njb-29	344	7	chatterjee	chatterjee	PROPN
njb-29	344	8	m	m	PROPN
njb-29	344	9	,	,	PUNCT
njb-29	344	10	madhubala	madhubala	PROPN
njb-29	344	11	r	r	PROPN
njb-29	344	12	:	:	PUNCT
njb-29	344	13	role	role	NOUN
njb-29	344	14	of	of	ADP
njb-29	344	15	aquaglyceroporin	aquaglyceroporin	PROPN
njb-29	344	16	(	(	PUNCT
njb-29	344	17	aqp1	aqp1	PROPN
njb-29	344	18	)	)	PUNCT
njb-29	344	19	gene	gene	NOUN
njb-29	344	20	and	and	CCONJ
njb-29	344	21	drug	drug	NOUN
njb-29	344	22	uptake	uptake	NOUN
njb-29	344	23	in	in	ADP
njb-29	344	24	antimony	antimony	NOUN
njb-29	344	25	-	-	PUNCT
njb-29	344	26	resistant	resistant	ADJ
njb-29	344	27	clinical	clinical	ADJ
njb-29	344	28	isolates	isolate	NOUN
njb-29	344	29	of	of	ADP
njb-29	344	30	leishmania	leishmania	PROPN
njb-29	344	31	donovani	donovani	PROPN
njb-29	344	32	.	.	PUNCT
njb-29	345	1	am	be	AUX
njb-29	345	2	j	j	PROPN
njb-29	345	3	trop	trop	PROPN
njb-29	345	4	med	me	VERB
njb-29	345	5	hyg	hyg	PROPN
njb-29	345	6	.	.	PROPN
njb-29	345	7	2008	2008	NUM
njb-29	345	8	,	,	PUNCT
njb-29	345	9	79(1	79(1	NUM
njb-29	345	10	):	):	PUNCT
njb-29	345	11	69	69	NUM
njb-29	345	12	-	-	SYM
njb-29	345	13	75	75	NUM
njb-29	345	14	.	.	NUM
njb-29	345	15	30	30	NUM
njb-29	345	16	.	.	PUNCT
njb-29	346	1	el	el	PROPN
njb-29	346	2	fk	fk	PROPN
njb-29	346	3	,	,	PUNCT
njb-29	346	4	messier	messy	ADJ
njb-29	346	5	n	n	NOUN
njb-29	346	6	,	,	PUNCT
njb-29	346	7	leprohon	leprohon	PROPN
njb-29	346	8	p	p	PROPN
njb-29	346	9	,	,	PUNCT
njb-29	346	10	roy	roy	PROPN
njb-29	346	11	g	g	PROPN
njb-29	346	12	,	,	PUNCT
njb-29	346	13	guimond	guimond	PROPN
njb-29	346	14	c	c	PROPN
njb-29	346	15	,	,	PUNCT
njb-29	346	16	trudel	trudel	PROPN
njb-29	346	17	n	n	PROPN
njb-29	346	18	,	,	PUNCT
njb-29	346	19	saravia	saravia	PROPN
njb-29	346	20	ng	ng	PROPN
njb-29	346	21	,	,	PUNCT
njb-29	346	22	papadopoulou	papadopoulou	PROPN
njb-29	346	23	b	b	PROPN
njb-29	346	24	,	,	PUNCT
njb-29	346	25	legare	legare	PROPN
njb-29	346	26	d	d	PROPN
njb-29	346	27	,	,	PUNCT
njb-29	346	28	ouellette	ouellette	NOUN
njb-29	346	29	m	m	NOUN
njb-29	346	30	:	:	PUNCT
njb-29	346	31	role	role	NOUN
njb-29	346	32	of	of	ADP
njb-29	346	33	the	the	DET
njb-29	346	34	abc	abc	PROPN
njb-29	346	35	transporter	transporter	PROPN
njb-29	346	36	mrpa	mrpa	PROPN
njb-29	346	37	(	(	PUNCT
njb-29	346	38	pgpa	pgpa	PROPN
njb-29	346	39	)	)	PUNCT
njb-29	346	40	in	in	ADP
njb-29	346	41	antimony	antimony	ADJ
njb-29	346	42	resistance	resistance	NOUN
njb-29	346	43	in	in	ADP
njb-29	346	44	leishmania	leishmania	PROPN
njb-29	346	45	infantum	infantum	PROPN
njb-29	346	46	axenic	axenic	PROPN
njb-29	346	47	and	and	CCONJ
njb-29	346	48	intracellular	intracellular	ADJ
njb-29	346	49	amastigotes	amastigote	NOUN
njb-29	346	50	.	.	PUNCT
njb-29	347	1	antimicrob	antimicrob	PROPN
njb-29	347	2	agents	agents	PROPN
njb-29	347	3	chemother	chemother	PROPN
njb-29	347	4	.	.	PUNCT
njb-29	347	5	2005	2005	NUM
njb-29	347	6	,	,	PUNCT
njb-29	347	7	49(5	49(5	NUM
njb-29	347	8	):	):	PUNCT
njb-29	347	9	1988	1988	NUM
njb-29	347	10	-	-	SYM
njb-29	347	11	1993	1993	NUM
njb-29	347	12	.	.	PUNCT
njb-29	348	1	31	31	NUM
njb-29	348	2	.	.	PUNCT
njb-29	349	1	decuypere	decuypere	PROPN
njb-29	349	2	s	s	PROPN
njb-29	349	3	,	,	PUNCT
njb-29	349	4	rijal	rijal	PROPN
njb-29	349	5	s	s	PROPN
njb-29	349	6	,	,	PUNCT
njb-29	349	7	yardley	yardley	PROPN
njb-29	349	8	v	v	PROPN
njb-29	349	9	,	,	PUNCT
njb-29	349	10	de	de	PROPN
njb-29	349	11	ds	ds	PROPN
njb-29	349	12	,	,	PUNCT
njb-29	349	13	laurent	laurent	PROPN
njb-29	349	14	t	t	PROPN
njb-29	349	15	,	,	PUNCT
njb-29	349	16	khanal	khanal	PROPN
njb-29	349	17	b	b	PROPN
njb-29	349	18	,	,	PUNCT
njb-29	349	19	chappuis	chappuis	PROPN
njb-29	349	20	f	f	PROPN
njb-29	349	21	,	,	PUNCT
njb-29	349	22	dujardin	dujardin	PROPN
njb-29	349	23	jc	jc	PROPN
njb-29	349	24	:	:	PUNCT
njb-29	349	25	gene	gene	NOUN
njb-29	349	26	expression	expression	NOUN
njb-29	349	27	analysis	analysis	NOUN
njb-29	349	28	of	of	ADP
njb-29	349	29	the	the	DET
njb-29	349	30	mechanism	mechanism	NOUN
njb-29	349	31	of	of	ADP
njb-29	349	32	natural	natural	ADJ
njb-29	349	33	sb(v	sb(v	PUNCT
njb-29	349	34	)	)	PUNCT
njb-29	349	35	resistance	resistance	NOUN
njb-29	349	36	in	in	ADP
njb-29	349	37	leishmania	leishmania	PROPN
njb-29	349	38	donovani	donovani	PROPN
njb-29	349	39	isolates	isolate	VERB
njb-29	349	40	from	from	ADP
njb-29	349	41	nepal	nepal	ADJ
njb-29	349	42	.	.	PUNCT
njb-29	350	1	antimicrob	antimicrob	PROPN
njb-29	350	2	agents	agents	PROPN
njb-29	350	3	chemother	chemother	PROPN
njb-29	350	4	.	.	PUNCT
njb-29	350	5	2005	2005	NUM
njb-29	350	6	,	,	PUNCT
njb-29	350	7	49(11	49(11	NUM
njb-29	350	8	):	):	PUNCT
njb-29	350	9	4616	4616	NUM
njb-29	350	10	-	-	SYM
njb-29	350	11	4621	4621	NUM
njb-29	350	12	.	.	PUNCT
njb-29	351	1	http://www.ncbi.nlm.nih.gov/pubmed/?term=persson%20l%5bauthor%5d&cauthor=true&cauthor_uid=17101681	http://www.ncbi.nlm.nih.gov/pubmed/?term=persson%20l%5bauthor%5d&cauthor=true&cauthor_uid=17101681	PROPN
njb-29	351	2	http://www.ncbi.nlm.nih.gov/pubmed/?term=heby%20o%5bauthor%5d&cauthor=true&cauthor_uid=17101681	http://www.ncbi.nlm.nih.gov/pubmed/?term=heby%20o%5bauthor%5d&cauthor=true&cauthor_uid=17101681	PROPN
njb-29	351	3	http://www.ncbi.nlm.nih.gov/pubmed/?term=chatterjee%20m%5bauthor%5d&cauthor=true&cauthor_uid=17101681	http://www.ncbi.nlm.nih.gov/pubmed/?term=chatterjee%20m%5bauthor%5d&cauthor=true&cauthor_uid=17101681	PROPN
njb-29	351	4	http://www.ncbi.nlm.nih.gov/pubmed/?term=madhubala%20r%5bauthor%5d&cauthor=true&cauthor_uid=17101681	http://www.ncbi.nlm.nih.gov/pubmed/?term=madhubala%20r%5bauthor%5d&cauthor=true&cauthor_uid=17101681	PROPN